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Technological advances and decreasing costs in genome sequencing have greatly
sped up the rate of identification of the genetic causes of inherited disease. One
such human disorder in which genome sequencing is being applied in hope that the
genetic causes will be identified is malignant hyperthermia (MH). MH is an auto-
somal dominant pharmacogenetic disorder which has long perplexed researchers
due to its phenotypic and genetic complexity. Individuals susceptible to MH are
at risk of a sometimes deadly hypermetabolic episode of skeletal muscle triggered
by potent volatile general anaesthetic agents. Although the genetic origin of the
disorder has been determined in over half of all MH families, there are many
families for which the origin has not yet been elucidated. This research aimed to
identify genetic variants that may be pathogenic for MH-susceptibility in six New
Zealand families for which the genetic cause has not yet been identified. Targeted
next-generation sequencing of the genome was undertaken on a number of indi-
viduals from each family. Bioinformatic approaches were developed and applied
to identify candidate genetic variants. Segregation analysis was carried out for
some of the identified candidate variants, which failed to establish an association
with MH-susceptibility, although a number of variants were ruled out as being
pathogenic for MH-susceptibility. Additionally, a common polymorphism that
has been previously postulated to have a modifying effect on MH-susceptibility
was identified within a large MH family. A genotype/phenotype association study
was carried, however the study did not find an association. Overall, this work
has reinforced that MH does not have a simple, easily identifiable genetic origin,
suggesting there is one or more missing elements to the current understanding of
MH. Importantly, it has established an effective MH-specific bioinformatic pro-
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DHPR dihydropyridine receptor
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FRET Förster resonance energy transfer
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GATK Genome Analysis Toolkit
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Muscle is a soft tissue of animals which functions to produce motion and
force. There are three major muscle types, two being forms of striated muscle
(skeletal and cardiac muscle) and the third being non-striated (smooth muscle).
Striated muscle has repeat units called sarcomeres, which are not present in non-
striated muscle. Biochemical differences of the three muscle types give rise to
their specialised functions; going forward the focus will be on skeletal muscle
(SM).
SM is so named as it is attached to the skeletal system. Contraction events
of SM are controlled in a voluntary fashion by the somatic nervous system, as
opposed to non-voluntary contraction events of cardiac and smooth muscle. A
contraction event occurs when an electrochemical current is transduced from the
brain to a motor neuron through the nervous system. Motor neurons contact cells
of SM, forming a neuromuscular junction, ultimately allowing a nerve impulse to
trigger a molecular event within SM cells (myocytes) which gives rise to motion
and force.
1.1.1 Skeletal muscle structure and function
SM is made up of bundled fascicles, which are themselves bundles of muscle
fibres. Muscle fibres are large multi-nucleated cells rich in mitochondria and
myofibrils. Myofibrils are units of the myocyte containing specialised proteins
which make up the contractile units, sarcomeres, contained within myofibrils
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(Figure 1.1).
Thick and thin myofilaments make up a myofibril. Thin filaments are com-
prised of the proteins actin and titin; thick filaments of the proteins myosin and
nebulin. It is the ‘climbing’ of the head structure of myosin along the poly-
merised actin filaments, referred to as cross-bridge cycling, which gives rise to
force generation. The mechanism by which this is thought to occur is referred to
as the sliding filament theory (Figure 1.2). Crucially, this climbing action of the
myosin head along the thin filament is controlled by the cytoplasmic availability
of calcium ions because Ca2+ binding to troponin unblocks the actin binding site.
Ca2+ availability is indirectly controlled by the conveyance of a nerve impulse in
a process called excitation-contraction coupling (ECC).
Figure 1.1: A schematic representation of a single muscle fibre
The muscle fibre contains bundles of myofibrils, protein-rich rod-like structures that contain the
contractile units sarcomeres. Surrounding the myofibrils is a web-like organelle, the sarcoplasmic
reticulum (SR). The SR holds and controls the release of Ca2+ into the cytoplasm. Ca2+ acts
as a signalling molecule for a large number of cell processes, one of which is the initiation of
cross-bridge cycling. Transverse tubules (T-tubule) are invaginations of the sarcolemma which
assist in the propagation of an action potential to the SR. Figure from Blausen.com staff1,
distributed under a CC BY 3.0 license.
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Figure 1.2: Schematic representation of a sarcomere and the sliding filament theory
The sliding filament theory postulates that force generation is achieved through cross-bridge
cycling within the contractile unit of the myocyte - the sarcomere. Cross-bridge cycling involves
cyclic attachment and detachment of the myosin head to the actin filament, which pulls the actin
filament toward the centre of the sarcomere. Ca2+ binding to troponin controls the attachment
of the myosin head to actin, ultimately allowing the sarcomere to cycle between a relaxed and
contracted state in a Ca2+-dependent manner. Figure from David Richfield2, distributed under
a CC BY-SA 3.0 license.
1.1.2 Excitation-contraction coupling
A defining feature of myocytes is the presence of the sarcoplasmic reticulum
(SR), a modified smooth endoplasmic reticulum. The SR contains intracellular
stores of Ca2+, the primary purpose of which is to allow for regulated and rapid
increases in cytoplasmic Ca2+ to initiate cross-bridge cycling through troponin
binding. The molecular events that result in Ca2+ release from the SR and
subsequently muscle contraction are collectively termed excitation-contraction
coupling (ECC).
At the neuromuscular junction, the contact point between a nerve and a
myocyte, a nerve impulse is transmitted to the myocyte via a rapid release of
acetylcholine (ACh) into the synaptic cleft of the nerve cell. ACh binds to ACh
receptors of the plasma membrane (PM), termed the sarcolemma, of the my-
ocyte. This triggers the opening of cation channels, leading to a rapid flow of
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ions across the membrane, which causes a sudden depolarisation at the mem-
brane surface. This depolarisation is said to generate an action potential, which
travels down the transverse tubules of the sarcolemma. This is sensed by the
dihydropyridine receptor (DHPR), an L-type membrane channel protein embed-
ded in the T-tubule membrane, which undergoes a conformational change upon
recognition of an action potential. Physical coupling between DHPR and the
ryanodine receptor (RyR) Ca2+ channel leads to RyR channel opening upon the
conformational change of DHPR3, 4. RyR resides in the SR membrane, and its
opening causes a release of Ca2+ from the SR into the cytoplasm to initiate mus-
cle contraction. Aside from direct RyR accessory proteins to be discussed, the
functional interaction between DHPR and RyR is modulated by Stac3 and JP-45
in skeletal muscle. These proteins are both thought to be auxiliary DHPR sub-
units, however their exact roles are yet to be fully understood. Stac3 seems to be
required for ECC as determined by mouse experiments5, while JP-45 is required
for the correct functional expression of DHPR6.
1.1.3 The ryanodine receptor
The ryanodine receptor is a very large, homotetrameric channel responsible for
the passive conductance of Ca2+ from the SR. The muscle-specific RyR channel,
RyR1, is encoded by the RYR1 gene. The other isoforms of RyR, encoded
by distinct genes, are RyR2, which is expressed in heart, and RyR3, expressed
primarily in brain. The properties of each isoform vary and relate to their tissue-
specific function7, but the focus from here will be on RyR1.
A single RyR1 subunit is approximately 5000 amino acids in length, encoded
by the 106-exon RYR1 gene. The majority of the RyR1 channel resides cytoplas-
mically, with the remainder of the protein residing within the SR membrane and
the SR lumen8. The size of RyR1 allows it to be regulated by a range of proteins
and other effectors. Additionally, it is subject to a number of post-translational
modifications (PTMs). This regulation results in tight control of RyR1-mediated
Ca2+ release, allowing it to respond rapidly to changes in Ca2+ levels, as well
as energy and reduction-oxidation (redox) states, of the myocyte (summarised in
Figure 1.3).
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1.1.3.1 RyR1 regulation
RyR1 is able to sense both cytoplasmic and SR Ca2+ levels through the Ca2+-
binding proteins calmodulin (CaM) and calsequestrin (CsQ), respectively. This
subjects RyR1 to negative feedback regulation, so that increasing levels of cy-
toplasmic Ca2+, and decreasing levels of SR Ca2+, both lead to RyR1 channel
closure. CaM is a cytoplasmic RyR1-interacting protein which inhibits RyR1
channel opening when Ca2+-bound, but activates RyR1 when not Ca2+-bound9.
Additionally, an allosteric change of RyR1 is induced when it is bound to Ca2+
which may increase its affinity to CaM10. Another RyR1 cytoplasmic interact-
ing Ca2+-binding protein, S100A1, is thought to alter the CaM-bound structure
and modulate RyR1 activity11. On the other hand, CsQ resides within the SR
lumen and plays a comparable but opposite role to CaM by increasing the RyR1
open-channel state with increasing SR Ca2+ 12. When CsQ’s RyR1 regulatory
function was first identified, it was discovered that this effect was dependent on
other RyR1 binding partners13. These other important partners were determined
to be triadin and junctin, SR-membrane associated proteins residing in the SR
lumen. These proteins interact with RyR1 and CsQ, as well as each other14.
Triadin is thought to anchor CsQ to the SR membrane, and junctin to modulate
CsQ’s inhibition of RyR115, 16. In mouse models, it has been found that through
association of JP-45, CsQ may also indirectly modulate DHPR to allow negative
regulation of ECC in response to depletion of SR Ca2+ stores17.
Homer 1 and FKBP12 are two other proteins which regulate RyR1 activity
in a non-Ca2+ dependent manner. Homer 1 is a direct interactor18 and modula-
tor of RyR1 channel activity19. Two different splice variants of the protein have
been shown to activate or inhibit open channel probability in a dose-dependent
manner20. FKBP12’s role on the modulation of RyR1 is contentious, with re-
search suggesting the protein stabilises both the open and closed state of RyR1
during ECC21, 22. FKBP12 also acts in a pathway involving RyR1 regulation
by phosphorylation in response to cAMP (cyclic adenosine monophosphate) lev-
els: Increases in the concentration of cAMP leads to phosphorylation by protein
kinase A of RyR1 which enhances the probability of RyR1 being in an open chan-
nel state23. Decreasing cAMP levels lead to RyR1 dephosphorylation by protein
phosphatase 1 which allows binding of FKBP12, and this RyR1-FKBP12 inter-
action enhances the RyR1 closed channel state probability23. In agreement with
what is known about the effect of RyR1 phosphorylation, hyperphosphorylation
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of RyR1 has been associated with disease states in which there is a constitu-
tive abnormal (‘leaky’) Ca2+ release from RyR1 in resting muscle24, 23. FKBP12
binding to RyR1 is reduced by S -nitrosylation, another PTM of RyR125. Via al-
terations in cellular redox states, S -nitrosylation of RyR1 occurs at physiological
O2 pressure (pO2), which acts to activate RyR1. High pO2 leads to removal of
S -nitrosylation and activation of RyR1 and consequently an increase in muscle
force production26.
Other PTMs of RyR1 occur in response to changes in pO2, allowing dynamic
Ca2+ release dependent on the O2 demand of muscle
26, 27. These are S -oxidation,
S -palmitoylation and S -glutathionylation. All of the aforementioned PTMs occur
via molecular pathways involving a number of proteins and molecular species: It
is beyond the scope of this review to detail them. Additionally, the co-localisation
of nitric oxide synthase, an enzyme which produces the signalling molecule nitric
oxide, to RyR1 is associated with its nitration and increased Ca2+ release from
the SR28. Whether or not RyR1 nitration is directly causative of its activation
has not been established. Nevertheless, it suggests another mechanism by which
RyR1 activity may be regulated.
Small allosteric effectors of RyR1 are Mg2+, adenosine triphosphate (ATP),
and as previously mentioned, Ca2+. ATP and Ca2+ activate RyR1 by binding to
activation sites29, 30. Mg2+ binding exerts an inhibitory effect on RyR1 by both
competing for binding at activation sites of ATP and Ca2+ and by binding to
inhibitory sites31, 32.
1.1.4 Calcium homeostasis of myocytes
Ca2+ signalling by RyR1 to initiate muscle contraction has been discussed,
but how is general Ca2+ homeostasis maintained in the myocyte? The flow of
Ca2+ also occurs back into the SR from the cytoplasm, as well as between the
cytoplasm and the extracellular spaces (summarised in Figure 1.4). Sarco/endo-
plasmic reticulum Ca2+ ATPase (SERCA) is the active transporter responsible for
the reuptake of Ca2+ into the SR34. SERCA demands a phenomenal amount of
the cell’s energy: in mice it was determined that in resting muscle, to maintain low
cytosolic Ca2+, SERCA contributes to at least 40% of O2 consumption
35. Phos-
pholambin and sarcolipin are understood to be direct regulators of SERCA36, 37.
Within the SR, CsQ acts as a Ca2+ buffer by binding to it, which reduces the
‘workload’ of SERCA by lowering the Ca2+ concentration of the SR.
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Figure 1.3: Schematic representation of RyR1 and its interacting proteins and lig-
ands, as well as its post-translational modifications
The dihydropyridine receptor (DHPR), which transverses the sarcolemma, signals ryanodine
receptor 1 (RyR1) opening by a conformational change upon recognition of an action poten-
tial3, 4. Stac3 associates with DHPR and may be necessary for correct ECC5. JP-45 assists
with the functional interaction between DHPR and RyR16, and may also associate with calse-
questrin (CALSQ) to provide cross-talk between the ECC molecular machinery and sarcoplas-
mic reticulum (SR) Ca2+ levels17. Calmodulin (CaM) and CALSQ regulate RyR1 in response
to Ca2+ concentrations of the cytoplasm and sarcoplasmic reticulum (SR), respectively9, 10, 12.
S100A1 is a Ca2+-binding protein which regulates RyR1 activity by modulating CaM’s binding
to RyR111. Junctin and triadin are SR membrane-bound proteins which modulate the ac-
tion of CALSQ13, 14, 15, 16. Expression of two different Homer 1 isoforms differentially regulate
RyR1 in a dose-dependent manner18, 19, 20. FKBP12 may stabilise both the open and closed
RyR1 channel state21, 22. FKBP12 binding occurs in RyR1’s dephosphorylated state23: protein
kinase A (PKA) phosphorylates RyR1 in response to increases in cyclic AMP (cAMP) concen-
tration23. Redox state-dependent PTMs of RyR1 are S -nitrosylation (S -n), S -oxidation (S -o),
S -palmitoylation (S -p) and S -glutathionylation (S -g) which allow RyR1 to be regulated by
pO2 of the myocyte
25, 26, 27. ATP, Mg2+ and Ca2+ are allosteric effectors of RyR129, 30, 31, 32.
Image is adapted from Sophie Burling with permission33.
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1.1.4.1 Store-operated calcium entry
Store-operated Ca2+ entry (SOCE) is responsible for the replenishment of SR
Ca2+ stores through entry of extracellular Ca2+. In SOCE, the protein stromal
interaction molecule 1 (STIM1) senses and responds to decreasing Ca2+ levels of
the SR lumen by translocating to the junction of the SR and PM, triggering the
tetramerisation of Orai1, producing a functional Ca2+ channel which transverses
both the PM and SR membrane and works to pump Ca2+ into the SR38.
1.1.4.2 Calcium channels of the plasma membrane
A number of PM Ca2+ channels function to control Ca2+ flux between the
cytoplasmic and extracellular spaces. NCX is a Na+/Ca2+ antiporter which rec-
tifies Ca2+ gradients during action potential generation through Ca2+ export39.
The active transporter PMCA is also a Ca2+ export channel of the PM responsi-
ble for maintaining low cytoplasmic Ca2+ 39. TRP (transient receptor potential)
channels also contribute to Ca2+ homeostasis. This diverse family of cation chan-
nels mediates signalling events by flow of cations in response to a wide range of
stimuli. TRPs are present within the PM and SR of skeletal muscle, with the
subfamilies TRPC and TRPV being selective for Ca2+ 40. Channels may be
activated by temperature and certain ligands. Although the extent of the TRP
channel’s contribution to Ca2+ homeostasis within skeletal muscle is not currently
fully understood, TRPC isoforms may significantly contribute to abnormal Ca2+
influx in the muscle disorder Duchenne muscular dystrophy41.
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Figure 1.4: Schematic representation of ion channels contributing to Ca2+ home-
ostasis within the myocyte
Ca2+ is represented as blue circles; arrows represent direction of ion movement. Muscle con-
traction results from the generation of an action potential triggered by a nerve stimulation
event. The action potential travels down transverse-tubules (T-tubule), invaginations of the
sarcolemma. The dihydropyridine receptor (DHPR) responds to this by undergoing a confor-
mational change. Physical coupling between DHPR and ryanodine receptor 1 (RyR1) leads to
RyR1 channel opening which results in a passive flow of Ca2+ from the sarcoplasmic reticulum
(SR) into the cytoplasm, where Ca2+ initiates muscle contraction through binding to troponin.
Sarco/endoplasmic reticulum Ca2+ ATPase (SERCA) actively pumps Ca2+ back into the SR34.
During prolonged muscle contraction SERCA Ca2+ transport alone cannot replenish SR Ca2+
stores and so the store-operated Ca2+ entry (SOCE) pathway, which involves the proteins stro-
mal interaction molecule 1 (STIM1) and Orai1, is activated to allow extracellular Ca2+ uptake
directly into the SR38. Ca2+ plasma membrane channels NCX and PMCA mediate Ca2+
transport over the plasma membrane (sarcolemma) in response to action potential generation
and to ensure optimal Ca2+ levels are maintained within the cytoplasm39. Transient receptor
potential channels (TRPC), of which there are a number of isoforms, are understood to uptake
Ca2+ in response to a variety of signals and stimuli40. Original artwork.
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1.2 Malignant hyperthermia: A pharmacogenetic
disorder of muscle
Volatile anaesthetic drugs are given routinely for surgery and are generally
considered safe. However, a person susceptible to the genetic disorder malignant
hyperthermia (MH) is at risk of a hypermetabolic episode triggered by certain
potent volatile anaesthetic agents42. An MH episode is life-threatening and must
be treated immediately to prevent death. Secondary complications, such as rhab-
domyolysis (breakdown of protein) leading to kidney failure, may occur. Drugs
that may induce an MH episode in susceptible individuals are volatile anaesthetic
compounds, including halothane and sevofluorane, as well as the depolarising
muscle relaxant suxamethonium42. Non-volatile anaesthetic drugs should not
trigger an MH episode in susceptible individuals. MH-susceptible (MHS) indi-
viduals are usually asymptomatic, although exercise- and heat-induced MH-like
episodes have been reported43. An MHS individual may not react to general
anaesthetics in the first instance: Several surgeries may be uneventful before an
MH episode occurs42.
An MH episode presents as muscle rigidity, increased CO2 production, ele-
vated blood K+, hyperthermia and tachycardia42. On a cellular level, these symp-
toms are understood to be caused by dysregulation of Ca2+ homeostasis within
myocytes42. This causes persistent muscle contraction, leading to sustained heat
production and excess CO2 production through oxidative metabolism. Deple-
tion of ATP stores causes breakdown of myocytes, leaking K+ and proteins into
the bloodstream, with the latter causing rhabdomyolysis. Dantrolene is the only
known effective treatment against a suspected MH episode as it is an antagonist
of the Ca2+ release channel of myocytes, RyR142.
1.2.1 The genetics of malignant hyperthermia
MH is understood to be inherited in an autosomal dominant manner. Initial
genetic work established that in some families MH-susceptibility was linked to
chromosomal segment 19q12-13.1 (MHS1 locus), containing the gene RYR1 44.
Since then, according to European Malignant Hyperthermia Group (EMHG)
guidelines, 48 variants § of RYR1 have been accepted as pathogenic for MH45,
§accepted EMHG variants available at https://www.emhg.org/diagnostic-mutations
Hopkins et al.45 contains EMHG guidelines for the acceptance of an MH-pathogenic variant.
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with many more identified RYR1 variants thought to be associated with MH-
susceptibility. Aside from the MHS1 locus, other loci have been associated with
MH-susceptibility: MHS2 (17q11.2-q24)46, MHS3 (7q21-q22)47, MHS4 (3q13)48,
MHS5 (1q32)49 and MHS6 (5p)49. But only the MHS5 locus, which harbours the
gene CACNA1S (encoding DHPR subunit Cav1.1), has been conclusively linked
to MH-susceptibility. Cav1.1 directly interacts with RyR1
50. Two CACNA1S
variants have been classified as pathogenic for MH by the EMHG, with a number
of other variants suspected to be pathogenic51, 52.
Over 50% of MH-susceptible families harbour a pathogenic RYR1 or CACNA1S
variant. A variant within the gene of the DHPR regulatory subunit, β1a, has
been linked to MH-susceptibility but is not currently accepted by the EMHG as
pathogenic for MH53. MH has also been linked to another gene, STAC3, encod-
ing the DHPR-associated protein Stac3: the variant is thought to cause Native
American myopathy which predisposes sufferers to MH-susceptibility54. The ge-
netic cause of MH in other families is currently unknown. If a genetic variant
is suspected of being pathogenic for MH-susceptibility, segregation analysis is
carried out to see if the variant follows the MH-susceptibility trait within a fam-
ily. If segregation is established, a cohort of MH negative (MHN) individuals
are then tested for the variant. If the variant is not present in any MHN indi-
vidual, the variant is functionally characterised if possible. For RYR1 variants,
Ca2+-release assays are carried out using mammalian cells transfected with RYR1
cDNA containing the variant of interest55, 56. Hypersensitivity of the RyR1 chan-
nel to RyR1 agonists can confirm that the suspected variant is likely to lead to
an MH-susceptible phenotype. At present, these Ca2+ release assays have not
been successfully carried out on other genes of interest to MH research due to the
difficulty in culturing myocytes which act functionally the same as in vivo.
Prevalence estimates of MH vary, and depend on the manner in which the
disorder’s presence is defined. MH-pathogenic variant prevalence is estimated at
around one in 800 individuals57, whereas the actual number of suspected MH
episodes may be between one in 10,000 to 250,000 anaesthetics58, 59. Of course,
due to the genetic nature of the disorder, there are MH ‘hot spot’ regions. For
example, in Palmerston North, New Zealand, approximately one in 175 persons
receiving general anaesthetics are treated as MH-susceptible due to the presence
of a few very large founder families within the region.
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1.2.2 Testing for malignant hyperthermia
The current accepted, gold-standard diagnostic method for MH is the in vitro
contracture test (IVCT). The IVCT involves exposing a sample of skeletal mus-
cle tissue taken from the quadriceps muscle of a patient, approximately 4 cm
long and 1 cm deep, to increasing concentrations of contracture-triggering agents
halothane and caffeine60. The contractile response of the muscle tissue to these
triggering agents is subsequently measured; a positive IVCT result is recorded
when a specific contractile response occurs above a threshold concentration of
halothane or caffeine. Contractile response is measured in grams of force. A per-
son with a positive IVCT result for both caffeine and halothane is labelled MHShc
(from here also referred to as MHS), whereas a positive test for only halothane
or caffeine is termed MHSh or MHSc, respectively. However, the latter two are
treated as an MH-susceptible diagnosis for clinical purposes and as such should
not be given MH-triggering anaesthetics. A person with a negative IVCT test
result is labelled MHN and can safely receive volatile anaesthetic agents.
1.2.2.1 Threshold contracture values
The threshold values for caffeine and halothane can differ among IVCT test-
ing facilities because each facility has their own ‘in-house’ controls61. For nega-
tive (MHN) controls, facilities perform the IVCT on leftover muscle from ortho-
pedic surgeries on individuals with normal, non-MH-like anaesthetic responses.
Therefore the corresponding contracture values for individuals diagnosed as MHS,
MHSh, MHSc and MHN may differ. With this being said, in Australia, contractile
responses of over 0.2 g for halothane and caffeine are diagnosed MHS45. In New
Zealand, this threshold is 0.4 g for halothane and 0.2 g for caffeine61. IVCT re-
sponse values at or near these thresholds are regularly referred to as ‘borderline’,
and due to the potential for variability in IVCT result diagnoses between testing
facilities, these values could be described as falling within an IVCT contractile
response ‘grey area’. This has important implications for the identification of
MH-pathogenic variants within a family due to the possibility that an individ-
ual diagnosed as MHS with borderline IVCT values may not actually harbour a
variant pathogenic for MH.
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1.2.2.2 Limitations of the IVCT
The IVCT is both costly to the healthcare system and invasive to the patient.
Perhaps its largest flaw is that it has a relatively low specificity rate (the rate at
which MH negative individuals are labelled MH-susceptible), estimated at 6%62.
This low specificity ensures that MHS individuals are not misdiagnosed, as with it
comes a very high sensitivity rate (the rate at which MHS individuals are labelled
MHN) of <1%62. One major goal of MH research is to find a more effective
diagnostic test; determining the genetic cause of MH may allow the IVCT to be
superseded by DNA-based diagnostic methods. Unfortunately, misdiagnosis of
MH-susceptibility due to the inaccuracy of the IVCT is likely to be hindering
efforts to identify the genetic cause of MH.
1.2.3 The current biochemical understanding of malig-
nant hyperthermia
It is well established that MH is caused by abnormal and excessive Ca2+
release from the SR. There is a loss of normal Ca2+-release negative feedback
regulation. This is caused specifically by volatile anaesthetic agents, and addi-
tionally by the PM depolarising muscle relaxant suxamethonium. It is obvious
that an understanding of the mechanism of action of these pharmaceutical agents
would help to understand the pathomechanisms of MH. Unfortunately, the mech-
anisms of action of volatile anaesthetics are currently mostly unknown. More is
known about the effect of suxamethonium however: It competes with ACh for
binding to the ACh receptor at the synaptic cleft of the myocyte. Normally,
acetylcholine is released from the receptor upon binding and quickly hydrolysed,
allowing another successive round of acetylcholine release from the motor neuron
and binding to the receptor. However, suxamethonium is not hydrolysed and
has an extended effect, disallowing repolarisation of the myocyte to occur. How
exactly suxamethonium action causes RyR1 channel opening is unknown. What
is known is that RYR1 variants that have been functionally characterised in vitro
as well as ex vivo using patient tissue samples cause a destabilisation of the RyR1
closed channel state, making RyR1 hypersensitive to activation upon exposure to
triggering agents56, 55, 42.
Based on what is known about MH aetiology, it is plausible that unknown
MH-pathogenic variants will be present within genes encoding proteins with a role
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in ECC. The variant could lead to a dysfunction of the protein, causing RyR1
hypersensitivity. Although suspicion has long been cast on genes with a role in
ECC, currently no variants of these genes other than those falling within RYR1,
CACNA1S and STAC3 have been linked to MH. Interestingly, the role of the
protein Stac3 was only recently identified, suggesting that there could certainly
be other currently unknown proteins important for ECC and/or RyR1 regulation.
These could themselves be core components of the ECC multi-protein complex or
direct RyR1 modulators, but alternatively could be important for the functional
expression of ECC components or RyR1 modulators.
There are a number of other possibilities. It could be that an unknown MH-
pathogenic variant falls within a gene encoding a protein involved in the PTM of
RyR1, either directly or indirectly. Acute or chronic alterations in Ca2+, redox
or energy states may lead to PTMs of RyR1. Incorrect PTM of RyR1 could
cause the channel to become hypersensitive. Alternatively, the pathogenesis may
involve another myocyte Ca2+ channel or a protein involved in the regulation of a
Ca2+ channel. As there is much to be understood about MH, and there are many
families with yet-to-be discovered MH-pathogenic variants, these possibilities,
and others, will have to be explored if the cause of MH is to be fully understood.
1.2.4 Malignant hyperthermia and other diseases
There are well-established links between MH-susceptibility and a number of
muscle diseases (myopathies). The most closely coupled to MH-susceptibility is
central core disease (CCD), a non-degenerative myopathy causing muscle weak-
ness and MH-susceptibility63. It presents histologically as muscle fibres contain-
ing ‘cores’: Regions with reduced mitochondrial activity spanning longitudinally
down the muscle fibre63. RYR1 variants are most commonly the cause of CCD64.
However, these variants have been characterised as leading to ‘leaky’, rather than
hypersensitive, RyR1 channels, whereas MH-pathogenic RYR1 variants are char-
acterised as hypersensitive and sometimes leaky65, 66. ‘Leaky’ variants lead to a
constant leak of Ca2+ which is thought to cause muscle weakness due to a decrease
of Ca2+ in the SR.
Other myopathies which may predispose individuals to MH-susceptibility are
King-Denborough syndrome, multi-minicore disease and central nuclear myopa-
thy, with RYR1 variants also being linked to these disorders67, 68, 69, 70.
Tubular aggregate myopathy (TAM) is a disease which is characterised by
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atrophy of type II muscle fibres and formation of tubular aggregates histologically
visible under the microscope. TAM sufferers may be at risk for MH71. TAM has
been linked to STIM1 gain-of-function mutations which lead to constitutive flow
of extracellular Ca2+ into the SR72, but it is currently unclear how this leads to
the TAM phenotype.
MDMA-induced hyperthermia is an abnormal, often lethal metabolic episode
triggered by 3,4-Methylenedioxymethamphetamine (MDMA) which has symp-
toms mirroring those of an MH episode: muscle contraction, metabolic acidosis
and rhabdomyolysis73. Importantly however, the mechanism by which MDMA-
induced hyperthermia is triggered is thought to differ from MH: It has been
hypothesised that it is mediated by a hypothalamic response which releases nore-
pinephrine and by an increase in thyroid hormone, both triggered by MDMA,
which leads to hyper-activation of the myocyte mitochondrial uncoupling-protein
3 (UCP3)74, 75, 76. UCP3 mediates passive proton leakage across the inner mi-
tochondrial membrane causing a futile cycle which expends ATP and produces
heat, causing the symptoms of an MDMA-induced hyperthermia episode74. De-
spite this, the similarity between the conditions is certainly noteable.
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1.3 Whole exome sequencing for the discovery
of disease-causative genetic variants
Improvements in the quality and affordability of next-generation sequencing
(NGS) methods have rapidly changed the way in which genetic diseases are re-
searched. When trying to identify the cause of a heterogeneous genetic disease
or a genetic disease with unknown aetiology, NGS is now often carried out in the
first instance. This has sped up the rate of discovery of previously-elusive causes
of genetic diseases77.
Currently, 1-2% of the human genome is thought to contain protein-coding
genes78; the remaining genome, aside from non protein-coding genes which play
important roles in the control of gene expression, is sometimes labelled as ‘junk’
DNA, although there is growing evidence that this DNA plays a vital role in chro-
matin structure and gene regulation79. It is believed that pathogenic variation
in the protein-coding regions (the exome) of the genome contributes to the vast
majority of genetic disorders.
1.3.1 The principle of whole exome sequencing
Whole exome sequencing (WES) is a targeted alternative to whole genome
sequencing (WGS) which involves capture and enrichment of the exonic genomic
regions prior to sequencing. To achieve this, biotinylated RNA or DNA probes
(also called baits) with sequences corresponding to exonic DNA sequences are
used to pull-down (capture) the exonic DNA from adaptor-ligated, fragmented
gDNA. This is followed by amplification using the polymerase chain reaction
(PCR) which results in a pool of DNA which should represent the known exome.
NGS methods are then applied to sequence the amplified exome. Other targeted
approaches to sequencing include gene panels, where probes corresponding to
specific target genes are used to sequence a more limited set of genes of interest.
Why is WES chosen over WGS? Although WGS allows examination of the
entire genome, there are two main reasons that WES is carried out as an al-
ternative to WGS for genetic disease studies: The first reason is that it is less
expensive, being approximately four-fold cheaper than WGS80; the second reason
is that only the region of the genome most likely to harbour pathogenic variation
is sequenced, creating much less data, meaning less computation time and anal-
ysis (which both come at a cost). Interpretation of variation within the exome
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is also considerably more manageable. Despite these reasons, studies have found
that WGS is better able to detect variation of the exome compared to WES81, 82.
However, these studies are not entirely relevant today due to improvements in
WES technology in recent years, with more recent studies suggesting that dispar-
ities between WGS and WES in terms of exome variant detection are minimal
and may constitute ≈ 1% of the human exome83, 84.
1.3.2 Weaknesses of WES
Although WES is often chosen in genetic disease research for the reasons
described above, it does have drawbacks. Any sequencing step which involves
capture and/or amplification of nucleic acid leads to the potential for sequenc-
ing bias, and this is certainly the case for WES. Allele distribution bias and
allelic dropout are seen in WES data due to both capture and PCR amplification
steps, which may prevent variant identification during computational processing.
For the capture step, both polymorphic and rare variation of the genome may
inhibit or completely prevent probe binding80, leading to hidden heterozygos-
ity or no sequence read data in the region containing variation. Due to PCR’s
inherent stochastic processes, the same loss of information may also be seen85.
Additionally, there is likely to be a prejudice in WES kit probe design against
less-represented genetic populations, especially indigenous populations. It has
been suggested that WES kit probes be designed to alternative haplotypes to
reduce this bias80. Extremes of GC (guanine/cytosine) sequences are problem-
atic for WES due to the necessity of PCR amplification80, 86, 82, 81. PCR also
reduces the ability to identify copy-number variation (CNV), however, a number
of programmes designed specifically to detect CNVs in targeted sequencing data
have recently emerged and are leading to improvements in the diagnostic yield of
WES87, 88.
Overall, it is evident that if cost and computational resources are not factors,
WGS is a better option. But currently, WES is the preferred option for genetic
disease studies. As WGS becomes more affordable and the necessary computa-
tional infrastructure more accessible, WGS will undoubtedly become the norm.
Indeed, although there is currently incentive for genetic disease researchers to
choose WES over WGS, this could be preventing important advancements in the
understanding of genetic disease caused by non-coding variation or CNVs.
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1.3.3 WES kits
There are a number of commercially available WES kits (specific technologies
and probe designs used to carry out WES sequencing). The major WES kit man-
ufacturers are Nimblegen (now Roche), Illumina, and Agilent, producing SeqCap
EZ Exome Library (Nimblegen), TruSeq Exome Enrichment Kit (Illumina), Nex-
tera Rapid Capture Exome Kit (Illumina) and Sure Select Human All Exon Kit
(Agilent), respectively. These WES kits differ in their probe type, strategy of tar-
get capture, and genomic target regions89, making some better suited for certain
research applications. For example, Agilent’s Sure Select Human All Exon Kit
uses RNA probes approximately 120 nucleotides in length which bind to the tar-
get adjacent to one another, whereas Nimblegen’s SeqCap EZ Exome Library kit
uses higher-density, variable-length DNA probes which overlap against the target
region86. As summarised in Warr et al. (2015)89, these distinctive approaches of
exome capture culminate in different strengths and weaknesses of each kit. For
example, Agilent’s design is superior for small indel (insertion/deletion) detection,
whereas Nimblegen tends to capture more SNVs (single nucleotide variants)90.
Additionally, the WES kits are designed using different transcriptome databases:
as discussed in Section 1.4.4, there is no clear consensus on what constitutes the
human exome. This means that the genomic target regions of WES kits differ,
resulting in variants that will be detected by some kits but not others90. It is
important to note that the research presented by Chilamakuri et al.90 in 2014
is likely outdated; more recent studies in this area were not identified. WES
kit designs have undoubtedly changed and improved, and indeed the data pre-
sented in this thesis suggests that (see Chapter 3.2.2). However, it is important
to acknowledge the differences in WES kits, especially if WES data from multiple
WES kits will be pooled together in a genetic disease study.
1.4 Bioinformatic tools for variant discovery
With an increase in the ability to perform NGS has come a substantial increase
in the volume of NGS data, and with this has come a vast number of tools to
analyse these data. Although there are commercial options available, many tools,
or programmes, are freely available for each step of NGS data processing. Here,
the general computational steps involved in a bioinformatic pipeline for variant
discovery in genetic disease research will be explained, and a selection of these
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freely available tools will be presented and discussed.
1.4.1 Pre-processing of reads
Raw sequence read data is trimmed to remove adaptor sequences and, if ap-
plicable, de-multiplexed to remove sample-specific sequence tags. This is followed
by performing quality-control on the reads, which involves removing reads that
do not meet pre-defined criteria in terms of read quality. This results in two (if
paired-end sequencing has been carried out as is often the case) analysis-ready
fastq files per sample. Fastq files also contain encoded information, obtained from
the sequencing machine, about the quality of each called nucleotide.
1.4.2 Sequence alignment
Sequence alignment (also called mapping) is carried out to align the reads
from the fastq file to a reference genome sequence. This results in a bam file,
which contains binary information about which position of the reference genome
(if any) each sequence read from the fastq file has aligned to. Bam files also
encode mapping quality scores, which give an indication of the likelihood that
each read has been mapped to the genomic position from which it originated.
Coverage statistics may be calculated using bam files. Coverage is defined as the
number of reads aligned to a given base or genomic region. The term coverage
is synonymous with read depth, or depth. Coverage can provide an indication of
the success of sequence alignment, and by extension, the quality of NGS data91.
There are two main sequence alignment programmes commonly used for hu-
man NGS data: BWA-MEM92 (burrows-wheeler aligner) and bowtie293. These
programmes differ in the algorithms that they employ to carry out sequence
alignment. BWA-MEM is designed for short-read alignment of sequences of high
similarity, such as in the case of human sequence reads against the human refer-
ence genome, and is a popular choice of aligner for WES92.
1.4.2.1 Human reference genome
Since the human genome was first sequenced, there have been multiple re-
leases of the human reference genome. Hg38, released in 2013, is the current
human reference genome major release. It is beneficial to use the most recent
release as it constitutes the most current understanding of the sequence of the
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human genome. Hg38 includes alternative loci in genomic regions of high vari-
ability between individuals and populations. Despite this, the previously released
reference genome, hg37, is still in use today, as many tools and programmes are
only compatible with hg37.
1.4.3 Variant calling
Variant calling involves making inferences about the presence of a variant
based on mismatches between sequence reads and the reference genome. Vari-
ant calling programmes ‘call’ a variant by taking into account the quality of
the sequence read data, the mapping quality scores, and the proportion of reads
containing the mismatch. A list of called variants is given, along with a ‘confi-
dence’ score (quality score) representing the probability that the variant is actu-
ally present, in the form of a VCF (variant call format). Variants can be filtered
based on this quality score. This is termed hard filtering, as it involves applying
a threshold to remove variants that do no meet a certain quality score. Applying
hard-filtering to remove false-positive variants will come at the expense of losing
true variants, and so the thresholds applied in hard filtering are dependent on the
purpose of the study. For example, it may be beneficial to have a low stringency
when searching for disease-causative genetic variants to ensure variants of interest
are not missed.
Current popular variant callers include the Genome Analysis Toolkit (GATK)
HaplotyperCaller94, Strelka295, Samtools96 and FreeBayes97. Because these pro-
grammes differ in their method of variant calling, there is some lack of concor-
dance between them, with some outperforming others in certain areas98, 99, 100.
For example, GATK HaplotyperCaller has been found to be superior for indel
identification, but has under-performed in SNV identification when compared to
Samtools100, 99 and Freebayes99. Despite this, GATK HaplotypeCaller appears to
be the most popular variant calling platform for WES studies currently. Strelka2
is a relatively recent programme, released in 2018, which is suggested by the
developers to outperform GATK HaplotypeCaller in terms of both speed and
variant calling accuracy95. A recent comparison of these two variant calling plat-
forms drew the same conclusions94. Overall, it is important to understand that
variant calling platforms may yield different results with the same data, and as
suggested by O’Rawe et al. (2013)98, it may be beneficial to use multiple variant
calling pipelines to reduce the chance of missing a disease-causative variant.
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1.4.4 Variant annotation
Following variant calling, variant annotation is carried out to predict the effect
that a variant may have, in turn allowing variants to be prioritised. Broadly,
there are two types of variant annotation: the first and more fundamental type is
categorisation; and the second is functional effect prediction. Both of these will
be discussed.
1.4.4.1 Variant categorisation
Variant categorisation involves identifying whether a variant falls within a
known or predicted gene, and whether it is predicted to change the gene’s en-
coded product or expression of the gene (e.g. exonic, intronic, missense, nonsense,
synonymous, splice-site acceptor, etc.). Categorisation of a variant is of course
reliant on what is known of the set of human genes and the human transcrip-
tome. There are two widely used datasets which contain a collection of known
or predicted genes and transcripts: Ensembl101 and RefSeq102. Although these
datasets contain many of the same genes and transcripts, they differ to a sig-
nificant extent. These differences can be attributed to the level of stringency
applied by Ensembl and Refseq to accept a predicted gene or transcript into the
dataset. Although Refseq is a smaller dataset than Ensembl, it is not simply a
subset of the Ensembl dataset103. An important study highlighted the somewhat
extreme effect these differences can have on variant categorisation. The research,
which analysed the outcome of variant categorisation using both Ensembl and
Refseq datasets, found only 44% concordance in predicted loss of function (LOF)
variants103, which are of great interest in genetic disease research.
Popular variant annotation software includes ANNOVAR104, Variant Effect
Predictor (VEP)105 and SnpEff106. These programmes apply both categorisation
and functional effect prediction annotations to variants. As well as the differences
found between transcript datasets, McCarthy et al.103 found significant differences
in annotations applied to variants when comparing ANNOVAR and VEP.
1.4.4.2 Variant functional annotation
There are multiple types of variant functional annotations. A common type of
annotation is to determine a variant’s frequency within the general population, or
subsets of the population. This is termed the allele frequency (AF). There are a
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number of databases containing human AFs including 1000 Genomes107 and gno-
mAD108 (genome aggregation database). Currently, the largest of the common
databases is gnomAD, with 140,000 human genomes and exomes. Using the AF
in genetic disease studies can be a powerful method to filter variants: when the
gnomAD database was initially released, it was determined that 90% of variants
previously reported to be likely-pathogenic by genetic disease researchers were
present at frequencies too high to be causative of genetic disease109. However,
although the AF can help to rule out variants unlikely to be causative of a rare
genetic disease, it is not possible to determine a variant’s likely pathogenicity
based on an AF alone. This is because the majority of variants identified in hu-
man NGS experiments will be rare (defined as < 0.5%)110. In most AF databases
including gnomAD, variant data is obtained from individuals who do not suffer
from disease. However, it is possible that data from individuals with an undiag-
nosed genetic disorder, such as MH-susceptibility, may be present. Often these
databases, as in the case of gnomAD, have AFs for ethnicity-specific subsets of
variant data. Currently, European individuals are over-represented in the data.
Noteably, AFs are not presented for Māori and Pacific Islander populations, likely
owing to a lack of genomic data collected from these populations. This has impli-
cations for genetic disease research in New Zealand as variants which are common
and non-pathogenic within individuals from Māori and Pacific Islander popula-
tions may appear novel or very rare in AF databases, which may mislead research
directions. There is potential for greater representation of other populations; re-
cently, the GenomeAsia 100K Project was launched, with plans to sequence a
large number of genomes from Asian populations111.
A more intricate but highly useful functional annotation is pathogenicity pre-
diction (prediction of deleteriousness), for which there are many types. Predic-
tions may be based on the conservation of a nucleotide or amino acid sequence
at the variant position between species or amongst human genomes, the amino
acid change, or in silico protein structural predictions. More recently, ensemble
methods of pathogenicity prediction, which gather predictions from a range of
tools, combining the power of the aforementioned pathogenicity prediction types
as well as AFs, have become more popular. Commonly used ensemble tools in-
clude CADD112 and REVEL113. CADD combines 60 different pathogenicity tool
annotations into a single ‘CADD score’. CADD scores are derived in the fol-
lowing manner: Using pathogenicity annotations, all possible SNVs within the
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human genome are ranked against one another from least likely to be pathogenic
to most likely. Raw rankings for all SNVs are then scaled and normalised to all
other SNV scores to obtain scaled scores which represent the estimated deleteri-
ousness relative to all other potential SNVs. For example, a score of 10 means
the SNV is in the top 10% of SNVs, a score of 20 within the top 1% of SNVs,
a score of 30 in the top 0.1% of SNVs, and so on. Often, a CADD score of over
15 is classed as being potentially pathogenic114, but there is no strict definition.
REVEL combines 13 different pathogenicity tool annotations113; it differs from
CADD in that the developers focused on combining pathogenicity prediction an-
notations adept at sorting rare neutral variants from rare deleterious mutations.
Their own benchmarking suggested REVEL to be superior to CADD and other
prediction methods for identifying pathogenic variation113. Another recent study
confirmed this finding but also determined that CADD tends to have a higher
sensitivity (ability to identify truly pathogenic variants) compared to REVEL and
other pathogenicity prediction tools115. One study which compared pathogenic-
ity predictions of known MH-pathogenic variants found that CADD identified all
known MH-pathogenic variants as likely pathogenic (using a CADD score cut-off
of 15) although it had very low specificity compared to other tools tested114. It
is important to note that pathogenicity predictions may be useful for the priori-
tisation of variants but cannot be relied upon to determine whether a variant is
pathogenic or not.
Annotation of gene function is also useful. Gene Ontology (GO)116, 117 terms,
which give information about gene function, can be applied to variants. Similarly,
Online Mendelian Inheritance in Man (OMIM)118 is an online database contain-
ing useful information about human genetic disease and genes linked to genetic
disease. OMIM accessions can be applied to variants to identify whether the gene
has been previously associated with genetic disease.
dbSNP119, a public archive of all known human genetic variation, can be used
to determine what is known about an identified variant. Each variant present in
this database has a dbSNP identifier which can be used to quickly determine the
AF of a variant and whether the variant has previously appeared in the scientific
literature.
To determine whether a gene is expressed in tissues of interest, gene expres-
sion databases are available. These include GTEX120 and the Human Protein
Atlas121. The Human Protein Atlas provides GTEX expression data as well as
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its own expression data. Gene expression data must be used with some caution
however. For example, a search for the gene encoding FKBP12 (FKBP1A) on
the Human Protein Atlas suggests that there is very low, or no expression, of
this gene within skeletal muscle. Yet this protein has a well-defined role in RyR1
modulation within skeletal muscle21, 22. Additionally, genes expressed early in
muscle differentiation won’t necessarily be expressed in a mature myocyte. Yet
this does not preclude the gene from being of interest to a muscle disorder, as
it is possible that a variant in a gene involved in muscle maturation could be
pathogenic to the mature myocyte. As an example, the protein Dusp4 has re-
cently been found to be implicated in correct muscle differentiation122, yet is not
expressed in mature skeletal muscle. If gene expression data were relied upon
absolutely when carrying out muscle disease research, a variant within the gene
encoding Dusp4 may be disregarded.
1.4.4.3 Variant filtering and prioritisation
Variants may be filtered based on variant annotation and other information,
such as the phenotype of individuals harbouring the variant. There are a num-
ber of programmes designed for filtering, such as Variant Annotation and Filter
Tool (VarAFT)123 and GEnome MINIng (GEMINI)124. VarAFT is a graphical
user interface programme whilst GEMINI is a command line programme, making
VarAFT more user-friendly for researchers not experienced with the command
line. Both of these programmes allow variant filtering based on an inheritance
model (e.g. autosomal dominant, X-linked recessive) as well as filtering based
on variant category, AF and pathogenicity prediction. VarAFT integrates gene
expression data from the GTEX database and KEGG125 to allow filtering based
on gene expressivity and function.
1.4.5 Detection of copy-number variation
In comparison to WGS, the ability to detect copy-number variation (CNV) us-
ing WES data is reduced due to the necessity of target capture. Target capture in-
creases the variability of coverage in WES, making it harder to determine whether
an exonic region with significant deviation from the mean coverage is actually the
result of a CNV. Nevertheless, there are a number of programmes designed to de-
tect CNVs using WES data. These include CNVkit126 and CODEX2127.
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1.4.6 Tool installation and use
The installation and use of many bioinformatic tools can be challenging, owing
to the fact that many of these require use of the command line. This is a major
hurdle for researchers, especially those who are not experienced with bioinformatic
analyses. Even for experienced bioinformaticians, installation of tools can be
difficult: One study found that up to 50% of randomly selected bioinformatics
tools were either difficult to install (could not be installed within 15 minutes)
or impossible to install (defined as not being installed within 2 hours)128. This
can mean that even if suitable bioinformatics tools are selected for a project,
installation may not be possible.
1.4.7 Which tools are best to use?
This review should make apparent the wealth of tools and resources available
for WES data analysis for the identification of variants of interest in genetic dis-
ease studies. There are also a large number of other popular tools which have not
been addressed here. Combinations of these tools result in an enormous number
of potential bioinformatic pipelines. Although research has been undertaken to
address which pipelines are superior for certain tasks, due to the ever-evolving
nature of bioinformatic tools and resources, this research is likely to be quickly
invalidated. If time and cost were no obstacle, the most effective option would
be to run WES data through a number of pipelines to reduce the risk of missing
a genetic variant causative of the disease in question. But as time and cost are
important considerations, small differences in the performance of WES kits and
bioinformatic pipelines may have to be disregarded, especially if difficulties in
tool installation and use are encountered for the chosen pipeline. However, there
are a number of easily implemented actions that may decrease the potential for
missing variants of interest. For example, the variant annotation and filtering
programme VarAFT, which uses ANNOVAR, applies both Ensembl and Refseq
annotations, which are known to differ significantly, to variants.
What is likely to be useful is the re-analysis of WES data as the disease in
question becomes better understood, and as more powerful bioinformatic tools
and resources become available. Confirming this, a recent study concerning rare
human genetic disease found that yearly re-analysis using the most recent bioin-
formatic resources and tools is diagnostically useful129.
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1.5 Project background
This project set out to determine the underlying genetic basis of MH in six
families. In these families, variants with potential to cause MH within genes
RYR1, CACNA1S and STAC3 had previously not been identified, or identified
variants had been ruled out as being the sole causative agent of MH. Previously
obtained WES data from each family was used in an attempt to identify variants
with potential to be pathogenic for MH.
1.5.1 Significance of study
Currently, the IVCT is the only available pre-symptomatic MH diagnostic
method for families where familial pathogenic variants have not been identified.
This method involves an expensive, time-consuming and potentially traumatic
muscle biopsy. Aside from the invasiveness of the procedure, the IVCT is not
considered completely specific, with a significant false-positive rate62. This means
that individuals may be falsely diagnosed with MH-susceptibility, potentially
leading to unnecessary future medical intervention. The overarching aim of MH
genetic research is thus to achieve a DNA-based diagnostic test, and this firstly
requires the identification of the pathogenic genetic variant in an MH-susceptible
family. Understanding of the genetics and biochemistry of the disorder may also
further understanding of myocyte physiology and biochemistry, as well as the
aetiology of muscle disease. Additionally, this project aimed to establish bioin-
formatic methods with the potential to identify genetic variants of interest within
families with MH. These methods could also be used for other complex genetic
disorders with currently unknown genetic origin.
1.5.2 Hypothesis of study
Rare genetic variation present within the exonic region of the genome, leading
to a protein sequence or protein expression change, is linked to MH-susceptibility
in each family under study.
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1.5.3 Aims of study
• To develop a bioinformatic pipeline that: efficiently processes whole exome
sequencing data to obtain genetic variants present within each family un-
der study; and enables effective and dynamic filtering and prioritisation of
variants of interest.
• To select candidate variants that may contribute to the presence of MH-
susceptibility in each family.
• To carry out genotyping within each family to establish whether there is a
correlation between a variant of interest and MH-susceptibility.
1.5.4 Assumptions of study
1.5.4.1 Cause of MH
In this study, it is assumed that the pathogenic genetic variant in each family is
present in the exonic region of the genome. Additionally, unless stated otherwise,
it is assumed that MH-susceptibility in each family is due to a single genetic
variant.
1.5.4.2 Accuracy of phenotypic data
One assumption is that the phenotypic data is accurate. To obtain pheno-
typic data for each individual, data transfer steps included manual recording to
an excel spreadsheet from a hospital database followed by handwritten recording
by the supervisor of this project. Handwritten records were then obtained and
recorded in a separate spreadsheet by the student conducting the research. This
was necessary for two reasons: Firstly, access to the MidCentral DHB database
is strongly restricted and does not allow mass information download; secondly,
these steps ensured decoupling of DNA numbers from individual identifying in-
formation. Although caution and accuracy was exercised during data transfer
and recording, each of these steps did increase the potential for human error.
Additionally, as discussed in Chapter 1.2.2, results of the IVCT cannot be
completely relied upon to distinguish actual MH-susceptible individuals from MH
negative individuals.
28 CHAPTER 1. INTRODUCTION
1.6 Families
The six families under study are labelled A, B, C, D, E and F. In all of
these families MH is inherited in an autosomal dominant manner. WES data
from MHShc, MHSh, and MHN individuals belonging to these six families were
obtained to try to identify a potentially pathogenic genetic variant. gDNA and
IVCT results were available for other individuals from these families, with the
exception of family F, allowing for segregation analysis on identified variants of
interest. Due to phenotypic complexities, variant analysis was carried out in
a unique and discretionary manner for each family. For example, some MHS
and MHN individuals obtained borderline IVCT values meaning it was consid-
ered possible they did not, or did, carry a pathogenic MH variant regardless of
their diagnosis. Additionally, some families suffer from a myopathy additional to
MH-susceptibility. For these reasons and others, the strategy for variant anal-
ysis was modified for each family accordingly (see Table 1.1). Each family and
their specific considerations are described in detail below. A table containing all
individuals for which WES samples were obtained, and their IVCT results, are
available in Appendix A.33.
Consideration Adaptation to general strategy
MHS IVCT result borderline or
MHSh/MHSc
These individuals may not carry a potentially pathogenic
variant
Presence of a known or sus-
pected MH-pathogenic variant
within RYR1 or CACNA1S
MHS individuals carrying these variants may not carry
the other potentially pathogenic variant
Presence of a myopathy Increases unknown variant’s potential to be present in
a gene which may not normally be considered to have
involvement in MH-aetiology
Large and branched family Increases the possibility of the presence of a second po-
tentially pathogenic variant
Table 1.1: Examples of the considerations taken with all families and consequently
the adaptations made to the general strategy of variant analysis
The general strategy of variant analysis for each MH family involves: retaining all variants
carried by MHS individuals and not MHN individuals; searching for variants within genes that
could conceivably play a role in RYR1 and/or ECC regulation, Ca2+ homeostasis or energy
metabolism within myocytes; and making the assumption that there is a single unknown MH-
pathogenic variant within the family.
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1.6.1 Family A
In this family the male proband (II-5, Figure 1.5) had a suspected MH reaction
following administration of volatile anaesthetic agents. IVCT results determined
the proband and others within the family to be MHS (Figure 1.5). Subsequent
analysis by DNA sequencing failed to identify a potential pathogenic variant in
RYR1, CACNA1S or STAC3.
1.6.1.1 Approach to variant analysis
WES data was previously obtained from five individuals, two diagnosed MHS
(II-2 & II-5) and three MHN (III-1, III-3 & III-4), corresponding to DNA num-
bers 1480, 1253, 1908, 1652 and 1653, respectively. The IVCT values for the MHS
individuals are above borderline, although the proband, AII-5, had relatively low
contracture values of 0.6 g and 0.4 g for halothane and caffeine, respectively.
gDNA from two other individuals, one MHS (II-3) and one MHN (III-2), cor-
responding to DNA numbers 1479 and 1576, respectively, was also available.
Variant analysis was carried out with the presumption that all MHS individuals
carried the unknown pathogenic variant and all MHN individuals did not carry
the pathogenic variant.










































































































1.6.2 Family B - A large kindred discordant for a pathogenic
RYR1 variant
This large, highly branched Māori family from the Manawatu region was the
first known MH family in New Zealand and has been the subject of ongoing study.
An RYR1 variant was originally identified and subsequently demonstrated to be
pathogenic for MH130. However, at least one other pathogenic variant is thought
to be present within the family due to discordance between the familial RYR1
variant and MHS. IVCT results and gDNA samples were available for over 120
individuals belonging to this family.
1.6.2.1 Pathogenic RYR1 T4826I variant
Initial investigation identified an RYR1 variant (NC 000019.10:g.38580094C>T,
dbSNP: rs121918595), Thr4826Ile (T4826I), now accepted to be MH-pathogenic
according to EMHG guidelines. Indeed, this variant is used as a positive control
in experimental studies carried out for MH research. Nevertheless, the family is
highly discordant for RYR1 T4826I: a large number of MHS individuals do not
harbour this pathogenic variant. Notably, MH-susceptibility isn’t linked to the
RYR1 gene 19q13.2 locus in the discordant branches of the family130, suggesting
the cause of MH is not due to an RYR1 variant for these individuals.
1.6.2.2 RYR1 I3253T variant of uncertain significance
An RYR1 variant (NM 000540.2:c.9758T>C, dbSNP: rs375626634), Ile3253Thr
(I3253T) protein coding change, was previously discovered in this family. Two
of the eleven family B individuals analysed through WES, 533 (VI-3, Figure 1.6)
(MHS) and 1731 (VII-1, Figure 1.6) (MHS), carry this variant. It is unknown if
this variant is causative of, or contributes to, an MH phenotype. It is possible
that it may be an MH-modifying variant, meaning it has the potential to modify
the effect of a second MH-pathogenic variant.
1.6.2.3 Approach to variant analysis
WES data was previously obtained from the gDNA of 10 individuals from
this family belonging to two familial branches separated by three generations
(Figure 1.6). Eight of these individuals are MHS (IV-2, DNA number 82; V-2,
DNA number 1412; V-7, DNA number 1772; VI-1, DNA number 1367; VI-3,
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DNA number 533; VI-5, DNA number 919; V-II, DNA number 1731), one MHSh
(V-4, DNA number 27) and one MHN (V-5, DNA number 26). However, due to
uncertainty about the phenotype of individual 26, this individual was assumed
to be of unknown phenotype throughout this project. One MHS individual, 82,
carries RYR1 T4826I.
Currently, little is understood of the MHSh phenotype, with few known MHSh
individuals carrying an RYR1 pathogenic variant. It is therefore possible that
MHSh individual 27 may or may not carry the MH pathogenic variant, and variant
analysis and filtering was carried out with this in mind. Additionally, because
MHS individual 82 carries RYR1 T4826I, they may not be a carrier of a second
suspected MH-pathogenic variant. However, this individual provides the familial
link between both branches of the family being studied through WES analysis and
so should carry a shared pathogenic variant. The other possibility is that there is
a third pathogenic variant in the family and that the two branches being studied
have both of these currently unidentified variants. Overall, these possibilities
paint a complex picture and resulted in an approach to variant analysis that was
modified from the general strategy. Individual 27 was not required to carry a
specific variant for that variant to proceed to the final list variants of interest.
Additionally, it was considered that individuals 1731 and 533 may not carry an
unknown MH-pathogenic variant because of the presence of the RYR1 I3253T
variant with unknown significance. Because there is some uncertainty of the
phenotype of individual 26, this individual was not used for segregation analysis,
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1.6.3 Family C - MH susceptibility with central core dis-
ease
In addition to MH-susceptibility, some individuals in this family suffer from
CCD (Figure 1.7). CCD phenotypic data was unavailable for most individuals
and is not given in the pedigree. One individual, III-7, is MHSh.
1.6.3.1 Approach to variant analysis
WES data was previously obtained from five individuals within the family,
two MHS (II-1, DNA number 1360; II-12, DNA number 1273) and three MHN
(II-4, DNA number 1928; III-2, DNA number 1474; III-4, DNA number 2338).
CCD is often associated with MH-susceptibility as judged by IVCT (see Section
1.2.4). The fact that MH-susceptibility may be secondary to the CCD phenotype
in this family broadens the spectrum of genes that may harbour a pathogenic
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1.6.4 Family D - discordant for a CACNA1S variant
A male proband (II-2, DNA number 1128) experienced an MH-like episode
following administration of general anaesthetics and was later diagnosed MHS by
IVCT. The IVCT determined a number of others in the family to be MHS or
MHSc (Figure 1.8).
1.6.4.1 CACNA1S T1009K variant
Previous WES analysis identified a CACNA1S variant, NM 000069:c.3026C>A
(dbSNP: rs200224590) with a predicted coding change threonine to lysine at
amino acid position 1009 (T1009K), which was found to have a degree of co-
segregation with MHS in the family (Figure 1.8). Noteably there is an individ-
ual, III-6, discordant for the variant for whom IVCT values are significantly above
borderline (1.9 g for halothane, 1.3 g for caffeine).
So far, the significance of this CACNA1S variant is unclear. The variant has
been found in a second MH-susceptible family for which no pathogenic RYR1
variant has been identified51, 52. It is predicted to be pathogenic by multiple
prediction algorithms (CADD score: 29.8), both due to its presence in a highly
conserved pore domain region of DHPR and the nature of the amino acid substi-
tution: An uncharged polar residue to a basic residue. However, due to current
limitations of experimental systems exploring functional consequences of vari-
ants that do not fall within RYR1, functional studies have not yet been reported
for CACNA1S T1009K. Overall, the variant is predicted to be likely pathogenic
using the American College of Medical Genetics and Genomics standard and
guidelines131.
1.6.4.2 Involvement of an unknown variant
The presence of individual III-6 discordant for CACNA1S T1009K suggests
that another as yet unknown MH-pathogenic variant may be present within the
family.
1.6.4.3 Approach to variant analysis
WES data was previously obtained from gDNA of four individuals including
the proband (II-2, DNA number 1128), two other MHS individuals (III-1, DNA
number BW1; III-3, DNA number 1172) and an MHN individual (III-2, DNA
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number 932). WES data from the discordant family member, III-6, was not
obtained. The presence of the CACNA1S T1009K variant raises the possibility
that an unknown pathogenic variant may not be carried by all MHS individuals
within the family, and consequently, variant analysis was modified accordingly.
It is possible that there is a variant pathogenic for MH in individual III-6, who
does not harbour the CACNA1S T1009K variant, and which is not carried by
other MHS individuals within the family. This would assume CACNA1S T1009K
is pathogenic for MH. As genotype filtering was carried out under the assump-
tion that all three MHS individuals, for which WES were obtained, harbour the
unknown MH-pathogenic variant, and WES data from individual III-6 was not
obtained, the variant will not be identified if this is the case. The halothane con-
tracture force recorded for individual III-3 (DNA number 1172), 4.2 g, is much
higher than other MH individuals within this family. If CACNA1S T1009K is
pathogenic, and there is another MH-pathogenic variant within the family, the
cause of this extreme halothane contracture value may be due to this individual
harbouring both MH-pathogenic variants. Nevertheless, WES data from individ-
ual 1172 was not studied alone due to time constraints and low WES data quality
(see Chapter 3.2.2).










































































































1.6.5 Family E - MH susceptibility and a myopathy
An MH-like episode was observed in the male proband (III-7, Figure 1.9) fol-
lowing administration of volatile anaesthetic agents for acute appendicitis and a
subsequent IVCT diagnosed the patient MHShc. The patient and other family
members (for which complete phenotypic data is not available) had been previ-
ously diagnosed with mild myotonic dystrophy type I (DM1); this was associated
with a DMPK gene CTG repeat expansion (87 repeats) present within the fam-
ily132, 133. Other family members have since been tested by IVCT, with both
MHShc and MHSh diagnoses in addition to MHN (Figure 1.9). The branch of
the family fathered by II-2 resides in Australia and thus DNA availability was
limited for these individuals.
1.6.5.1 RYR1 R1679H variant
An RYR1 variant (NM 000540.2:c.5036G>A, dbSNP: rs146504767), with pre-
dicted coding change arginine to histidine at amino acid position 1679 (R1679H),
was identified in the family (Figure 1.9). The variant has a strong degree of seg-
regation with MHS, however, it was disproven to be solely causative due to sub-
stantial discordance: individuals IV-1 and IV-4, MHSh and MHShc, respectively,
did not carry R1679H, whilst MHN III-5 did carry the variant. Nevertheless, in
vitro calcium release experiments using HEK293T cells transiently expressing the
variant revealed that it did confer a small yet significant increase in sensitivity to
RYR1 -channel agonist 4-CmC compared to cells expressing WT RYR1 (personal
communication, Professor K M Stowell, SFS, Massey University). Collectively,
these results indicate that the RYR1 R1679H variant may contribute to the pres-
ence of MH in this family, but it does not wholly explain it due to the discordance
between the variant and MH-susceptibility observed.
1.6.5.2 DMPK trinucletoide expansion
A DMPK CTG repeat expansion of greater than 34 is considered to be
pathogenic for DM1132. Pathogenic CTG repeat expansions were identified in
the proband of family E as well as other family members (Figure 1.9). Genetic
linkage exists between the repeat and the RYR1 R1679H variant due to the prox-
imal location of the genes on chromosome 19: DMPK is located at chromosomal
position 19q13.32, RYR1 at position 19q13.2, and so it is therefore not surprising
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to see segregation of the DMPK repeat and the RYR1 variant for all individuals
tested within the family.
1.6.5.3 Involvement of an unknown variant
DM1 is thought to have the potential to lead to abnormalities in Ca2+ home-
ostasis due to reported alternative splicing of RYR1 and ATP2A1 133. It is tempt-
ing to presume that this repeat variant, along with the putative disease-modifying
RYR1 variant, R1679H, explains the presence of MH in this family. However, the
presence of the CTG expansion and the RYR1 variant is not completely concor-
dant with susceptibility to MH, with MHN individual III-5 carrying 69 DMPK
CTG repeats and the RYR1 R1679H variant. Additionally, MHShc individual
IV-4 carries neither the DMPK CTG expansions or RYR1 variant. Overall, it
seems possible that the presence of a so far unknown variant may be the cause
of MHS in the family, with the potential that other variants, such as the RYR1
R1679H and DMPK repeat expansion, have a modifying effect.
1.6.5.4 Approach to variant analysis
WES data was previously obtained from individuals II-2 (MHS), III-8 (MHS,
DNA number 1247), IV-2 (MHS, DNA number MS1) and IV-6 (MHN, DNA
number 1680). It is important to note that although individual IV-2 has been
diagnosed MHShc through IVCT, the contracture values, 0.2 g and 0.3 g for
halothane and caffeine, respectively, are borderline, meaning a diagnosis of MHSc
may have been made in another IVCT testing facility. Conversely, individual IV-6
was diagnosed MHN although the IVCT contracture value for halothane was 0.2
g (0 g for caffeine), a level which may have constituted a diagnosis of MHSh in
another IVCT testing facility. Additionally, individual II-4 was diagnosed MHN
with contracture values of 0.2 g for halothane and 0.4 g for caffeine, certainly
classifiable as borderline. This is significant as it raises the possibility of an
MH-pathogenic variant being inherited maternally on the branch of the family
containing the proband. This would suggest the presence of a second unknown
MH-pathogenic variant on the other branch. Further WES were obtained from
individuals IV-4 (MHS, DNA number 44), III-7 (MHS, DNA number 2253), III-9
(MHS, DNA number 1379) and IV-7 (MHN, DNA number 2259).
Due to the complexity of family E’s phenotype and the variability of IVCT
results between individuals, variant genotype filtering (see Chapter 3.3.1) was
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adapted accordingly. For example, individual IV-2 (DNA number MS1) was not
required to carry a variant for the variant to proceed through the genotype filter
due the individual’s borderline IVCT values.
1.6.6 Family F
WES data was obtained from the gDNA of three MHS individuals (4003, 4004,
4005) from this Australian family. WES from MHN family members were not
available which eliminated the possibility of filtering variants by genotype with
the bioinformatic pipeline. Additionally, gDNA from other individuals within
the family was not available, limiting the opportunity to carry out segregation
analysis for any variants of interest. This meant that a higher burden-of-proof
was required to pursue a variant of interest due to the difficulty in obtaining
additional gDNA samples. Overall, these two issues culminated in a challenging
variant analysis task when compared to other families. A pedigree for this family
was not available.










































































































































































































































• 5x HOT FIREPol® Blend Master Mix Ready to Load with 7.5 mM MgCl2
(Cat. No. 04-25-00120), Solis BioDyne, Tartu, Estonia
• Gel Loading Dye, Purple (6X) (Cat. No. B7024S), NEB®, Ipswich, MA,
USA
• InvitrogenTM 1 Kb Plus DNA Ladder (Cat. No. 10787018), ThermoFisher
Scientific
• Wizard® Genomic DNA Purification Kit (Cat. No. A1120), Promega,
Madison, WI, USA
• Gentegra®-DNA (Cat. No. GTD4010-PBC), Gentegra®, Pleasanton, CA,
USA
• LightCycler® 480 High Resolution Melting Master (Cat. No. 04909631001),
Roche Diagnostics, Mannheim, Germany
• PerfeCTa® qPCR ToughMix® (Cat. No. 97065-958), QuantaBio, Beverly,
MA, USA
• FastStartTM Taq DNA Polymerase GC-RICH Solution 5x concentrated
(Cat. No. 12032902001), Roche Diagnostics, Mannheim, Germany
• LightCycler® 480 Genotyping Master (Cat. No. 04707524001), Roche
Diagnostics, Mannheim, Germany
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• ScrFI restriction enzyme (Cat. No. R0110S), NEB®, Ipswich, MA, USA
• 10x CutSmart® Buffer (Cat No. B7204S), NEB®, Ipswich, MA, USA
• LightCycler® 480 Multiwell Plate 96, white (Cat. No. 04729692001), Roche
Diagnostics, Mannheim, Germany
• ExoSAP-ITTM PCR Product Cleanup Reagent (Cat. No. 78200.200.UL),
Applied BiosystemsTM, ThermoFisher Scientific
2.2 Ethical approval
The Central Regional Ethics Committee and Ministry of Health (New Zealand)
ethics approval code is MWH/03/04/018. Patient approval was given to anal-
yse patient genetic data for MH-related research. Incidental findings were not
reported nor analysed.
2.3 Sterile water
Unless otherwise stated, all dH2O was Milli-Q
® filtered.
2.4 PCR amplification
Unless otherwise stated, all PCR reactions were carried out in the following
manner. A reaction mixture containing 4 µL 5x HOT FIREPol® Blend Master
Mix Ready to Load with 7.5 mM MgCl2, 1 µL each of 5 µM forward and reverse
primer, 14.5 µL dH2O, and 0.5 µL 50 ng µL
−1 gDNA was set-up on ice in a 0.2
mL PCR-tube. A thermocycler machine was used with the following conditions:
12 minutes 95 ℃; 30 cycles of 95 ℃ for 10 seconds, variable primer annealing
temperature for 30 seconds, 72 ℃ for 20 seconds; followed by 72 ℃ for 5 minutes.
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2.5 DNA agarose gel electrophoresis
Unless otherwise stated, DNA fragments were separated using 0.8% agarose
(for fragments > 0.3 kb) or 1% agarose (for fragments < 0.3 kb), TAE buffer (40
mM Tris-acetate, 1 mM EDTA, pH 8.0) and 0.2 µg mL−1 ethidium bromide. Six
x DNA Gel Loading Dye (NEB®, Cat. No. B7024S) was used, if the DNA did
not already contain HOT FIREPol®Blend Master Mix Ready to Load, to assist
with DNA loading and to visualise DNA migration. Approximately 200 ng of
DNA sample was loaded into each lane alongside 3 - 5 µL of 50 ng µL−1 1 Kb
Plus DNA ladder (InvitrogenTM). Electrophoresis was carried out in TAE buffer
at 100 V for 40 - 60 minutes in TAE and the resulting DNA bands visualised
using ultraviolet light.
2.6 DNA concentration measurements
The DeNovix DS-11 FX+ spectrophotometer (herein referred to as DeNovix)
was used to measure DNA concentrations by absorbance at 260 nm for both ds-
DNA and ss-DNA. Alternatively, DNA quantification was estimated by carrying
out agarose gel electrophoresis on DNA alongside a 50 ng µL−1 1 Kb Plus DNA
ladder (InvitrogenTM), which contains DNA fragments of known concentrations,
to aid in quantification.
2.7 Whole exome sequencing
2.7.1 Sample and library preparation
gDNA was extracted from patient muscle tissue or from whole blood.
2.7.1.1 Muscle tissue gDNA extraction
Approximately 150 mg of patient muscle tissue was obtained and frozen in
liquid nitrogen. The frozen tissue was ground into a powder using a steel mortar.
Six hundred µL nuclei lysis solution (Wizard® Genomic DNA Purification Kit)
was added to the powder and the solution was mixed with a glass homogeniser
followed by a 15 minute incubation at 65 ◦C. The solution was cooled to room
temperature and 200 µL protein precipitation solution (Wizard® Genomic DNA
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Purification Kit) was added to the solution and mixed using a vortex. It was
cooled on ice for five minutes and centrifuged at 9500 x g for four minutes. The
supernatant was transferred to a tube containing 600 µL isopropanol and mixed
gently followed by centrifugation at 9500 x g one minute. The supernatant was
removed and 100 µL of 70% ethanol was added followed again by centrifugation
at 9500 x g for one minute. The supernatant was removed and, following air
drying of the DNA pellet, 100 µL TE buffer was added for resolubilisation of the
DNA.
2.7.1.2 Whole blood gDNA extraction
gDNA was isolated from 3 mL patient whole venous blood using the Wizard®
Genomic DNA Purification Kit kit (Promega) according to the manufacturer’s
instructions.
2.7.1.3 gDNA quality control
The quality of extracted gDNA was assessed by two methods: DNA gel elec-
trophoresis and the DeNovix spectrophotometer. For DNA gel electrophoresis,
approximately 200 ng of gDNA was run on an agarose gel and analysed for mi-
gration distance, mass and degradation. For the DeNovix spectrophotometer, 1
µL of gDNA was loaded and A260/A280 ratio readings were obtained, with a ratio
of 1.7-2.0 indicating suitable gDNA quality.
2.7.1.4 gDNA preparation for shipment
For gDNA samples sent for MGI-sequencing (2019 samples), GenTegra®-
DNA was used for ambient temperature storage and transport of gDNA samples.
gDNA quality was analysed using the DeNovix spectrophotometer and by DNA
gel electrophoresis.
gDNA was diluted as necessary to a concentration of 50 ng µL−1 with TE
buffer. Following the manufacturer’s instruction, 20 µL of diluted DNA was
pipetted into the GenTegra®-DNA 0.5 mL tubes and mixed by pipetting to
achieve a final mass of 1 µg gDNA per sample. gDNA was dried using a Savant
SC100 SpeedVac machine.
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2.8 Genotyping methods
2.8.1 Sanger sequencing
To confirm the presence of a variant, Sanger sequencing was carried out
through the Massey Genome Service on 400 ng of purified (using ExoSAP-ITTM
PCR Product Cleanup Reagent (Applied BiosystemsTM) according to the man-
ufacturer’s instructions) PCR products using 4 pmol of primer (see Appendix
A.1 for primer sequences). Geneious® version 9.1.8 was used for computational
analysis of sequencing chromatrograms.
To confirm the presence of a variant, Sanger sequencing was carried out on
200 ng of PCR product with 4 pmol µL−1 primer through the Massey Genome
Service using BigDyeTM Terminator Version 3.1 chemistry on an ABI3730 DNA
Analyzer.
2.8.2 High resolution melting analysis
To perform high-throughput genotyping, high resolution melting (HRM) anal-
ysis was carried out. HRM analysis is a rapid and relatively inexpensive technique
which exploits differences in DNA melting behaviour of small amplicons which
differ by only a single base pair.
2.8.2.1 Principle of HRM
Fluorescent, saturating DNA binding dye is present within the HRM reaction
mixture to monitor DNA melting over a temperature range. PCR is initially
carried out to produce an amplicon (up to ∼100 bases) containing the position
of the SNV of interest. Melting curve analysis is then carried out. Firstly, the
temperature is increased for denaturation of the amplicon to occur, and then the
temperature is reduced so as to encourage the single strands to anneal (duplex for-
mation) even if there is a single nucleotide mismatch between two strands (which
occurs if there is a SNV present in a heterozygous state). Duplexes containing a
mismatch are referred to as heteroduplexes. For a heterozygous variant, there will
be populations of both homo- and hetero-duplexes present during melting curve
analysis. These two populations are detected as the temperature is increased as
they melt at different rates, therefore leading to differential fluorescence changes
when compared to reactions containing only homoduplexes. Homozygous SNVs
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can also be differentiated from wild-type amplicons as these homoduplexes will
melt at different rates. The results of melting curve analysis are presented in
the form of a graph with temperature on the x-axis and change in fluorescence
(465-510 nm)/time on the y-axis. A sample with a SNV will have a characteristic
heteroduplex double peak compared to a wild-type sample with a characteristic
homoduplex single peak. A sample with a homozygous SNV in a homozygous
state will have a characteristic shifted homoduplex single peak.
2.8.2.2 HRM assay method
HRM assays were carried out on a LightCycler® 480 Instrument (Roche).
This machine performs PCR followed by melting curve analysis of the produced
amplicon. Unless otherwise stated, HRM reactions were carried out in the fol-
lowing manner: Individual reactions containing 5 µL LightCycler® 480 High
Resolution Melting Master (Roche), 0.6 µL each of 5 µM forward and reverse
primer, 1.2 µL 25 mM MgCl2, 2.1 µL PCR-grade H2O and 0.5 µL of 50 ng µL
-1
gDNA or 0.5 µL PCR-grade H2O as a negative control. Each 10 µL reaction was
pipetted into a single well of a LightCycler® 480 Multiwell Plate 96 (Roche).
The following conditions were carried out on the LightCycler® 480 Instrument
II: 10 minutes 95 ℃ (initial denaturation); 45 cycles of 95 ℃ for 10 seconds (de-
naturation), variable primer annealing temperature (annealing) for 10 seconds,
72 ℃ for four seconds (amplification); and lastly for melting curve analysis, 95 ℃
(denaturation), 40 ℃ for 1 minute (amplicon annealing), and 76 ℃ for one second
at a ramp rate of 0.02 ℃ per second to 92 ℃, with 25 fluorescence acquisitions
taken for each ℃ increase. Control genotypes confirmed by Sanger sequencing
were assayed alongside unknown genotypes.
2.9 Bioinformatic pipeline
All sequence read data was obtained in the form of trimmed (removal of adap-
tor sequences required for sequencing) and de-multiplexed (removal of sample-
specific adaptor sequences) paired fastq files from the WES service provider.
Additionally, all read data obtained had been quality filtered according to the
specifications of the company.
All commands used in this project are given in the ‘scripts’ directory of the
following GitHub repository: https://github.com/sormond/Masters.
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Supplementary material for this thesis is given in the ‘supp material’ directory
of the above GitHub repository.
2.9.1 Alignments
Fastq files were aligned to the hg38 human reference genome using bwa92 mem
(version 0.7.17) to create sam alignment files (scripts/bwa samtools.sh)
Samtools96 (version 1.7) view, sort and index functions were used to convert
sam files into sorted bam files with an index file for faster computation (script-
s/bwa samtools.sh).
2.9.2 Marking PCR duplicates
Picard’s134 (version 2.8.1) MarkDuplicates was used to mark PCR duplicates
within the bam file (scripts/mark duplicates.sh).
This step was not initially a part of the pipeline but was added for the new
2019 MGI-sequenced WES for family B and E. The step was also carried out on
bam files for samples to be used for copy-number variant (CNV) detection prior
to CNV detection as this was required for the programme (see Section 2.9.8 and
Chapter 3.5). All WES samples within final family VCFs of families B and E
were obtained from bam files for which duplicates were marked, whereas WES
samples within all other family VCFs were not obtained from bam files for which
duplicates had been marked. For family B and E, due to the presence of MGI-
sequenced samples, the READ NAME REGEX flag of the MarkDuplicates tool
was set to null to avoid optical duplicate detection, which is only applicable to
Illumina-sequenced samples. This flag was applied to both MGI-sequenced and
Illumina-sequenced samples from these families for consistency.
2.9.3 Variant calling
The Genome Analysis Toolkit (GATK)135 (version 4.1.3.0) was used to call
variants. This process requires three tools: HaplotypeCaller, CombineGVCFs
and GenotypeGVCFs. HaplotypeCaller is used to create an initial intermediate
variant file, a gVCF, for each individual (scripts/variant calling gatk.sh). Then,
CombineGVCFs is used on these individual gVCFs to create a whole-family
gVCF. Lastly, joint-genotyping is carried out on each family with Genotype-
GVCFs.
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2.9.4 Variant annotation
SnpEff106 version 4.3t was used for variant categorisation annotation (script-
s/snpeff.sh). This annotation step was carried out as the subsequent ANNOVAR
annotation did not apply ‘Refseq’ accessions to the variants, which was necessary
for the addition of GO annotations (see Section 2.9.4).
VarAft123 version 2.16, also described in Chapter 3.3, was used to apply AN-
NOVAR104 and other functional effect annotations. VarAFT varied from other
programmes used in this work in that it is has a graphical user interface as op-
posed to command line interface and therefore commands used for each step
cannot be given. However, an explanation of how the programme was used can
be found below. A list of all annotations and the database versions from which
annotations were applied by VarAFT can be found in Appendix A.32.
2.9.4.1 VarAFT
VarAFT takes a VCF as input. For family VCFs, ‘Multi Samples’ is specified
within VarAFT. Additionally, the genome version, hg38, and the dbSNP version
to be used (147 for all annotations in this project), are specified. VarAFT then
carries out annotation of the VCF. An annotation file, which differs significantly
from VCF format, is produced which contains all variants and their respective
annotations.
To filter variants in VarAFT based on their annotations and genotype of
a sample, the manual filtering tool is selected, followed by ‘Custom Analysis’.
The desired genotype is selected for each sample. For all families in this study,
all sample genotypes were set to ‘ND’ (not defined) because genotype filtering
was carried out using a custom python script (described in Chapter 3.3.1) prior
to VarAFT annotation and filtering. Variants are then filtered by variant type
and AF by unchecking the necessary boxes. These variants of interest are then
exported as a txt file. These files are referred to as ‘variants of interest’ lists.
2.9.4.2 addAnnotations python script
A custom python script was written to apply the snpEff-applied RefSeq anno-
tations from the VCF which were not carried on to the VarAFT output variant
lists (scripts/ addAnnotations.py). This was necessary for the application of GO
annotations.
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2.9.4.3 GO annotations
Gene ontology (GO) terms were applied to the variants of interest lists using
a custom R script (scripts/addGOanno.R).
2.9.5 Querying of variants against gene lists
A custom python script was used to query VarAFT output variants of interest
lists against genes of interest lists (scripts/geneList.py). Gene lists are available
at https://github.com/sormond/Masters/supp material/.
2.9.6 Genotype filtering using gtFilter
A custom python programme, gtFilter (scripts/gtfilter), was used to filter
variants based on variant genotype and sample phenotype. The programme was
used according to the instructions within the README file †. The script was
run on the snpEff-annoted family VCFs prior to VarAFT. A ‘pos’ and ‘neg’ text
file was given for each family according to each family’s specific considerations
(see Chapter 1.6 & Chapter 3.3.1). These files can be found in supplementary
material. The gtFilter programme was not used on the family F family VCF as
there was no MHN WES sample from this family.
2.9.7 Family F snpSift
SnpSift106 (version 4.3t, part of the snpEff programme) was used to pre-
filter the family F VCF prior to VarAFT annotation and filtering (scripts/s-
npsift familyF), for reasons described in Chapter 3.6.
2.9.8 Detection of copy-number variation
CNVkit126 (version 0.9.7.dev0) was used for detection of copy number variants
(CNV) (scripts/cnvkit.sh). See Chapter 3.5 for details of how detection of CNV
was carried out for each family.
†README file available at https://github.com/sormond/gtfilter
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2.9.9 Coverage analysis
2.9.9.1 WES kit target coverage
Picard’s CollectHsMetrics was used for calculation of coverage over the WES
kit target region (scripts/collectHsMetrics.sh). This tool accepts the bam file,
target and bait intervals, as well as the reference genome fasta file used for the
alignment. Target and bait intervals are created using Picard’s BedToInterval-
List. Samtools faidx is first used to create a dictionary file of the genome reference
which is required for the BedToIntervalList tool. The target interval is the ge-
nomic coordinates of the kit’s target sequencing region, whilst the bait interval
is the genomic coordinates of the region that the kit’s baits are designed to an-
neal to. The bait design was not available for the WES kits used for this project.
Therefore, the target region interval file was given for both bait and target inputs.
Plots of average target coverage and proportion of target bases with low cov-
erage were made using the ggplot2136 R package version 3.2.1 (scripts/cover-
age plots.R). Prior to running this script, the CollectHsMetrics output was con-
verted into a csv file and a ‘Year’ column was added containing the year that the
WES sample was sequenced. A csv file containing coverage data for all families
is available at:
https://github.com/sormond/Masters/supp material/coverage supp material.csv.
2.9.9.2 Coverage over a specific region for CNV analysis
Mosdepth137 version 0.2.3 was used to calculate per-base coverage bed files
over the WES kit target region (scripts/mosdepth.sh). The Sushi138 version 1.22.0
R package was used to visualise coverage of the genomic region containing a
suspected CNV (scripts/sushi plots.R).
2.9.10 Visualisation of alignments






This chapter will describe bioinformatic method development and the various
analyses carried out to identify variants of interest (VOI) from each family. The
VOI identified using these methods are presented and discussed in Chapter 4.
Figure 3.4 gives the workflow of the bioinformatic pipeline.
Throughout the project, methods for identification of VOI were altered and
refined over time. For example, problems with whole exome sequencing (WES)
quality and compatibility of WES samples were identified early on, and it was
determined that the software used for variant filtering could not handle these
issues, possibly leading to a proportion of variants of interest being inadvertently
discarded. Due to this, a python programme for genotype filtering was developed
and successfully employed for the remainder of the project, and WES was carried
out on other individuals from two of the families.
This chapter will begin by discussing measurements of read coverage and the
identification of coverage issues in some WES samples. Then, it will discuss
the development, logic and use of the methods and programmes used for variant
annotation, variant filtering, and selection of variants of interest. The general
methods and scripts used for the bioinformatic steps can be found in Chapter 2.
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3.2 Coverage analysis
There are a multitude of tools available for measurements of sequencing cov-
erage, but for proper analysis of targeted sequencing data such as WES, these
tools need to calculate the coverage over the genomic coordinates of the target
regions covered by the WES kit (WES kits vary in their exome target regions).
Coverage analysis provides a good estimate of the quality of WES data: higher
coverage of the target region generally correlates with increased true positive
variant identification80.
3.2.1 Methods of coverage analysis
Target regions are given by the kit manufacturers in the form of a bed file. At
minimum, a bed file contains three columns in the following order: the chromo-
some name; the beginning base coordinate; and the ending base coordinate. A
bed file may have additional columns containing other information, such as the
genes that fall within a given coordinate, or the read depth at a given coordinate.
For the WES samples in this study, multiple WES kits were used: SureSelectXT
Human All Exon V6 (Cat. No. 5190-8863, Agilent); Nimblegen SeqCap v3 (Cat.
No. 06465684001, Roche Nimblegen); and a SureSelect Human All Exon (Agilent)
kit produced during or prior to 2010 (the catalogue number or version number
for this kit could not be confirmed). The target regions differ among these kits.
The target region bed file for the SureSelect Human All Exon (Agilent) kit could
not be obtained for family B WES sample 533, so the coverage metrics were cal-
culated using the SureSelectXT Human All Exon V6. A list of WES samples and
the WES kits used is available in Appendix A.33.
Because these target region bed files were given in hg37 coordinates, to allow
compatibility with the genome version used throughout the pipeline, target re-
gion bed files were converted from human reference genome hg37 coordinates to
hg38 coordinates with the Galaxy LiftOver online tool using the public server at
usegalaxy.org on the Galaxy web platform140.
Picard’s134 CollectHsMetrics tool was used for calculation of coverage met-
rics over the WES kit target region (scripts/collectHsMetrics.bsh). Additionally,
mosdepth137 was used for coverage analysis of more specific genomic intervals.
This is described further in section 3.5.
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3.2.2 Results of coverage analysis
Data of coverage results obtained using CollectHsMetrics for all WES samples
are available in the supplementary material directory of https://github.com/
sormond/Masters (supp material/coverage supp material.csv). Plots of average
target coverage (the mean coverage over the genomic region targeted for capture
by the WES kit) and the proportion of target bases with low coverage are given
in Figures 3.1 and 3.2. Average target coverage and proportion of target bases
with low coverage are generally inversely correlated, however this is dependent on
evenness of coverage so it is still useful to plot and assess both of these metrics.
The results suggest that there is a large degree of variance of WES quality for
different WES samples within each family. In these plots, the WES samples are
grouped, using colour sets, by the year in which the WES samples were sequenced.
WES obtained more recently appear to be of higher quality. One anomaly to this
trend is WES sample 1908 from family A, which was sequenced in 2017, the year
following sequencing of the other WES samples from this family. As the WES kit
and platform are the same for all samples in this family, it is possible that low
gDNA quality for this sample was the cause of lower WES quality.
Importantly, the coverage results indicate that for most families, there are a
number of WES samples in which the WES quality may be problematic. For WES
sample 533 from family B, the average target depth is significantly lower than all
other WES samples within this family, and almost 50% of target region bases have
less than 10x read depth. This may be due to the fact that the WES kit target
region bed file used for the analysis differed from the actual WES target kit used:
it is likely that the more recent WES kit (SureSelectXT Human All Exon V6)
has a larger target region due to improved predictions and confirmation of exonic
regions of the genome. Prior to WES of a new batch of samples (2019 samples)
from family E, approximately 60% of target region bases had less than 10x read
depth for all WES samples. WES sample 1928 from family C had significantly
lower average target coverage compared to WES samples sequenced in the same
batch, possibly due to low gDNA quality.
3.2.3 Family B WES kit differences
For family B, WES have been obtained from individuals on two relatively
distant branches of the family (see Figure 1.6). The WES samples from one
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branch, corresponding to individuals 26, 27, 82, 456, 1367 and 1412, were se-
quenced recently (2016 and 2017) with the same WES kit (SureSelectXT Human
All Exon V6). The WES samples from the other branch (excluding WES from
2019), corresponding to individuals 533, 919, 1731 and 1772, were sequenced in
2010 and 2012 with WES kits that differed from the newer SureSelectXT Hu-
man All Exon V6 WES kit samples. This has implications for identification
of variants shared amongst these two branches of the family: variants may fall
within regions which are not targeted by both of the different WES kits used,
and so will be identified in only one branch and thus may be excluded during
variant filtering. To measure the extent of this problem, the percentage of bases
where coverage was low (defined as a read depth of less than 15) for at least
one of the 10 family B WES samples (excluding WES from 2019) over the most
recent WES kit release, SureSelectXT Human All Exon V6, was calculated (script-
s/low cov test.bsh). This script used mosdepth for calculations of coverage and
Bedtools141 version 2.29.0 merge and intersect tools. This determined that cov-
erage was low in 57% (3.5 x 107 bases/ 6.1 x 107 bases) of the total number of
bases within the SureSelectXT Human All Exon V6 target region for at least one
of the 10 WES samples. Recognition of this issue was important for informing
how genotype variant filtering was carried out, as discussed in Section 3.3.1.
3.2.4 New WES for family B and E
Due to problems with WES kit differences in family B, and low coverage in
family E, further WES was carried out (2019 samples). Ideally, re-sequencing of
family D and family F would have been carried out due to low coverage, but this
was not possible due to financial constraints.
All new WES was carried out using DNA nanoball sequencing technology on
an MGISEQ-2000 machine with the SureSelectXT Human All Exon V6 kit. For
family B, MHS individual 1731 was re-sequenced (1731 new), and MHN individ-
ual 251 was sequenced for the first time. Both of these individuals belong to the
branch of family B containing older WES samples, and so the addition of these
new WES was intended to enhance variant detection from that side of the family.
For family E, MHS individuals 44, 1379 and 2253, and MHN individual 2259,
were sequenced for the first time. The addition of discordant individual 44, the
only MHS individual in family E that does not carry the RYR1 R1679H variant
or the extended DMPK repeat allele, was useful as the MH-susceptibility in this
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individual cannot be explained by the presence of these two known variants. The
addition of the family E proband 2253 was useful as this individual is bona fide
MHS, having previously suffered an MH episode.
Methods for preparation of gDNA for WES are described in Chapter 2.7.1.
Agarose gel electrophoresis images of gDNA samples for these new WES from
family B and E can be found in Appendix A.1.
The coverage of the new WES samples was relatively high (2019 samples from
Figure 3.1) and this new WES data was used going forward. Herein, the new WES
sequencing samples will be referred to as ‘MGI-sequenced WES samples’ or ‘2019
WES samples’.
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3.3 Variant filtering
Variant filtering can be used in various ways to establish criteria for retention
or removal of variants. The following are general types of variant filtering which
were used in this project:
• Genotype. Retaining variants shared only among certain individuals. For
example, variants present only within individuals sharing a phenotype (such
as MHS).
• Functional effect. Retaining only certain types of variants. For example,
variants that are predicted to lead to a protein sequence change.
• Allele frequency. Retaining only those variants present at a given popu-
lation allele frequency (AF). For example, variants that are present in 1%
or less of the population.
• Pathogenicity prediction. Retaining only variants which meet a certain
threshold for prediction of pathogenicity/deleteriousness.
• Tissue expressivity. Retaining only variants within genes expressed in a
given tissue.
• Gene. Retaining variants based on the gene role or the gene’s presence in
a list of genes of interest.
• Position. Retaining only variants present in a given region within the
genome. For example, variants which fall within an MH-susceptibility locus.
Described further in Section 3.4.2.
Specific details of variant filtering, using the types of filtering described above,
are given below. Unless otherwise stated, all variants presented in this work were
obtained from filtering in the manner described in the sections below.
3.3.1 Filtering by genotype
An effective method of variant filtering for the discovery of variants associ-
ated with a phenotype is through genotype filtering. This involves inferring the
expected carriers (the genotype) of a disease-pathogenic variant based on pheno-
typic information. In the case of a highly penetrant, autosomal-dominant genetic
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disorder, the approach to genotype filtering may be clear-cut: all affected individ-
uals would be expected to carry the pathogenic variant, whereas the non-affected
individuals would not be expected to carry the pathogenic variant. Therefore,
genotype filtering would involve retaining only those variants carried by affected
individuals. However, due to the disease aetiology of MH (see Chapter 1.2),
some adaptations to genotype filtering were made. Strictly adhering to genotype
filtering rules which assumes all MHS individuals harbour the variant and all
MHN individuals do not harbour the variant may lead to the exclusion of the
MH-pathogenic variant. Family-specific considerations and adaptations to vari-
ant analysis were discussed in depth in Chapter 1.6, with a summary of examples
of these considerations and the adaptations made presented in Table 1.1.
Initially, VarAFT123 was used for genotype filtering. However, although
VarAFT does allow filtering of variants by genotype, it was determined that
it did not allow sufficiently flexible genotype filtering. This flexibility was re-
quired for two reasons, one of which was the phenotypic complexity of MH as
described above. The second reason was that it was determined that there would
be problems caused by variants that were not genotyped for one or more samples
within a family. This is because, for a given variant to pass through genotype
filtering in VarAFT, each sample must have been genotyped for that variant. A
more technical explanation is as follows. In VarAFT, one would set the expected
genotype for each disease carrier (MHS) to ‘homozygous’ or ‘heterozygous’ (1/1
or 1/0 within the genotype field of a VCF, respectively), and to ‘absent’ for each
MHN sample (0/0 within the VCF genotype field). For a given variant, if any
one sample contained a ‘./.’ string within the genotype field, meaning that no
genotype was inferred (unknown genotype), the variant would automatically be
discarded and not proceed through the genotype filter, even if all other genotypes
met the programmed conditions. This is problematic, as with increasing num-
bers of samples within a family VCF, comes an increasing probability that one
or more samples is not genotyped for a given variant due to a lack of coverage in
that region. This problem is further exacerbated when combining WES samples
obtained with different WES kits, as described in Section 3.2.3.
Due to both of these issues, it was necessary to design a system of variant
genotype filtering which considered that there were numerous possible combi-
nations of individuals carrying the pathogenic variant within each family, and
that there may be individuals present with an unknown genotype. A python
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programme, gtFilter, was written to address this.
3.3.1.1 gtFilter for genotype filtering
gtFilter (https://github.com/sormond/gtfilter) is a boolean algebra programme
which takes in a VCF and two tab-delimited files: one containing a list of sample
names expected to harbour the pathogenic variant (‘pos’ samples), and one con-
taining a list of sample names not expected to harbour the pathogenic variant
(‘neg’ samples). The output is a VCF containing only those variants meeting
those genotype conditions. Additionally, the programme has an optional ‘le-
niency’ flag. This flag accepts an integer which represents the number of ‘pos’
samples that are not required to carry the variant. In the case of MH, this takes
into account low specificity rates of the IVCT. However, if there is an individual
within the family who may or may not carry an unknown pathogenic variant (for
example, an individual who is MHS equivocal or borderline, or an MHS individ-
ual who already carries a known variant that may be pathogenic for MH), one
would simply not list the sample name on either ‘pos’ or ‘neg’ files. This would
mean that gtFilter would not take into consideration the genotype of this sample
for each variant. The programme automatically passes an unknown genotype of
a sample: For example, a variant that has only been called in one and no other
samples will pass the genotype filter if the genotype conditions are met for that
one sample. The programme has no tolerance for an MHN sample carrying a
variant as the IVCT has a very high sensitivity rate and so it is highly unlikely
that an MHN individual carries an MH-pathogenic variant. A further explanation
of the logic of the programme is presented in Figure 3.3.
3.3.1.2 gtFilter parameters for each family
Table 3.1 gives the gtFilter script ‘pos’ and ‘neg’ WES samples for each family,
based on the IVCT diagnosis of each individual. Because the IVCT results from
individual MS1 (MHS) were borderline (see Appendix A.33 for IVCT values),
the MS1 WES sample was not included in either ‘pos’ or ‘neg’ lists, meaning
the gtFilter programme did not take this genotype into account when filtering
variants. IVCT values from individuals 1474 (MHN) and 1928 (MHN) from family
C could be considered as borderline, but in this case were still given as disease
‘neg’ as the IVCT values for all other MHS individuals within the family were
much higher. As there is uncertainty about the phenotype of individual 26, WES
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Figure 3.3: Logic of the gtFilter programme for genotype filtering
In this example, three samples (A, B & C) are listed in ‘pos’, and three others (D, E & F) listed
in ‘neg’.‘Variant 1’ is the first variant encountered by the programme. After ‘passing’ (retaining
the variant and adding it to the output VCF) or ‘failing’ (discarding the variant) variant 1, the
programme will then repeat this process on all other variants present within the input VCF.
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sample 26 from family B was not included. Additionally, the WES from sample
27 from family B was not included because of individual 27’s MHSh diagnosis,
meaning they may not harbour an MH-pathogenic variant.
The ‘leniency’ argument was used for family B and E due to the larger number
of samples and more complex phenotypes present within the families. For both
of these, this was set to two, meaning up to two of the ‘pos’ samples were not
required to carry a variant for the variant to pass through the filter.
Family F variants were not genotype-filtered because all WES samples were
MHS.
3.3.2 Filtering by functional effect
Filtering by functional effect was carried out in VarAFT. This variant filtering
involved selecting only those variants that were categorised as exonic (excluding
synonymous) or splicing.
3.3.3 Filtering by allele frequency
Filtering by AF was carried out in VarAFT. The AF threshold was 0.01 (1%)
for gnomAD and 1000G AF databases which is conservative as it is above the
predicted MH-incidence rate. After this filtering step, variants and all annotations
applied by VarAFT were exported from VarAFT. These variant lists will be
referred to as variants of interest. All subsequent filtering steps were carried out
manually on the VarAFT-output variants of interest lists.
3.3.4 Filtering by pathogenicity prediction
VarAFT applies pathogenicity predictions from a large number of pathogenic-
ity predictor tools. No specific threshold was applied for pathogenicity prediction.
However, predictions of pathogenicity were taken into account when manually se-
lecting variants of interest. CADD scores (described in Chapter 1.4.4) are given
in the final selected variants of interest tables in Chapter 4.
3.3.5 Filtering by tissue expressivity
The Human Protein Atlas121, a tissue expressivity database, as well as the
scientific literature, were queried manually to ascertain whether the gene was
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Table 3.1: gtFilter parameters for each family
This table gives the gtFilter python programme parameters for each family. ‘Pos’ contains
the WES samples that were given in the ‘pos’ file for gtFilter (assumed to carry the unknown
pathogenic variant) whereas ‘Neg’ contains the WES samples that were given in the ‘neg’ file
(assumed to not carry the unknown pathogenic variant). The leniency column gives the leniency
parameters for each family, with a value of ‘none’ meaning the argument was not invoked.
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expressed in skeletal muscle. No hard filtering was applied for tissue expressivity
because databases are not necessarily complete or accurate, and it is common to
find conflicting expression information. Additionally, and especially in the case
of families with myopathies, it may be the case that the pathogenic variant is
not present within a gene that is expressed in mature skeletal muscle, as the gene
may be expressed only early on in myoblast differentiation and turned off after
differentiation has occurred.
3.3.6 Filtering by gene
Gene ontology (GO) annotations116, 117, which give information about known
and predicted gene function, were applied to the VarAFT-output variant lists
using a custom R script (scripts/addGOanno.R). As an example, the GO anno-
tations applied to the RYR1 gene include ‘calcium channel activity’, ‘calcium
ion binding’, ‘calmodulin binding’, ‘muscle contraction’, ‘junctional sarcoplasmic
reticulum membrane’ and ‘release of sequestered calcium ion into cytosol by sar-
coplasmic reticulum’. These annotations allowed quick identification of gene roles
to ascertain the importance of a variant.
A custom python script was written to query VarAFT-formatted variant lists
against gene lists (scripts/geneList.py). A custom curated gene list (available at
supp material/curated genes.txt), which was expanded upon throughout the
project, was queried. This list included genes with an established link or relevance
to MH, myopathies, calcium or energy homeostasis in skeletal muscle, ECC, or
sarcolemma depolarisation or repolarisation. The list was compiled from both
literature searches and personal communications. Additionally, a muscle gene
disease list142 (http://musclegenetable.fr), which was much more comprehensive
than the custom curated list, was obtained and queried against
(supp material/NM disease genes.txt).
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Figure 3.4: Bioinformatic pipeline for variant calling, annotation and filtering
* refers to a step which was not carried out on all WES data (see Chapter 2.9.2).
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3.4 Explorations of variant data
Aside from these filtering methods described, variants of interest were explored
by identifying variants or genes in common between families and by identifying
variants falling within MHS loci.
3.4.1 Shared variants of interest between families
Variants of interest that were shared between families, as well as rare, pre-
dicted pathogenic variants within the same gene, were identified. To do this,
variants of interest lists for each family were concatenated and sorted based on
gene name. The resulting file was manually analysed to identify these variants.
Results are reported in Chapter 4.9.
3.4.2 Variants falling within MHS loci
Variants of interest falling within MHS loci (Table 3.2), with the execption of
MHS1 and MHS5 which harbour the genes RYR1 and CACNA1S, respectively,
were identified manually. Variants within final variants of interest lists presented
in Chapter 4 which fall within MHS loci are indicated as such.
Locus Chr Position OMIM
MHS2 17 27,400,000 - 72,900,000 154275
MHS3 7 77,900,000 - 107,800,000 154276
MHS4 3 103,100,000 - 111,600,000 600467
MHS6 5 0 - 48,800,000 601888
Table 3.2: Previously identified MHS loci46, 47, 48, 49
‘Chr’ is chromosome. ‘Position’ is hg38 genomic coordinates. OMIM is the OMIM accession
for the MHS loci.
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3.5 Detection of copy-number variation
Identification of copy-number variation (CNV) was carried out using CNVkit.
CNVkit is a programme for identification of CNVs using targeted sequencing data.
The programme takes in bam files from a ‘tumor’ sample and a ‘normal’ sample.
The ‘tumor’ sample can refer to any phenotype not carried by the ‘normal’ sample.
The programme can be run without a ‘normal’ sample (an MHN individual) if
one is not available from a family (it is then said to be compared to a ‘flat
reference’), but the efficacy of CNV-detection may be reduced and there will
be no exclusion of CNVs present within the family that are not related to the
disease. CNVkit requires the genome reference and a bed file containing the WES
kit target region. It is important that PCR duplicates are marked in the bam
files when using CNVkit to assist the programme with detection of true read copy
numbers. For WES from all families except family B and E, duplicates had not
been marked. Therefore, the bam files of only those WES samples to be used
for CNV identification were re-processed with Picard’s MarkDuplicates tool as
described in Chapter 2.9.8. It is also important that WES samples that were
compared were also sequenced with the same sequencing method and with the
same WES kit. Where possible, WES samples with the highest average coverage
within the family, and from individuals that were not considered borderline MHS
or MHN, were used.
3.5.1 WES samples used for CNV detection
Table 3.3 gives the WES samples used for CNV analysis within each fam-
ily. For family B, two WES samples from MHS individuals were screened for
CNVs: individuals 1731 and 1412. As 1731 was MGI-sequenced, the WES sam-
ple from MHN individual 251, also MGI-sequenced, was used as the ‘normal’
sample. There was no suitable MHN WES sample to use as the ‘normal’ sample
for sample 1412, and so a flat reference was used. For family F, the WES sample
of individual 4004 (MHS) was used against a flat reference as no MHN WES
sample was available from this family.








F 4004 flat reference
Table 3.3: WES samples used for CNV detection from each family
‘B1’ is family B MGI-sequenced samples, ‘B2’ is family B Illumina-sequenced samples.
3.5.2 Analysis of predicted copy-number variation
If CNVkit suspected the presence of a single copy deletion, evidence of SNP
heterozygosity over the suspected deleted area upon visual inspection of the align-
ment often ruled this out. Additionally, the presence of an alternative haplotype
within the suspected deleted region would often explain the detection of a dele-
tion, as the reads have likely mapped to the alternative chromosome.
To visualise coverage of the genomic regions containing a suspected CNV,
plots were made in R using the Sushi package138 with mosdepth per-base coverage
metrics.
3.6 Family F special case
Because family F had no MHN WES samples, an additional filtering step was
applied to reduce the final number of variants to be analysed. snpSift106 (version
4.3t, part of snpEff) was used to filter the snpEff annotated family VCF to re-
tain only those variants predicted to cause a protein coding change (see Chapter
2.9.7 for method). This was done to significantly reduce the number of variants
needed to be analysed within VarAFT, which cannot handle large variant num-
bers. Filtered VCFs were then annotated and analysed using VarAFT, with an
additional step whereby variants were filtered so that only variants heterozygous
or homozygous in all samples were retained.
Chapter 4
Variants of interest
This chapter presents variants that were identified in each family which may
be related to their malignant hyperthermia (MH) and/or myopathy phenotype.
Although segregation analysis was performed on select variants of interest, testing
segregation of all variants was beyond the scope of this project. Rare variants
that are shared among families, or genes containing rare variants shared among
families, are also given here, even if they do not have an obvious link to the
current biomolecular understanding of MH.
4.1 Methods
For detailed methods and method development, see Chapter 3. Unless oth-
erwise stated, variant lists given here are final selected variants of interest. This
means that the variants segregate with the disease according to the WES data
(the details of expected segregation differs amongst families, as described in Chap-
ter 1.6 & section 3.3.1), that they are present at a gnomAD allele frequency (AF)
of ≤ 0.01, and that they are predicted to alter the protein sequence of a gene’s
encoded protein. Additionally, they have been selected for the final list of variants
of interest because they have some relevance to skeletal muscle, calcium home-
ostasis, energy metabolism, and/or muscle disease. Some variants with relevance
to skeletal muscle do not have a clear relevance to the understanding of MH
pathophysiology, but are presented because no other suitable candidate variants
were identified within the family.
For primer sequences used for testing of segregation of the variants, see Ap-
pendix A.1.
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4.2 Number of identified variants
Table 4.1 gives variant numbers for each family at each major stage of variant
filtering.
Family VCF gtFiltered <0.01 AF &
protein changing
VOI
A 430897 90601 156 6
B 3052842 2201899 145 7
C 1075991 563575 142 4
D 2264434 872848 246 3
E 2888835 1341484 221 4
F 4413113 N.A. 74 2
Table 4.1: Variant numbers at each major stage of the variant filtering pipeline
‘VCF’ is the number of variants in the whole family VCF. ‘gtFiltered’ is the number of variants
after applying genotype filtering using the gtFilter python script. ‘<0.01 AF & protein changing’
is variant numbers after VarAFT filtering to remove variants that have an AF of greater than
0.01 and variants that are not predicted to alter the gene’s protein product. ‘VOI’ (variants of
interest) are final VOI that were manually selected from the VarAFT filtered variant list and
that are given in this chapter.
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4.3 Family A
Six final variants of interest identified are listed in Table 4.2.
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4.3.1 FAT1 I1478M SNV
A SNV in FAT1, predicted to lead to an isoleucine to methionine substitution
at amino acid position 1478 (Refseq accession: NM 005245), was identified in
family A. The variant is predicted to be pathogenic (CADD score: 23.3).
The encoded protein of FAT1 (OMIM: 600976) is a member of the cadherin
family. The cadherins are a group of proteins which are involved with cell-to-cell
adhesion. The protein is known to contribute to morphogenesis of the neuromus-
cular junction143 and was shown in a mouse knock-out study to be critical for the
correct formation of muscle144. This is of interest as incorrect functioning of the
neuromuscular junction could conceivably contribute to MH-susceptibility. Some
variants in the gene, thought to alter expression of the gene product, have been
linked to facioscapulohumeral muscular dystrophy151, a genetic disorder charac-
terised by progressive skeletal muscle weakness152, demonstrating that FAT1 may
be important for normal skeletal muscle function.
4.3.2 SLC22A3 T44M SNV
A SLC22A3 SNV identified in family A is predicted to lead to an alanine to
serine substitution at amino acid position 138 (Refseq accession: NM 021977).
The variant is predicted to be pathogenic (CADD score: 22.9).
SLC22A3 encodes Oct3, an extraneuronal organic cationic transporter pro-
tein. Variants in the gene have not been previously linked to disease, and little is
known about the protein’s function, except that it mediates transport of a variety
of non-charged and cationic organic molecules149. However, the variant is present
within the final variants of interest list as Oct3 is highly expressed in skeletal
muscle153 , 121.
4.3.3 VPS13A S1346A SNV
A SNV in VPS13A, predicted to lead to a serine to alanine substitution at
amino acid position 1346 (Refseq accession: NM 001018037), was identified in
family A. The variant appears to be novel as it was not found on any database.
It is not predicted to be pathogenic (CADD score: 7.946).
VPS13A encodes a protein involved in lyososomal and endosomal cycling of
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proteins which has been implicated in mitochondrial size maintenance and clear-
ance150. It is expressed highly in a number of tissues including skeletal mus-
cle. Variants in VPS13A have been linked to choreoacanthocytosis, a neurolog-
ical disorder with symptoms including myopathy and involuntary muscle move-
ments154. This variant is of interest because of the mitochondria’s key role in
energy homeostasis: It is plausible that dysfunction of the mitochondria lead-
ing to energy dysregulation, such as in an 3,4-Methylenedioxymethamphetamine
(MDMA)-induced hyperthermic episode, could have a role in MH.
4.3.4 PPARGC1A A138S SNV
A SNV within PPARGC1A, predicted to lead to an alanine to serine substi-
tution at amino acid position 138 (Refseq accession: NM 013261), was identified
in family A. The variant appears to be novel as it could not be found on any
database. It is predicted to be pathogenic (CADD score: 23.9).
PPARGC1A encodes a well-studied muscle transcriptional cofactor, PGC1α.
The protein is expressed highly in skeletal muscle, where it controls the expression
of genes involved in energy metabolism145. PGC1α is understood to be involved
in muscle fibre-type switching (transitioning between fast and slow-twitch muscle
fibre) and regulation of mitochondrial biogenesis145.
Amino acid position 138 of the protein resides in the activation domain of
PGC1α, responsible for interactions with other co-factors and docking of nuclear
receptors155. An amino acid substitution in this position could potentially al-
ter the strength of interactions with these binding partners, which could effect
expression of the genes under the control of PGC1α.
The variant was selected for segregation analysis due to the gene’s key role in
muscle metabolism through control of gene expression, and because the variant
is novel.
4.3.4.1 Segregation analysis
Sanger sequencing was carried out on the two remaining family A members for
which gDNA and IVCT results were available. Although sequencing was repeated
a number of times due to the presence of contaminating sequence (Figure 4.1), the
results indicated that MHN 1576, child of 1479, carried the variant. The variant
was excluded from future analyses based on this, however, sequencing should be
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repeated using another set of sequencing primers to confirm that individual 1576
does carry the PPARGC1A variant.
Figure 4.1: Alignment of Sanger sequencing results for individual 1576 against the
PPARGC1A nucleotide sequence
The PPARGC1A A138S SNV position is indicated by the red arrow. Although there appears
to be some sequence contamination, the results suggest that this individual is likely to be
heterozygous, with peaks for both C and A nucleotides present in all four Sanger reads.
4.3.5 TLR3 G320R SNV
A TLR3 variant identified in family A, predicted to cause a glycine to argi-
nine substitution at amino acid position 320 (Refseq accession: NM 003265), is
predicted to be pathogenic (CADD score: 25.4). The amino acid at this position
is highly conserved (Figure 4.3).
Toll-like receptor 3 (TLR3), encoded by the gene TLR3 (NG 007278.1:5001-
20944), is a transmembrane receptor protein with a well-studied role in recog-
nition of pathogen-associated molecular patterns and subsequent activation of
the innate immune system. This activation results in the induction of type I
interferons and inflammatory cytokines156, leading to both an inflammatory and
immune response. TLR3 primarily localises to endosomal and endoplasmic retic-
ulum membranes.
Aside from a role in innate immune system activation, TLR3 has been more
recently implicated as a mediator of the myocyte inflammatory response, the mat-
uration of cardiac myocytes157, and the regulation of cardiac potassium channels
responsible for action potential regeneration. Although expression of TLR3 has
not been observed in skeletal muscle myocytes, it is very highly expressed in
myoblasts and in the muscle tissue of patients suffering from inflammatory and
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Figure 4.2: Alignment of Sanger sequencing results for individuals 1479 and 1576
against the TLR3 nucleotide sequence
The TLR3 G320R SNV position is indicated by the red arrow. The results indicate that
individual 1479 is heterozygous for the variant, whilst individual 1576 does not carry the variant.
HIV-myopathies146, 147.
In the cardiac tissue of mice, knock-out of TLR3 has been demonstrated
to affect the generation of an action potential by lengthening the time between
depolarisation and repolarisation of the membrane158. This effect was shown to
be independent of the inflammatory and immune signalling functions of TLR3,
but dependent on direct regulation by TLR3 on the proteosomal degradation of
subunits of the cardiac transient outward potassium channel, Kv4.2/4.3.
The variant was selected for segregation analysis due to the gene’s encoded
protein’s role in myocyte inflammatory response, myoblast expression, and be-
cause the protein has been implicated in the polarisation of the membrane in
cardiac muscle.
4.3.5.1 Segregation analysis
Individuals 1479 (MHS) and 1576 (MHN) were Sanger sequenced for the vari-
ant which revealed segregation with MH susceptibility (Figure 4.2). Further study
of the variant has not yet been undertaken. The next course of action would be
to establish an HRM assay to screen a population of MHN individuals for the
variant.
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Figure 4.3: Conservation of TLR3 glycine amino acid at position 320 amongst
species
Other species are mouse, rat, bovine, antelope, guinea pig and dog.
4.3.6 PRKAA1 K429R SNV
A PRKAA1 SNV, predicted to lead to a lysine to arginine substitution at
amino acid position 429 (Refseq accession: NM 006251), was identified in family
A. The variant falls within the MHS6 locus. It is predicted to be pathogenic
(CADD score: 18.6).
PRKAA1 encodes the α1 catalytic subunit of AMP-activated protein kinase
(AMPK), an energy-sensing protein kinase which regulates metabolism in re-
sponse to cellular energy states and intracellular Ca2+ concentrations148. AMPK
is composed of three subunits: α, β and γ. These subunits are each encoded by
multiple isoforms, allowing tissue-specific variation of the properties of AMPK159.
In skeletal muscle, α2 is the predominant α isoform, with moderate expression of
α1121 159. However, α2 is thought to have a nuclear role involving gene regulation,
whilst α1 remains within the cytoplasm160.
AMPK has an important role in myocyte energy homeostasis, and because
energy states contribute to the regulation of RyR1, the variant was chosen for
segregation analysis.
4.3.6.1 Segregation analysis
The WES data indicated that the variant was heterozygous in individuals
1480 and 1253 and absent from MHN individuals 1652 and 1653. WES coverage
at the variant site was low (depth of five) for MHN sample 1908, however the
reads indicated that the variant was not present in this individual (Appendix
A.2). IVCT results and DNA were available from only two other individuals
within family A. Sanger sequencing revealed segregation of the variant with MHS
(Appendix A.3).
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Next, an HRM assay was developed to screen the MHN population for the vari-
ant. An initial optimisation assay using sequenced samples 1576 and 1479 gave
a reasonable heteroduplex melting peak (Appendix A.4). The assay was carried
out on DNA from the five other family A individuals to confirm the genotypes
suspected through WES and to assess viability of the assay on a larger number
of samples (Appendix A.5). The melting curves suggested that MHN 1908, pre-
sumed wild-type from the WES data, was a carrier of the variant. Suspected
wild-type 1653 gave an unusual melting curve with a wide and small secondary
peak which suggested the individual to be a carrier of the variant. Alternatively,
gDNA degradation may have caused the secondary peak. Individuals 1908, 1653
and 1480 were Sanger sequenced to confirm their genotypes. The sequencing
revealed MHN 1908 to carry the variant, confirmed MHS 1480 as a carrier and
confirmed individual 1653 as wild-type for the variant (Figure 4.4). The finding
that 1908 was a carrier of the variant demonstrated how low sequence coverage
can conceal heterozygosity of a DNA sample, potentially misguiding future re-
search approaches. It provides a good example of allelic dropout in WES, and
underscores the importance of undertaking confirmatory Sanger sequencing as
early as possible if there is any ambiguity in WES data.
Overall, the finding that MHN individual 1908 carried the variant disproved
the possibility that the variant is pathogenic for MH, and the variant was not
pursued further.
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Figure 4.4: Alignment of Sanger sequencing results for individuals 1480, 1653 and
1908 against the PRKAA1 nucleotide sequence
The PRKAA1 K429R SNV position is indicated by the red arrow. The results indicate that
individuals 1480 and 1908 are heterozygous for the PRKAA1 variant whereas individual 1653
does not carry variant.
4.4 Family B
A list of variants of interest can be found in Table 4.3.
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4.4.1 KLHL21 A197V SNV
A SNV within KLHL21, predicted to lead to an alanine to valine subsitution
at amino acid position 197 (Refseq accession: NM 001324309), was identified in
family B. The variant is predicted to be pathogenic (CADD score: 15.6).
KLHL21, encoding KLHL21, belongs to a large protein family characterised
by the presence of kelch-repeat domains which are associated with protein-protein
interactions. Expression of KLHL21 is ubiquitous but it may be most highly ex-
pressed in skeletal muscle121. A number of proteins belonging to the kelch-repeat
domain family have important roles in skeletal muscle development and mainte-
nance, and variants in some of these genes, including KLHL1, KLHL9, KLHL16,
KLHL40 and KLHL41, have been implicated in a number of neuromuscular dis-
orders167. A precise role for KLHL21 in skeletal muscle has not been determined,
however it is known to form a part of Cullin E3 ubquitin ligase complexes, which
are involved in protein degradation and turnover161. The variant is of interest
due to the fact that variation in this family of genes are pathogenic for neuro-
muscular disorders. It is plausible that erroneous protein degradation could lead
to incorrect functional expression of proteins involved in calcium homeostasis or
excitation-contraction coupling (ECC).
4.4.2 LMO7 Q782E SNV
A LMO7 SNV, predicted to lead to a glutamine to glutamic acid subsitution
at amino acid position 782 (Refseq accession: NM 001366634), was identified in
family B. The variant has mixed pathogenicity predictions (CADD score: 13.51).
LMO7 encodes a protein which transcriptionally regulates a number of muscle
genes including emerin, a nuclear envelope protein critical for anchoring of the
nuclear membrane to the cytoskeleton162. Variants of the gene encoding emerin
are associated with Emery-Dreifuss muscular dystrophy168. No variants of LMO7
have been linked to disease, but a phenotype similar to Emery-Dreifuss muscular
dystrophy was observed in mice with an LMO7 knock-down169, although these
findings could not be replicated in another similar experiment170. The variant is
of interest due to the gene’s association with a disorder of skeletal muscle.
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4.4.3 AHNAK2 P1852L SNV
An AHNAK2 SNV, predicted to lead to a proline to leucine acid substitution
at amino acid position 1852 (Refseq accession: NM 001350929), was identified in
family B. The variant is predicted to be pathogenic (CADD score: 19.75).
AHNAK2 encodes AHNAK2, a member of the AHNAK family. The AHNAK
family also includes the protein AHNAK. AHNAK and AHNAK2 are closely re-
lated, with both sharing significant sequence identity, size (600 kDa) and struc-
tural features171. AHNAK2 is less studied than AHNAK, but both are believed
to share cellular roles, as mouse knock-out studies have suggested AHNAK2 com-
pensates for the absence of AHNAK171. In skeletal muscle, AHNAK and AH-
NAK2 localise to costameres, muscle cell structures which connect sarcomeres
to the sarcolemma163. In cardiac tissue, AHNAK is a modulator of the voltage-
dependent cardiac calcium channel Cav1.2
172. Both AHNAK and AHNAK2 have
been shown to interact with JP-45173. The variant is of interest because this
gene is highly expressed in skeletal muscle and it may be an interacting partner
of JP-45, an important ECC protein.
4.4.4 Compound CDRT1 variants
Two rare variants were identified in CDRT1, predicted to lead to threonine
to methionine, and glycine to glutamic acid substitutions at amino acid positions
373 and 82 (T373M & G82E), respectively (Refseq accession: NM 001282540).
Both variants are predicted to be pathogenic (CADD scores: 24.8 and 24.5). The
carrier status of the variants, inferred from the WES data, suggests the variants
segregate together, meaning carriers are cis compound heterozygotes. All WES
samples appear to carry both variants with the exception of the WES sample
from individuals 251 (MHN), 26 (MHN) and 919 (MHS), who are all wild-type for
both variants. WES sample 82 was called as wild-type for T373M and so is non-
concordant with the inferred haplotype (17 reads containing wild-type sequence,
2 reads with variant sequence), however is likely a carrier as this individual links
both branches of the family and appears to carry the CDRT1 G82E variant. This
implies that allele dropout may have prevented identification of this variant in
individual 82.
Duplications of chromosomal segment 17p11.2p12, which harbours CDRT1
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and the gene PMP22, are causative of the neuropathy Charcot-Marie Tooth syn-
drome (CMT)174. It is worth noting however that the duplication of PMP22
seems to be the causative agent of CMT, with point variants in PMP22 asso-
ciated with CMT, although this doesn’t rule out a pathogenic role for CDRT1.
Sufferers of CMT may be at risk of MH175. Aside from its relationship to this
disease, little is known about the function of CDRT1, although analysis of its
predicted protein structure implicates it in protein ubiquitination (as predicted
by Uniprot)165. Although no recent literature focused on the gene exists, the
original literature suggests high and specific skeletal muscle RNA expression176.
These variants are of interest due to the gene’s potential role in a neuropathy
which may put sufferers at risk of MH, and because two predicted pathogenic
variants were identified within the same gene.
4.4.5 PPIP5K1 R1081H SNV
A PPIP5K1 SNV, predicted to lead to an arginine to histidine substitution
at amino acid position 1081 (Refseq accession: NM 001354395), was identified in
family B. The variant is predicted to be pathogenic (CADD score: 26.1).
PPIP5K1 encodes diphosphoinositol pentakisphosphate kinase 1 (PPIP5K1),
an enzyme involved in inositol pyrophosphate cellular signalling. Specifically,
PPIP5K1 catalyses the conversion of inositol hexakisphosphate to diphospho-
inositol pentakisphosphate, and diphosphoinositol pentakisphosphate to
bis-diphosphoinositol tetrakisphosphate164. Inositol pyrophosphates are highly
phosphorylated signalling molecules which are involved in the regulation of a va-
riety of cellular processes including glucose homeostasis, stress response, protein
translation and phosphate homeostasis177 178. Inositol pyrophosphate signalling
has recently been implicated in alterations of calcium transients179. PPIP5K1 is
expressed in skeletal muscle180.
The variant was chosen for segregation analysis due to the gene’s potential
involvement in cellular signalling and metabolic control of myocytes, and because
the variant is predicted to be pathogenic.
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4.4.5.1 Segregation analysis
Sanger sequencing was carried out on individuals 1412 and 1731 which con-
firmed the genotypes suspected by WES (Appendix A.6). An initial HRM opti-
misation was carried out, which gave expected melting curves for wild-type 1731
and heterozygous 1412 (Appendix A.7). This HRM assay was then carried out on
both MHN and MHS individuals from family B, which revealed that the variant
did not segregate with MHS (Figure 4.5). The variant was excluded from further
analysis.
Figure 4.5: HRM melting curve for PPIP5K1 R1081H variant
1412 is confirmed heterozygous for the variant and 1731 is confirmed wild-type. The results
indicate that individuals 1010 (MHSc), 1282 (MHN), 1367 (MHS), 1632 (MHN) and 1772 (MHS)
are heterozygous for the variant, whereas individual 968 (MHS) is wild-type for the variant.
The genotype for individual 572 (MHS) is inconclusive as the single homoduplex peak is shifted
from the control wild-type peak.
4.4.6 TRPV2 R196C SNV
A TRPV2 variant, predicted to cause an arginine to cysteine substitution at
amino acid position 196 (Refseq accession: NM 016113), was identified in family
B.
TRPV2 encodes Trpv2, which belongs to the TRP ion channel protein family,
and more specifically to the transient receptor vanilloid (TRPV) family. TRPV2
is expressed ubiquitously with some expression in skeletal muscle121. The primary
function of TRPs is the mediation of sensory signalling by rapid ion influx or
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efflux in response to sensing of a specific signal. TRPVs are selective for Ca2+
and form homotetrameric channels, with evidence for coassembly of different
TRPV subunits to form heterotetrameric channels166. TRPV1, which encodes
Trpv1, is closely related to Trpv2, sharing over 50% sequence identity40. Recently,
it has been proposed that Trpv1 may contribute to MH susceptibility181, with
evidence suggesting that Trpv1 is activated by volatile anaesthetics in human
skeletal muscle. The researchers found that in a mouse model SR calcium release
upon exposure to the volatile anaesthetic isoflurane was increased significantly
by the presence of Trpv1 channels harbouring variants found in MH families181.
This provides evidence for non RyR1-specific calcium release from the SR upon
exposure to an MH-triggering agent, and potentially implicates TRPV channels.
The variant was chosen for segregation analysis due to the gene’s potential
role in myocyte Ca2+ homeostasis.
4.4.6.1 Segregation analysis
Sanger sequencing was carried out on individual 1367 (MHS) which confirmed
the presence of the heterozygous variant (Appendix A.8). An initial HRM optimi-
sation assay with 1367 gDNA and an MHN sample gave characteristic wild-type
and heterozygous melting curves (Appendix A.9) and so this HRM assay was car-
ried forward for genotyping of the wider family for the TRPV2 R196C variant.
This revealed discordance of the variant with MH susceptibility, with an MHN
individual (740) found to harbour the variant, and MHS individuals determined
to be wild-type for the variant (Figures 4.6 & 4.7).
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Figure 4.6: HRM melting curve for TRPV2 R196C variant
1367 (MHS) is confirmed heterozygous for the variant and 26 is confirmed wild-type (Appendix
A.8). The results indicate that individuals 27 (MHSh), 82 (MHS), 456 (MHS), 533 (MHS), 1412
(MHS), 1731 (MHS) and 1772 (MHS) are heterozygous for the variant, whereas individuals 26
(uncertain phenotype), 919 (MHS) and MHN are wild-type for the variant.
Figure 4.7: HRM melting curve for TRPV2 R196C variant
1367 is confirmed heterozygous for the variant and 26 is confirmed wild-type. The results
indicate that individuals 206 (MHS), 529 (MHS) and 740 (MHN) are heterozygous for the
variant, whereas individuals 386 (MHN) and 806 (unknown phenotype) are wild-type for the
variant.
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4.5 Family C
A list of variants of interest can be found in Table 4.4.
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4.5.1 SLC6A2 V428A SNV
A variant in SLC6A2 identified in family C, predicted to lead to a valine to ala-
nine substitution at amino acid position 428 (Refseq accession: NM 001172502),
is believed to be novel, as the variant was not present on any database. It is
predicted to be pathogenic (CADD score: 24).
SLC6A2 encodes the norepinephrine transporter (NET). NET is responsible
for the re-uptake of extracellular norepinephrine (NE) at synaptic clefts182. NE
elicits the ‘fight or flight’ response, triggering a range of physiological effects
which includes the promotion of glucose uptake in skeletal muscle186. In MDMA-
induced hyperthermia, it is thought that an elevation of NE triggered by MDMA
goes on to indirectly elicit an over-activation of a mitochondrial inner membrane
protein, UCP374. UCP3, a protein expressed highly and specifically in skeletal
muscle121 mediates the passive leakage of protons across the inner mitochondrial
membrane, diffusing the proton gradient. ATP is expended and heat is produced
by this futile cycle, causing the symptoms of MDMA-induced hyperthermia. For
further discussion on MDMA-induced hyperthermia and a link to another variant
identified in family D, see section 4.6.3. The SLC65A2 variant is of interest due
to the fact that it is novel and because the gene is involved in a physiological
pathway which is implicated in triggering a physiological response similar to a
MH episode.
4.5.2 PDPR A89T SNV
A PDPR variant, predicted to lead to an alanine to threonine substitution
at amino acid position 89 (Refseq accession: NM 001322118), was identified in
family C. The variant is not predicted to be pathogenic (CADD score: 13.1).
This variant is of interest due to the gene’s role in energy metabolism. PDPR
encodes the pyruvate dehydrogenase regulatory subunit, or PDPR, which makes
up part of the pyruvate dehydrogenase complex (PDC). The PDC carries out
the key reaction linking glycolysis and the TCA cycle - that is, the oxidative
carboxylation of pyruvate forming acetyl-CoA. PDPR decreases the sensitivity
of PDC to stimulatory Mg2+ 183. PDPR is ubiquitously expressed throughout
the body121. Genetic variation in this gene has not previously been shown to be
pathogenic for disease.
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4.5.3 ZFHX3 18-nucleotide deletion
A ZFHX3 variant identified in family C is an 18 nucleotide in-frame deletion,
predicted to lead to a deletion of 5 amino acids (Val-Ala-Ala-Ala-Ala) from amino
acid position 777 (Refseq accession: NM 006885).
ZFHX3 encodes ATBF1, a transcriptional regulator of myogenic and neuronal
differentiation184. Decreasing expression of ZFHX3 correlates with differentiation
of myoblasts into terminal muscle cells184. ATBF1 may be involved in regulation
of calcium homeostasis through control of gene expression. Using a mammary
epithelial cell line, ATBF1 was shown to regulate the expression of the calcium
channel TRPV6 and its knock-down led to a decrease in store-operated calcium
entry, whilst its over-expression had an opposing effect187. No ZFHX3 variant has
been associated with rare genetic disease. However, the gene has been implicated
in atrial fibrillation (AF), a disturbance of cardiac rhythm. Polymorphisms of
the gene, including intronic variants, have been associated with an increased
risk of AF188. In an atrial myocyte cell line, knock-down of ZFHX3 caused
a dysregulation of calcium homeostasis, with an increase in SR calcium store
content, increased expression of calcium homeostasis proteins including RYR2
and SERCA2, and increased activity of channels involved in action potential
generation189.
The deletion variant falls within an alanine-repeat region of the protein. The
predicted alteration of amino acid sequence from wild-type is as follows, with the
deleted sequence shown in bold:
wild-type sequence: QVFSHTAGAAAAAVAAAAAAANISSS
variant sequence: QVFSHTAGAAAAAAAANISSS
This alanine-repeat region is highly conserved amongst species (Figure 4.8).
Other deletion variants in this alanine-rich region that are predicted to lead to the
same 5 amino acid deletion, or a similar non-frameshift deletion in the same area,
have been identified previously. However, all of these variants have a gnomAD
AF of 6 0.0005. Due to the presence of central core disease in family C, this
variant is interesting as it is conceivable that the dysfunction of an important
transcriptional regulator of myogenesis could lead to incorrect expression and/or
assembly of the ECC molecular apparatus.
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Figure 4.8: Conservation of ZFHX3 amino acid sequence amongst species
The red underlined sequence indicates the deleted amino acid sequence. Other species are
bovine, dog, macaque, mouse and rat.
4.5.4 LRRC75B P274L SNV
An LRRC75B variant was identified in family C. It is predicted to lead to
a proline to leucine substitution at amino acid position 274 (Refseq accession:
NM 207644). The variant is predicted to be pathogenic by multiple pathogenicity
predictors (CADD score: 29.5) and is present at a low AF (gnomAD AF: 0.0007).
LRRC75B encodes a leucine-rich repeat protein. Little is understood about
its cellular role, however, a study using an immortalised mouse myoblast cell line
found that the encoded protein has a role in myogenic differentiation185. The
variant is of interest due to its high pathogenicity score and the gene’s potential
role in myocyte maturation.
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4.6 Family D
A list of variants of interest can be found in Table 4.5.
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4.6.1 NEB S6170L SNV
An NEB variant predicted to lead to a serine to leucine amino acid substitu-
tion at position 6170 (Refseq accession: NM 004543) was identified in family D.
It is present at a low AF (gnomAD AF: 0.0002) and is predicted to be pathogenic
(CADD score: 25.4).
NEB (OMIM accession: 161650) encodes nebulin, a very large protein exclu-
sively expressed in skeletal muscle, responsible for correct assembly and length
maintenance of thin filaments in striated muscle190. Variants in NEB, most often
recessive, are associated with nemaline myopathy (NM), a heterogeneous genetic
disease causing muscle weakness and hypotonia193. NM presents histologically
as malformed Z-discs and aggregates of Z-disc proteins193. Although there is no
evidence that NM patients are susceptible to MH194, the variant is of interest
due to its high predicted pathogenicity and because of the protein’s importance
in the correct functioning of muscle. The NEB S6170L variant is reported as
being of unknown significance in relation to NM on ClinVar (ClinVar accession:
VCV000095119.1).
4.6.2 KBTBD13 G117C variant
A SNV within KBTBD13, encoding KBTBD13, predicted to cause a glycine to
cysteine substitution at amino acid position 117 (Refseq accession: NM 001101362),
was identified in individual BW1 of family D. Two out of four reads at the variant
position give evidence of the variant’s presence. There were no reads mapping
to this variant position for the other individuals of family D and therefore their
genotype for the variant is unknown.
Although there is low evidence for the existence of this variant, and no ev-
idence of segregation due to lack of coverage, this variant is reported due to
KBTBD13’s association with muscle disease: variants in KBTBD13 have been
associated with nemaline myopathy195, 196. KBTBD13 is an adaptor of the Cullin
E3 ubquitin ligase complex and a suggested pathogenesis of KBTBD13 -mediated
nemaline myopathy is that pathogenic variants of KBTBD13 prevent proper
turnover of important muscle-specific proteins192, 167. Additionally, the suspected
variant in family D is predicted to be pathogenic (CADD score: 24.6). This
variant is of interest due to the gene’s association with muscle disease.
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4.6.3 UCP3 Y294C SNV
A UCP3 SNV, predicted to lead to a tyrosine to cysteine substitution at
amino acid position 294 (Refseq accession: NM 003356), was identified in family
D. The variant appears to be novel as it was not found on any database. It is
predicted to be pathogenic (CADD score: 24.6).
UCP3 encodes mitochondrial uncoupling protein 3 (UCP3), belonging to a
family of transmembrane channel proteins that localise to the inner mitochondrial
membrane191. UCP3 is highly and specifically expressed in skeletal muscle197. As
the name suggests, uncoupling proteins are understood to uncouple the electron
transport chain and ADP phosphorylation by allowing passive proton leak down
the proton gradient191. The phosphorylation state (specifically phosphorylation
of tyrosine and serine) of UCP3 may be a mediator of its propensity for proton
passage76. UCP3 is thought to play a role in MDMA-induced hyperthermia74,
which has symptoms similar to that of an MH episode (see Chapter 1.2.4).
Segregation analysis was carried out on this UCP3 variant due to the gene’s
role in skeletal muscle energy metabolism and its association with a disorder of
similar aetiology to MH.
4.6.3.1 Segregation analysis
Sanger sequencing was carried out on individuals 2040 (MHS, heterozygous
for CACNA1S T1009K), 2041 (MHN) and 2013 (MHS, not a carrier of CACNA1S
T1009K). The variant was not carried by any of these individuals (Figure 4.9),
and the variant was therefore excluded from further analyses.
Figure 4.9: Alignment of Sanger sequencing results for individuals 2040, 2041 and
2013 against the UCP3 nucleotide sequence
The UCP3 Y294C SNV position is indicated by the red arrow. The results indicate that these
individuals do not carry the variant.
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4.7 Family E
A list of variants of interest can be found in Table 4.6.
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4.7.1 TMOD4 M332V SNV
A TMOD4 SNV predicted to lead to a methionine to valine substitution at
amino acid position 332 (Refseq accession: NM 013353) was identified in family
E. The variant has a gnomAD AF of 0.0045, which may be considered too high
to be pathogenic for MH when considering its incidence rate. The variant has
mixed pathogenicity predictions (CADD score: 13.8).
TMOD4 encodes tropomodulin 4, an actin regulatory protein expressed highly
and specifically in skeletal muscle which controls actin filament length by cap-
ping the pointed end of an actin filament to prevent further polymerisation and
depolymerisation198. The variant is of interest due to the genes role in skeletal
muscle contraction.
4.7.2 SLC16A10 I287V SNV
A SLC16A10 SNV predicted to lead to an isoleucine to valine substitution at
amino acid position 287 (Refseq accession: NM 018593) was identified in family
E. The variant identified is not predicted to be pathogenic (CADD score: 1.3).
SLC16A10 encodes monocarboxylate transporter 10, a plasma membrane
Na+-dependent transporter which controls extracellular aromatic amino acid home-
ostasis by the cellular efflux of amino acids199. The gene is highly expressed in
skeletal muscle199. It has not been previously linked to disease. The variant is
reported here due to the gene’s high skeletal muscle expression, however it is
unclear how the gene’s role could have a relationship to the pathogenesis of MH.
4.7.3 SYNE1 K7055R SNV
A SNV within SYNE1, predicted to lead to a lysine to arginine substitution
at amino acid position 7055 (Refseq accession: NM 033071), was identified in
family E. The variant is not predicted to be pathogenic, with a CADD score of
0.5.
SYNE1 encodes nesprin-1, a large nuclear membrane-associated protein which
makes up part of a protein complex linking the nucleoskeleton and the cytoskele-
ton200. Variants in SYNE1 have been associated with Emery-Dreifuss muscular
dystrophy (EDMD), a disease most commonly characterised by muscle contrac-
tures, elevated CK, myotonia and limb-girdle muscular dystrophy200. Noteably,
4.7. FAMILY E 101
there is significant overlap between symptoms of EDMD and myotonic dystro-
phy, the diagnosis present within family E. Additionally, variants in SYNE1 have
been linked to arthrogryposis multiplex congenita, a non-progressive muscle dis-
ease caused by abnormal muscle tissue fibrosis, resulting in muscle shortening,
which leads to joint contracture from birth201. The variant is of interest due to
the gene’s association with a muscle disease with symptoms closely related to the
the muscle disorder carried by family E.
4.7.4 DUSP4 A28T SNV
A DUSP4 SNV, predicted to lead to an alanine to threonine substitution at
amino acid position 28 (Refseq accession: NM 001394), was identified in family
E. The variant is predicted to be pathogenic (CADD score: 24.6).
DUSP4 encodes dual-specificity phosphatase 4 (Dusp4). Recently, Dusp4
has been implicated in skeletal myocyte differentiation - the first study which
has found a muscle cell-specific role for the protein122. The variant is of interest
because it is plausible that a protein involved in myocyte differentiation could lead
to incorrect functional expression of proteins involved in calcium homeostasis or
ECC.
4.7.5 Other variants of interest
Two other variants of note identified in family E are discussed below.
4.7.5.1 Previously identified RYR1 R1679H variant
This family has a previously identified RyR1 variant, R1679H. Although the
carrier status of this variant for family E was known, its presence provided an
opportunity to test whether the established bioinformatic pipeline was capable
of identifying the variant, and retaining it through the filtering steps.
After processing of the WES data of family E through the bioinformatic
pipeline, the variant was present in the final variants of interest list (not in-
cluded in Table 4.6), confirming the capability of the pipeline to identify rare,
predicted protein-changing variants which were segregating with MH within the
family, despite some degree of discordance.
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4.7.5.2 RYR1 E2820Q variant
The WES data indicated that individual 1247 was a carrier of an RYR1 SNV,
NM 000540.2:c.8452G>T, predicted to lead to a glutamic acid to glutamine sub-
stitution at amino acid position 2820 (Refseq accession: NM 000540). The variant
was predicted to be pathogenic and was not present on any database suggesting
it to be novel.
Two out of eight reads suggested the presence of the variant, however, lack
of coverage for the three other WES samples meant that their genotype could
not be inferred (the variant was identified prior to the new batch of WES being
carried out). Sanger sequencing was carried out, revealing that individual 1247
did not carry this variant (Appendix A.10). This suggested a WES error, although
alternatively allele dropout may have occurred during both WES and Sanger
sequencing. However, the variant was not pursued further.
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4.8 Family F
A list of variants of interest can be found in Table 4.7.
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4.8.1 ANO1 V499G SNV
An ANO1 SNV, predicted to lead to a valine to glycine substitution at amino
acid position 499 (Refseq accession: NM 018043), was identified in family F. The
variant is predicted to be pathogenic (CADD score: 24.2).
ANO1 encodes anoctamin 1 (also known as TMEM16A), a calcium-activated
chloride channel (CaCC). Anoctamin 1 is important for contraction of smooth-
muscle: channel opening leads to an efflux of Cl-, causing membrane depolar-
isation and subsequently muscle contraction202. Another CaCC, anoctamin 5
(encoded by ANO5 ), is a homologue of anoctamin 1 which is primarily expressed
in skeletal muscle204. ANO5 variants are associated with Miyoshi muscular dys-
trophy type 3 and limb girdle muscular dystrophy type 2L205. Recent evidence
by knock-down of anoctamin 5 suggests that it is responsible for the correct func-
tional expression of RYR1, DHPR and SERCA proteins206. Although anoctamin
1 is not known to play a role in skeletal muscle in humans, it was recently re-
ported that ANO1 contributes to skeletal muscle contraction intensity by action
potential modulation in zebrafish207. The variant is of interest due to the gene’s
potential role in action potential modulation: an MH episode involves persistent
activation of the RyR1 channel which could be caused by dysfunction of molecular
machinery involved in action potential generation.
4.8.2 SLC25A42 P9L SNV
A SNV within SLC25A42 identified in family F is predicted to lead to a proline
to leucine substitution at amino acid position 9 (Refseq accession: NM 001321544).
The variant has mixed pathogenicity predictions (CADD score: 12.15).
SLC25A42 (OMIM accession: 610823) encodes a mitochondrial coenzyme A
(CoA) transporter protein. CoA is a substrate in a number of crucial metabolic
pathways including the citric acid cycle and fatty acid oxidation. The gene is
highly expressed in skeletal muscle121. Variants in the gene are causative of
mitochondrial myopathies203. The variant is of interest due to the gene’s role in
energy metabolism.
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4.9 Variants of interest shared between families
4.9.1 WASHC2C variants
Rare, predicted pathogenic variants within the gene WASHC2C were identi-
fied in family A, B and F (Table 4.8). Two of these variants are presumed novel
as they could not be found in any database. The WASHC2C variant harboured
by family B has been previously reported and has a gnomAD AF of 0.00621. For
family A, the WES data suggests that the variant completely segregates with
MH susceptibility amongst the five individuals for which WES were obtained.
For family B, the WES data suggests that the variant is heterozygous in MHS
individual 1772 (MHS) (44 reads out of 99 with variant sequence), but not present
in MHS individual 919 (MHS) (0 out of 35 reads with variant sequence). There is
no coverage at the variant position for all other WES samples from family B. For
family F, the WES data suggests that all three individuals (all MHS) harbour
the WASHC2C variant.
WASHC2C encodes WASH complex subunit 2C, also known as FAM21C,
FAM21A and VPEF. The protein is a component of the WASH complex, in-
volved in endosomal sorting by regulation of the Arp2/3 complex, which is itself
involved in the induction of actin polymerisation208. Another component of the
WASH complex, strumpellin, encoded by WASHC5 (OMIM: 610657), has been
implicated in numerous human disorders. Variants in WASHC5 have been asso-
ciated with spastic paraplegia209 (a disease of motor neurons), Ritscher-Schinzel
syndrome210 (a developmental disorder affecting function of a number of organs),
and hyperkalemic periodic paralysis211 (a muscle disorder). Additionally, variants
in WASHC4, which encodes another member of the WASH complex, have been
implicated in a disorder characterised by mental retardation212. The pathophys-
iology of these variants in relation to these disorders is not currently understood.
Although there is no clear link between WASHC2C and a muscle phenotype,
it is interesting that variants affecting the WASH protein complex are implicated
in a range of disease phenotypes. The fact that rare WASHC2C variants were
identified in three of the six families under study is of interest. Further study,
beginning with segregation analysis within each of the three families for the re-
spective variants, could be undertaken to understand whether these variants may
be implicated in MH-susceptibility.
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4.9.2 GCGR R413W SNV
A rare, predicted pathogenic variant within GCGR, NM 000160:exon14:
c.1237C>T (dbSNP: rs757894502), was identified in families A and B. The vari-
ant is predicted to lead to an arginine to tryptophan substitution at amino acid
position 413 (Refseq accession: NM 000160). The variant has a gnomAD AF of
0.00005. For family A, the WES data suggests that the variant completely seg-
regates with MH susceptibility amongst the five individuals for which WES were
obtained. For family B, the WES data suggests that the variant is homozygous in
individuals 82 (MHS) and 456 (MHS), heterozygous in individuals 1772 (MHS),
1367 (MHS), 1412 (MHS), 26 (unknown) and 919 (MHS), and not present within
individuals 27 (MHSh), 251 (MHN), and 1731 (MHS). There is no coverage at
the variant position for individual 533 (MHS).
GCGR (OMIM accession: 138033) encodes the glucagon receptor, a G-protein
coupled receptor which binds glucagon and is responsible for the regulation of
blood glucose levels and glucose homeostasis. The amino acid position of the
variant (413) resides within the cytoplasmic domain of the protein213. The gene
is expressed highly in hepatic tissue, but not in skeletal muscle tissue. Although
glucagon signalling is not known to play a part in MH, it remains possible that
dis-regulation of glucose levels may have an effect on skeletal muscle energy home-
ostasis. Alternatively, the fact that both family A and B carry this rare variant
could be explained by an unknown familial link.
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4.10 Copy-number variation detection
4.10.1 Detection of known polymorphism CNVs leading
to method validation
A common polymorphism copy-number variant (CNV) that has been previ-
ously identified is reported in this section. This CNV is not thought to be of
relevance to MH or muscle disease, but is reported to validate the viability of
CNV detection using CNVkit.
4.10.1.1 Chromosome 11 duplication
A chromosome 11 duplication, approximately 30 kb in length, was identified in
WES sample 2253 from family E. The duplication has been reported previously
(dbVar accession: esv2759831) and has an estimated AF of 0.67 (out of 270
samples). Coverage of WES samples 2253 and 2259 over the chromosomal region
containing the suspect CNV is plotted in Figure 4.10.
4.10.2 Family A CNVs
No CNVs of interest were identified in family A.
4.10.3 Family B CNVs
Two CNVs of interest were identified in family B.
4.10.3.1 Chromosome 16 duplication
Individual 1731 appeared to have a duplication (4-fold normal copy number)
spanning approximately 106 kb, from base 74306327 to 74413250, at chromoso-
mal location 16q23.1. CNVkit reports the copy number of the region to be 4,
which which is likely from inspection of the coverage plot (Figure 4.11). This re-
gion harbours the gene LOC283922 whose role has not previously been reported,
however it is a pseudogene of PDPR (phosphate dehydrogenase pyruvate regula-
tory subunit), a key regulatory subunit of the pyruvate dehydrogenase complex.
It is unclear whether or not the pseudogene is expressed.
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Figure 4.10: Evidence of a chromosomal duplication of chromosome 11 in WES
sample 2253 from family E
The x-axis gives the chromosomal location, the y-axis the read depth.
4.10.3.2 Chromosome 17 deletion
An approximately 34 kb homozygous deletion within chromosome 17 (bases
64862900 - 64897300) was predicted by CNVkit for the WES sample from indi-
vidual 1412. However, as reads were present upon inspection of this region, it is
likely that there is at least one copy of the region present. This region harbours
the gene LRRC37A3, whose role is not currently understood. Expression of the
gene is reported as low on the Human Protein Atlas. Individual 1731 (MHS) did
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not appear to harbour the deletion upon inspection of WES alignment data.
Figure 4.11: Evidence of a chromosomal duplication of chromosome 16 in WES
sample 1731 from family B
The x-axis gives the chromosomal location, the y-axis the read depth. The position of the
LOC283922 gene is shown below the x-axis.
4.10.4 Family C CNVs
No CNVs of interest were identified within family C.
4.10.5 Family D CNVs
No CNVs of interest were identified within family D.
4.10.6 Family E CNVs
A chromosome 15 duplication of approximately 11 kb, from bases 101752800
to 101764500, was detected in the WES of individual 2253 (Figure 4.12). CNVkit
reports the copy number of the region to be 6. The region is not known to harbour
any genes.
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Figure 4.12: Evidence of a chromosomal duplication of chromosome 15 in WES
sample 2253 from family E
The x-axis gives the chromosomal location, the y-axis the read depth.
4.10.7 Family F CNVs
No CNVs were detected within family C.
4.10.8 Shared CNVs between families
4.10.8.1 Chromosome 22 duplication in family B and E
A duplication of chromosome 22 was detected in the MHS individuals under
CNV investigation in family B and E (Figure 4.13 & 4.14). The duplication
spans approximately 60 kb, from base 42500000 to 42560000, at chromosomal
location 22q13.2. The suspected duplicated region contains the genes SERHL
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and RRP7A.
This CNV has been reported in various publications214, 215, 216. Artuso et al.214
reports the duplication size as 49 kb between bases 42511781-42561110. Shu et
al.216 reports the size as 42 kb between bases 42508600-42550874.
Shu et al.216 reported an AF for a copy number of 3 and 4 to be 0.20 and
0.02, respectively, amongst 3913 individuals tested.
Figure 4.13: Evidence of a chromosomal duplication of chromosome 22 in WES
sample 1731 from family B
The x-axis gives the chromosomal location, the y-axis the read depth.
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Figure 4.14: Evidence of a chromosomal duplication of chromosome 22 in WES
sample 2253 from family E
The x-axis gives the chromosomal location, the y-axis the read depth.
4.10.9 KCNJ gene family
The KCNJ genes encode a family of inward rectifier potassium channel (Kir)
proteins which function to control resting membrane potential within excitable
cells and repolarisation of action potential by the conductance of K+ into the
cell217. Kir2 isoforms, including Kir2.2 and Kir2.1 (encoded by KCNJ12 and
KCNJ2 ), are the main Kir subfamily expressed in mammalian skeletal muscle121.
The channels form both homo- and hetero- tetrameric assemblies217. Identifying
variation in these proteins may be of interest to MH research as they play an
4.10. COPY-NUMBER VARIATION DETECTION 115
important role in excitability of myocytes and thus it is plausible that their dys-
function could lead to abberant action potential generation and ECC. Addition-
ally, KCNJ2 falls within the MHS2 locus, with KCNJ12 falling just outside of
this locus.
The genes KCNJ12 and KCNJ18 are paralogous218. Due to the high sequence
similarity of these paralogs, it is difficult to identify variants in these genes due
to misalignment of sequence. This problem was originally identified because rare,
predicted pathogenic variants which appeared in variants of interest lists were
being detected within KCNJ12 in all families under study. Inspection of the
sequence alignments of the KCNJ12 gene indicated that these were not true
variants as there was significant variation between the read sequences and the
genomic sequence to which they were aligning (Figure 4.15). Additionally, reads
were not mapping to KCNJ18.
A group of researchers trying to identify variants within KCNJ18 experienced
a similar issue218. The researchers were trying to identify variants within KCNJ18
as this gene is a candidate for the pathogenesis of thyrotoxic period paralysis: the
gene falls within the disease locus and its molecular function corresponds to the
condition’s manifestation which is muscle weakness and transient hypokalemia
(low blood potassium)218. The researchers found misalignment of these genes pre-
vented identification of potential variants of interest and so developed a method
to correctly map the genes218. Unfortunately, the paper’s methodology was not
explained sufficiently to allow it to be reproduced and the researchers could not
be contacted.
It could be of interest to pursue sequencing of these genes not only due to
their involvement in myocyte electrical excitability but also because it is likely
that mapping issues have previously prevented the identification of pathogenic
variants. Due to these mapping issues, it would be necessary to carry out Sanger
sequencing on the genes using well-designed primers which anneal to regions that
lack sequence similarity between the paralogs to identify variants.
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Figure 4.15: Visualisation of alignment of reads to the KCNJ12 gene representative
of all WES samples
WES sample 1652 is shown here at chromosomal position 21,415,000 - 21,420,000 of chromosome
17, which is the position of exon 3 of the KCNJ12 gene (RefSeq accession: NM 021012.5). The
red squares represent variation in the reads in comparison to the hg38 sequence which the read
is aligned to. The alignment data suggests that the reads are mismapping to this region. This
alignment represents alignment of all other WES samples analysed.
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4.11 Summary
To summarise, variants of interest were identified in all six families under
study. A number of variants were selected for segregation analysis. This ruled
out all but one variant as segregating with MH-susceptibility. In family A, a
SNV within the gene TLR3 (predicted to lead to an G320R amino acid substitu-
tion) was revealed to be segregating with MH-susceptibility for all seven family
members for which DNA was available. Due to the small sample size, further ev-
idence should be gathered, such as a population MHN screen, before the variant
is further pursued.
A number of rare, predicted pathogenic variants within the gene WASHC2C
were identified. Although it is unknown how the function of the WASH2C2 ’s
protein product could be related to the pathophysiology of MH, the variants
were reported due to the fact that they were identified in three different families
under study. It is unclear whether the WASHC2C variant identified in family
B is segregating with MH-susceptibility as there is no coverage at the variant
position for many of the WES samples. This is a good example of the power of
the established bioinformatic pipeline to identify variants that may be of interest
to MH, as this variant within family B would have been missed in other variant of
interest identification pipelines. Additionally, a rare, predicted pathogenic variant
was identified in the gene GCGR. It is unlikely that this variant is of interest to
MH as the gene is not known to be expressed in skeletal muscle, however it was
reported as the variant was identified in both family A and family B, who are not
thought to be related.
CNV analysis identified predicted CNVs in the families. It is unknown whether
or not these CNVs segregate with MH-susceptibility, as CNV analysis was only
undertaken in one MHN and MHS individual within each family. The next step
would be to analyse the other available WES for CNVs to ascertain whether
there is segregation with the disorder for any of the identified CNVs. A pre-
viously reported chromosome 22 duplication appears to be present in family B
and family E. Whether or not this is of interest is dependent on the exact copy
number in each family as a single duplication of the region seems to be a common
polymorphism, whereas a double duplication is significantly less common.
Mappability issues for two KCNJ genes were identified which are likely to
inhibit identification of variation in these genes. It could be of interest to sequence
these genes to identify potential variation.





The JSRP1 gene encodes JP-45, a small 331 amino acid transmembrane pro-
tein, enriched in skeletal muscle tissue, which resides in the sarcoplasmic retic-
ulum membrane6. It is thought to be a direct modulator of Cav1.1 activity
6.
Its N-terminal tail interacts with calsequestrin in the sarcoplasmic reticulum lu-
men and its C-terminal end interacts with Cav1.1 in the myoplasm
219. JP-45 is
required for the functional expression of Cav1.1, making it a key protein in the
development and maintenance of healthy adult skeletal muscle220.
A JSRP1 NC 000019.10:g.2252991C>G variant (dbSNP: rs80043033) leading
to a JP-45 glycine to alanine substitution at amino acid position 150 (G150A)
was identified in family B. This glycine resides in the sarcoplasmic reticulum lu-
menal domain of JP-456. The gnomAD AF of the variant is 0.2, classing it has
a common polymorphism. Although both the JSRP1 and RYR1 genes reside
on chromosome 19, JSRP1 G150A and RYR1 T4826I (also harboured by fam-
ily B) variants are not genetically linked due to the distance between the genes
(cytogenetic position 19p13.3 for JSRP1 and 19q13.2 for RYR1 ). In vitro hu-
man cell line calcium release experiments have previously established that JSRP1
G150A may alter the strength of excitation-contraction coupling in human skele-
tal muscle by leading to a decrease in DHPR activation sensitivity221. Yasuda
et. al (2013)221, with a sample size of 140 individuals, did not find a correlation
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between susceptibility to malignant hyperthermia (MH) and JSRP1 G150A vari-
ant status. Therefore the variant is not believed to directly cause - nor provide a
protective role - from MH susceptibility. However, its ability to alter the extent
to which the muscle cell reacts to an excitation event may mean that it can alter
the expressivity of an MH-related variant, potentially classing it as a disease-
modifying variant. This may explain some extent of the variability seen between
individuals in the IVCT within family B, including both those with and without
the RYR1 T4826I variant. The discovery of this variant in family B provided an
opportunity to carry out a robust genotype-phenotype association study due to
the substantial number of DNA samples and IVCT results available.
The hypothesis for this association study is that individuals carrying JSRP1
G150A will have reduced contracture values compared to individuals who do not
carry the variant. Additionally, reduction in contracture values will be more
pronounced for those homozygous for the variant.
5.2 Methods and method development
Extensive method development was required to determine a suitable assay for
large-scale genotyping of JSRP1 G150A. The following sections describe three
types of assays that were attempted: high resolution melting (HRM) analysis,
hybridisation probe analysis, and restriction length polymorphism (RFLP) geno-
typing. HRM and hybridisation probe assays were not adopted for genotyping
due to a number of problems encountered. An RFLP assay was ultimately chosen
for genotyping.
General methods used in this study can be found in Chapter 2. Primer and
probe sequences, and primer sets, can be found in Appendix A.1, Appendix A.2,
and Appendix A.3.
5.2.1 Confirming genotypes for use as controls
Sanger sequencing was carried out on family B gDNA samples 533, 919 and
1772 which confirmed the genotypes suspected through WES analysis (Appendix
A.11): 533 did not carry the variant (wild-type), 919 was homozygous for the
variant, and 1772 was heterozygous for the variant. These three samples were
used as controls in method development and final genotyping.
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5.2.2 High resolution melting assay
HRM assays are often the most time-effective and cost-appropriate method for
large-scale genotyping, and so this method was initially chosen for genotyping of
the JSRP1 G150A variant. Using HRM primer set 2, an initial HRM optimisation
assay using control samples 533 (wild-type) and 1772 (heterozygous) was able to
successfully distinguish the two genotypes (Appendix A.12). However, when this
assay was repeated with other samples, including homozygous 919, there was
difficulty in differentiating wild-type from homozygous samples. Although an
expected shift in the homozygous single melting peak with regards to the wild-
type single melting peak was observed, the shift was not pronounced enough
to easily distinguish between wild-type and homozygous genotypes (Appendix
A.13). This issue was further compounded by the fact that many gDNA samples
to be genotyped were older (some gDNA was isolated over 20 years ago) and
so were likely to be degraded to some extent. Degraded gDNA can lead to
melting curve shifts and can cause secondary peak formation even when no SNP
is present within an amplicon, meaning that unless a significant heteroduplex
peak is expected in the assay, some samples may be erroneously genotyped as
heterozygous.
This assay was repeated with replacement of 0.5 µL H2O with 0.5 µL 5x
FastStartTM Taq DNA Polymerase GC-RICH solution (Roche), but the addition
of this additive did not seem to improve the assay (Appendix A.14).
5.2.2.1 HRM primer redesign
HRM primers were redesigned to produce an amplicon shorter than that pro-
duced by HRM primer set 2 (amplicon length of 106 bp). Shorter amplicon sizes
allow greater resolution of SNVs by HRM. With a combination of newly designed
primers and primers from the original HRM primer sets, four new primer sets
were tested by PCR for amplification of the target product. HRM primer set 4
and HRM primer set 6, designed to produce amplicons of length 49 and 44 bp, re-
spectively, appeared to produce a product of the expected size over two annealing
temperatures tested. HRM primer set 5 produced an amplicon of the expected
size (88 bp). HRM primer set 3 did not produce a product. HRM primer sets 4
and 6 were chosen going forward as they produced the smallest amplicon sizes.
An initial HRM assay with HRM primer set 6 using three control genotypes
produced the expected melting peaks, with a more pronounced secondary peak
122 CHAPTER 5. JSRP1 POLYMORPHISM ASSOCIATION STUDY
present for the heterozygous control (Figure 5.1) when compared to assays with
HRM primer set 2. However, there was no improvement in the degree of shift
of the homozygous control single peak relative to the wild-type single peak. The
assay was repeated with HRM primer set 4, which gave similar results.
A method for resolving homozygous genotypes from wild-type genotypes us-
ing this HRM assay was devised which involved mixing suspected homozygous
genotype reactions with known wild-type genotype reactions (and vice-versa). It
was theorised that mixing equal amounts of wild-type and homozygous products
together should result in a melting curve which matches a heterozygous melting
curve due to the formation of heteroduplexes. This theory was tested by mixing
5 µL of wild-type 533 HRM reaction mixture with 5 µL homozygous 919 HRM
reaction mixture. A melting curve-only programme was carried out on this mixed
reaction. A heterozygous double melting peak which matched that of a known
heterozygous (529) melting peak was observed (Figure 5.2). This demonstrated
that it was possible to use this approach to distinguish homozygous genotypes
from wild-type genotypes using HRM.
Figure 5.1: Representative JSRP1 G150A genotype melting curve with HRM
primer set 6
Heterozygous 529 shows a characteristic double peak. Wild-type 533 shows a characteristic
single peak. Homozygous 919 shows a characteristic single peak shifted from the wild-type
peak. Negative control amplification was observed, with a melting peak which matched that of
the wild-type melting peak.
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Figure 5.2: Initial mixed melt curve for JSRP1 G150A homozygous genotype
confirmation
Mixing of equal parts of the HRM reaction mixture for wild-type sample 533 and homozygous
sample 919 produced a double peak closely resembling the heterozygous 529 melting curve.
5.2.2.2 Negative control amplification
Negative control amplification was observed in most assays carried out using
primer set 4 and 6, and this negative control melting curve was similar to that of
the wild-type melting curve (Figure 5.1). DNA contamination, or primer dimer
formation, were two potential explanations for the negative control amplification.
As amplification was still observed after changing stock solutions multiple times,
including the LightCycler® 480 High Resolution Melting Master (Roche) and
primer stocks, the amplification was likely caused by primer dimers. Testing
this hypothesis would require the determination of the length of the negative
control amplification product. A length that differed from the length of the
target product (44 bp) would suggest primer dimer formation.
5.2.2.3 Native polyacrylamide gel electrophoresis for determination of
negative control amplification size
Non-denaturing polyacrylamide gel electrophoresis was carried out to resolve
possible differences in the size of the negative control amplification product and
the positive control products. A 20% polyacrylamide gel was prepared contain-
ing the following: 6.25 mL 40% 29:1 acrylamide/bisacrylamide, 1.25 mL 5x TBE
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buffer, 5 mL dH2O, 125 µL 10% (w/v) APS (ammonium persulfate) and 12.5
µL TEMED (tetramethylethylenediamine). The electrophoresis was carried out
at 120 V for 8 hours. One µL GeneRuler Ultra Low Range DNA Ladder (Ther-
moFisher, Cat. No. SM1213) was loaded alongside products for fragment size
estimation.
Analysis of the product sizes indicated that the size of the positive control
amplification products (44 bp) and negative control amplification product were
the same (Figure 5.3), suggesting that presence of DNA contamination was the
cause of negative control amplification.
Because of the continued issues with development of an HRM assay, an alter-
native assay for large-scale genotyping was attempted.
Figure 5.3: 20% native polyacrylamide gel for determination of negative control
amplification product size for the JSRP1 HRM assay
DNA ladder is the GeneRuler Ultra Low Range DNA Ladder (ThermoFisher). Reaction A con-
tained 0.4 µL of 5 µM primers with no additives. Reaction B contained 0.6 µL of 5 µM primers
with 0.5 µL 5x FastStartTM Taq DNA Polymerase GC-RICH solution (Roche). Reaction C
contained 0.4 µL of 5 µM primers and 0.5 µL GC-RICH solution. gDNA from individual 1731
was added to reactions labelled ‘DNA’. dH2O was used in place of DNA for reactions labelled
‘H2O’.
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5.2.3 Hybridisation probe assay
5.2.3.1 Principle of the hybridisation probe assay
Hybridisation probe (HybProbe) analysis is a genotyping technique which in-
volves the use of fluorescently-labelled nucleic acid hybridisation probes for allele
detection and discrimination. It is similar to HRM in that discrimination of al-
leles is achieved by detection of changes in fluorescence - caused by DNA strand
melting - over a temperature range (melting curve differences). A HybProbe as-
say requires typical forward and reverse primers for amplification of a short (∼150
bp) amplicon containing the allele of interest, as well as anchor and sensor probes
which are designed to anneal adjacently to the same DNA strand within the am-
plicon region. A detailed explanation of the principle of the HybProbe assay is
given in Figure 5.4. A benefit of doing a HybProbe assay is that, unlike HRM, off-
target amplification should not alter the melting curve due to the requirement for
sequence complementarity between the probes and the target amplification prod-
uct. For the same reason, primer dimers are generally not an issue. Ultimately,
a HybProbe assay tends to allow clear discrimination of wild-type, heterozygous
and homozygous carriers for a given SNP.
In this study, a fluorescein-labelled sensor probe and a Cy5-labelled anchor
probe were used. Fluorescein has an absorbance range of ∼430-520 nm and an
emission range of ∼500-600 nm, whereas Cy5 (the acceptor) has an absorbance
range of ∼530-675 nm and an emission range of ∼630-780 nm. This spectral
overlap, demonstrated in Figure 5.5, allows FRET to occur when fluorescein is
exposed to its excitation wavelength.
5.2.3.2 Probe and primer design
The LightCycler® Probe Design Software 2.0 (Roche) was used to design the
HybProbe assay primers and probes. Primer and probe sequences can be found in
Appendix A.1 and Appendix A.2, respectively. The sensor probe, 16 nucleotides
in length, was designed, by default, to complement the sense strand of the variant
sequence. The primers designed by the software (HybProbe primer set 1) were
tested by PCR over a range of temperatures but were not used due to off-target
amplification (Appendix A.15). The fact that these primers were short, both
18 nucleotides, likely contributed to these problems as shorter primer lengths
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Figure 5.4: Principle of the HybProbe assay
The sensor probe, which has a fluorophore ligated to its 3’ end, is designed to hybridise to the
sequence containing the SNP, and is able to tolerate single nucleotide mismatches. The anchor
probe is designed to hybridise to the 3’ side of the sensor probe, on the same DNA strand,
and has a different fluorophore ligated to its 5’ end. Additionally, the anchor probe contains a
phosphate group at its 3’ end to prevent DNA elongation. One fluorophore is the donor, the
other fluorophore the acceptor. Light of a specific wavelength excites the donor fluorophore,
which will then transfer this energy to the acceptor fluorophore in a process known as Förster
resonance energy transfer (FRET). FRET will occur only if the donor and acceptor fluorophores
are within a range of a few bp, with FRET efficiency dropping considerably with distances of
greater than ∼10 nm222. Excitation of the acceptor fluorophore will then lead to detectable
emission at a specific wavelength. Over a certain temperature range, the anchor and sensor
probes will dissociate from the DNA strand, causing a decrease in FRET. The temperature
at which the sensor probe dissociates is dependent on the sequence complementarity, allowing
detection of a variant.
Figure 5.5: Absorption and emission spectra of fluorescein and Cy5 fluorophores
The spectral overlap represents the wavelengths at which absorption by Cy5 of emitted energy
from fluorescein occurs. The y-axis represents relative fluorescence intensity (no units).
increase the possibility of off-target amplification. The primers were redesigned
(HybProbe primer set 2) and were determined to exclusively amplify a product
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of an expected size of 183 nucleotides by gel electrophoresis.
5.2.3.3 HybProbe assay method development
Initially, the assay was carried out using PerfeCTa® qPCR ToughMix® (QuantaBio)
to the manufacturer’s suggested protocol. Unless otherwise stated, each 10 µL re-
action contained the following: 0.5 µL each of 5 µM forward and reverse primers,
100 nM each of sensor and anchor probes, 5 µL 2x PerfeCTa® qPCR ToughMix®
(QuantaBio), 0.5 µL 50 ng µL−1 gDNA, and a variable volume of dH2O to make
up to 10 µL. LightCycler® machine conditions were varied as stated but were
initially as follows: 95 ℃ for five minutes for initial denaturation; 40 cycles of 95
℃ for 10 seconds, 60 ℃ for 20 seconds, and 72 ℃ for 10 seconds for amplification;
95 ℃ for one minute, 60 ℃ for three minutes, and a target of 90 ℃ for melting
curve fluorescence acquisition; and lastly 45 ℃ for 30 seconds for cooling. A sin-
gle fluorescence acquisition was taken upon reaching the 60 ℃ target during each
amplification cycle. Five (continuous) fluorescence acquisitions per ℃ were taken
as the temperature was increased at a ramp rate of 0.11 ℃ per second between
45 ℃ and 90 ℃ during the melt curve cycle.
The first HybProbe assay carried out was unsuccessful, with no FRET changes
observed (Appendix A.16). Amplification did occur, as a product of the expected
size was visualised by agarose gel electrophoresis. Lowering of the probe binding
temperatures from 60℃ to 56℃, 52℃, and to as low as 45℃, did not improve the
assay. A variety of other assay conditions were tested, as listed below.
• Varying of sensor and probe concentrations. The sensor and probe
concentrations were both increased by 1.5- or 2-fold, or the sensor concen-
tration alone was increased 2- or 3-fold.
• Change of master mix. The LightCycler® 480 Genotyping Master
(Roche) was used‡.
• Addition of additives. 0.5 µL dH2O was replaced with 0.5 µL 5x FastStartTM
Taq DNA Polymerase GC-RICH Solution (Roche).
• Change of genotype. Throughout the assay optimisations, wild-type,
heterozygous and homozygous gDNA was used.
‡For the 5x LightCycler® 480 Genotyping Master, 2 µL was added in place of 5 µL of the
PerfeCTa® qPCR ToughMix®.
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None of the changes in conditions improved the assay.
The genomic region surrounding the variant site (within approximately 100
bp either side of the variant) was checked for known common polymorphisms.
Additionally, the WES data of individuals from family B was analysed for variants
in this region. No known polymorphisms or evidence of variation was discovered,
ruling out the possibility that probe binding was inhibited by the presence of an
unknown variant.
As fluorescence was not being detected, and amplification problems were ruled
out, attention was turned to the integrity of the fluorescent probes. Firstly, the
probe concentrations were confirmed to be correct by measurement with the De-
Novix spectrophotometer using the ssDNA sample type function. Next, fluores-
cence of the sensor and anchor probes was measured using the DeNovix DS-11
FX+ fluorometer. The sensor probe (fluorescein) was excited with 470 nm light
and the anchor probe (Cy5) with 635 nm light. Multiple measurements, using
a range of concentrations, determined that fluorescence of the sensor probe was
significantly lower, by a factor of approximately 75-fold, than that of the anchor
probe (Appendix A.17).
Because of a lack of sensor probe emission, a PCR was carried out using
the sensor probe and the JSRP1 G150A reverse sequencing primer to test for
the presence of the 3’ fluorescein modification: polymerisation should occur if
there is no 3’ modification. The PCR was carried out over three different primer
annealing temperatures: 56℃, 58℃ and 60℃. This PCR was carried out alongside
a control PCR with both forward and reverse JSRP1 G150A sequencing primers.
The PCR products were visualised by agarose gel electrophoresis (Figure 5.6).
No PCR products were observed for the reactions with sensor probe and reverse
primer. This did not rule out the possibility that the 3’ modification was not
present or was damaged, as lack of amplification may have been caused by sub-
optimal PCR conditions. The cause of sensor probe problems therefore remained
elusive.
The sensor probe was re-synthesised from IDT and the concentration and flu-
orescence of this new probe was measured on the DeNovix fluorometer as before.
There was a ∼3 fold increase in RFU compared to the previously synthesised sen-
sor probe (Appendix A.17), however, the RFU was still significantly lower than
the anchor probe.
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Figure 5.6: Agarose gel electrophoresis of PCR products testing for the presence
of a 3’ modification of the sensor probe
L is 1 kb+ DNA ladder. A, B and C are PCRs carried out, in the presence of gDNA, with the
HybProbe sensor probe and JSRP1 G150A reverse sequencing primer at annealing temperatures
of 56℃, 58℃ and 60℃, respectively. D is a negative control carried out with the same conditions
as B. E is a positive control carried out with both forward and reverse JSRP1 G150A sequencing
primers. A PCR product of the expected target size, 435 bp, is present in lane E.
5.2.3.4 Error in probe design
At a later time, it was discovered that the sensor probe sequence had been
designed incorrectly. The design was intended to complement an 18 nucleotide
stretch of DNA that included the G150A variant, however, the G>C variant was
incorrectly placed one nucleotide adjacent to the variant position (Figure 5.7).
Figure 5.7: Intended probe design sequence verses actual probe design sequence
A) is the wild-type sequence for the 18 nucleotide stretch. B) is the variant sequence, with
the bolded nucleotide being the variant. C) is the actual sequence, with the bolded nucleotide
being the incorrectly placed variant.
This would result in a one nucleotide mismatch for the wild-type sequence
and a two nucleotide mismatch for the variant sequence. This may explain some
of the issues that were encountered with this assay. However, sensor probes are
designed to have a one nucleotide mismatch from a wild-type sequence, and so
there should be a degree of tolerance for mismatches. As wild-type gDNA was
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used when attempting the assay under various conditions, there was only a one
nucleotide mismatch with this misdesigned probe.
Another explanation for the lack of fluorescence is that the amplicon or probes
may have been forming hair-pins, heterodimers or homodimers. The amplified
sequence, and the probes by default, are GC-rich and contain repetitive tri-
nucleotide strings GGG and CCC. This had previously made it difficult to design
suitable primers to the region surrounding the variant. Even if this was the case,
it does not explain the lack of sensor probe emission.
In conclusion, the cause of the assay failure was not determined and an alter-
native assay was investigated as described in the next section.
5.2.4 Restriction fragment length polymorphism genotyp-
ing
Three restriction enzyme cut sites were identified at the variant site: EcoRII,
PasI and ScrFI. ScrFI (NEB) was selected to carry out RFLP analysis. Table 5.1
and Figure 5.8 show the expected products after complete digestion by ScrFI for
wild-type, homozygous and heterozygous genotypes.
Genotype Expected product size/s
wild-type 81, 25
heterozygous 106, 81, 25
homozygous 106
Table 5.1: Expected fragment sizes upon ScrFI complete digestion
Sizes are given in bp.
Unless otherwise stated, each restriction digest using ScrFI was performed
in the following manner: PCR was carried out on gDNA of each sample to be
tested for the presence of the variant using HRM primer set 2 (Appendix A.3).
The PCR product was visualised by agarose gel electrophoresis for confirmation
of successful PCR (a product of 106 bp). One and a half µL 10x CutSmart®
(NEB®, Cat No. B7204S) Buffer, 0.4 µL 5,000 units mL−1 ScrFI and 13.1 µL
PCR product was added to a microcentrifuge tube. The reaction was incubated
at 37℃ for 60 minutes. Fourteen µL of this reaction was loaded onto a 2.2% TAE
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Figure 5.8: Schematic representation of expected fragment sizes upon SrcFI com-
plete digestion
agarose gel containing 0.2 µg mL−1 ethidium bromide and electrophoresis was
carried out at 100 V for approximately one hour. For each gel, digested geno-
typing standards were loaded alongside the digested unknowns. The genotyping
standards were wild-type 533, homozygous 919 and heterozygous 1772. The gels
were visualised under UV light for DNA band visualisation. Genotypes were de-
termined by comparing band patterns with the standards. If no digestion of the
106 bp PCR product was observed, the DNA sample was Sanger sequenced to
confirm a homozygous genotype and to disprove the alternative conclusion of a
failed restriction digest. A gel image from an initial proof-of-concept restriction
digest which was carried out on genotyping standards 533, 919 and 1772 can be
seen in Figure 5.9.
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Figure 5.9: Agarose gel electrophoresis of restriction digest products from genotype
standards for JSRP1 G150A RFLP assay
Gel is 2% agarose. Band labelled A is uncut 106 bp PCR product. B is 81 bp digested product.
C is 25 bp digested product. ‘wt’ is wild-type, ‘hom’ is homozygous, and ‘het’ is heterozygous.
Ladder is 1 kb+ DNA ladder. The red lines aid in identification of the DNA bands.
5.2.5 Statistical analysis
RStudio version 1.2.1335 and ggplot2 version 3.2.1136 with R version 3.6.1 was
used to perform statistical analyses and create plots (script available at https://
github.com/sormond/Masters/scripts/JSRP1 script.R). A linear regression model
was used to determine whether JSRP1 G150A carrier status had a predictor effect
on IVCT contracture values. As it has been previously established that RYR1
T4826I carrier status is a strong predictor of contracture values, an ANOVA test
was carried out on the following two linear models (where: c is contracture force
in grams, r is RYR1 T4826I carrier status and j is JSRP1 G150A carrier status):
c ∼ r
c ∼ r + j
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5.3 Results
One hundred and twenty-nine gDNA samples in total were genotyped for
JSRP1 G150A variant. Gel images of PCR and RFLP products for all sam-
ples can be found in Appendix A.22, A.23, A.24, A.25, A.26, A.27 and A.29.
Tabulated data of all samples and genotypes determined through RFLP anal-
ysis are presented in Appendix A.30 and Appendix A.31. The raw data file
used for the R script is available in the supplementary material directory of
https://github.com/sormond/
Masters (supp material/ JSRP1 association data.csv). Of these genotyped sam-
ples, 61 were wild-type, 63 were heterozygous, and five were homozygous. Aside
from the control homozygous sample 919, three other samples suspected homozy-
gous were Sanger sequenced, which confirmed their genotype (Figure 5.10). Raw
data is available
Figure 5.10: Alignment of Sanger sequencing results for individuals 6, 39 and 2075
against the JSRP1 nucleotide sequence
The JSRP1 G150A SNV position is indicated by the red arrow. The results indicate that these
individuals are homozygous for the variant.
IVCT halothane and caffeine contracture values are plotted against JSRP1
G150A variant status for all samples in Figure 5.11. Plots for samples that are
carriers or not carriers of RYR1 T4826I variant are given in Figures 5.12 and 5.13,
respectively. No significant association between JSRP1 G150A variant status for
either halothane (F1, 117 = 0.355, P = 0.519) and caffeine (F1, 117 = 0.266, P =
0.393) contracture values was observed ¶.
¶Out of 129 genotyped samples, eight were omitted from the statistical calculation because
RYR1 T4826I variant carrier status was unknown for these individuals or because a suspected
homozygous genotype was not confirmed by Sanger sequencing.
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Figure 5.11: IVCT halothane and caffeine contracture force with JSRP1 G150A
genotype for all samples tested
Figure 5.12: IVCT halothane and caffeine contracture force with JSRP1 G150A
genotype for all samples carrying the RYR1 T4826I variant
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Figure 5.13: IVCT halothane and caffeine contracture force with JSRP1 G150A
genotype for all samples that do not carry the RYR1 T4826I variant
5.4 Discussion
This study sought to establish whether harbouring the JSRP1 G150A poly-
morphism could lead to a reduction in IVCT contracture values. Previous cal-
cium release experiments using human cell lines harbouring the variant showed
it to lead to a decrease in the activation sensitivity of DHPR in EC coupling in
vitro 221, but it was unknown whether this would translate to contracture force
measured by IVCT. If this variant was determined to correlate with a decrease
in contracture force, it would be the first time a genetic variant which is not
suspected to be pathogenic for MH has been demonstrated to alter IVCT val-
ues. This is significant because to date, the considerable variation seen in IVCT
contracture force has not been successfully attributed to environmental and/or
genetic components, aside from suspected and confirmed MH-pathogenic vari-
ants. Identifying these other components may help to explain the complexity
of MH-susceptibility: For example, why an MH episode is not always triggered
in MH-susceptible individuals exposed to triggering volatile anaesthetic agents42
and the existence of rare heat- and temperature-induced MH episodes43.
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The results of this study were inconsistent with the hypothesis that the JSRP1
G150A variant is associated with IVCT contracture force for both halothane and
caffeine within family B. This does not entirely rule out the possibility that the
JSRP1 G150A polymorphism is a modifying variant however. It is possible that
carrying both copies of the polymorphism is necessary to see a significant effect
on the results of the IVCT, and with only four confirmed homozygous individuals
from family B, it is unlikely that these samples provided the statistical power to
see this effect. No JSRP1 variant homozygous individuals carrying RYR1 T4826I
were identified, and therefore it was not possible to statistically test whether har-
bouring two copies of the JSRP1 variant has a modifying effect on RYR1 T4826I.
The results of this experiment cannot be extrapolated to discern whether a ge-
netic variant may modify the effect of certain other MH-related variants (whether
that be unknown variants or known MH-pathogenic variants not within family
B). Additionally, as the IVCT protocol was designed to sensitively detect MH-
susceptibility, the results of the test cannot necessarily be used to determine how
a genetic variant may effect the extent of MH-susceptibility within an individual.
It is plausible that the variability seen in IVCT contracture values between
individuals is highly dependent on environmental factors, and that genetic ele-
ments, aside from MH-causative variants, do not significantly alter these values.
Unless any genetic factors contributing to this variability are identified, this will
largely remain unknown as it is not feasible to perform more than one IVCT
on an individual which would be required to determine the extent to which the
environment contributes to the variability.
Chapter 6
Conclusion
It is important that the underlying molecular mechanisms of malignant hy-
perthermia (MH) be understood so that individuals within these families can
be diagnosed by genetic screening as opposed to the in vitro contracture test
(IVCT), the current invasive diagnostic test employed for MH diagnosis. Ad-
ditionally, identifying MH-pathogenic variants may improve the current under-
standing of the inner workings of the myocyte. This could have implications
for understanding and treatment of other muscle disorders. Unfortunately, this
research did not conclusively uncover variants which seem to strongly associate
with MH-susceptibility.
Excellently summarised in Frésard & Montgomery (2018)223, there are a num-
ber of possible reasons that a suspected pathogenic variant may not be detected
in WES analysis. These include the following:
1. The pathogenic variant was missed
It may be that an MH-pathogenic variant is present within a final variants of
interest list, but that it was discarded as a candidate variant because the protein
function of a gene did not seem relevant to MH aetiology. The fact that the
cause of MH in almost half of all MH families is unknown suggests that there may
be missing pieces to the puzzle in the understanding of MH, and so it is quite
plausible that researchers are searching for variants in the wrong genes. It may
also have been missed due to a current limited understanding of a gene’s function.
Even if a protein-coding gene and its product has been characterised, there may
be alternative unknown gene transcripts or roles of the protein. Alternatively, a
pathogenic variant may fall within one of the number of known genes which are
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not captured through WES224. Additionally, the identification of mappability
issues within the KNCJ gene family has suggested that variants within genes
that could potentially be of interest to MH research may not be identified.
2. The pathogenic variant does not lie within the exome
One assumption of this study was that the MH-pathogenic variants were present
within the exome. Although variants within the exome currently account for the
vast majority of known pathogenic variants, it is possible that many pathogenic
variants causing disease are being missed because of a focus on the exome. Disease
causative non-coding variants are known to impact normal gene regulation225.
Although it is hard to imagine how a variant which alters a gene’s expression
could be pathogenic for MH because MH is not a loss-of-function phenotype and
known pathogenic MH variants are gain-of-function56, 55, 42, this avenue should
not be ruled out.
3. Monogenic aetiology does not sufficiently explain malignant hyper-
thermia
A recurring issue in MH genetics is the presence of discordance226, 130 within fam-
ilies with variants which are believed to be pathogenic for MH. This could be
due to misdiagnosis by IVCT62, but another explanation could be the presence
of currently unknown disease modifying variants. This could be preventing the
identification of MH-pathogenic variants. A disease modifying variant may alter
the expression of a gene harbouring a pathogenic variant, and thus could affect
the disease phenotype. For instance, the phenotype of an MH-pathogenic variant
could be masked by a second variant, leading to an MHN diagnosis in an individ-
ual carrying the MH-pathogenic variant. This would prevent the identification
of the pathogenic variant, as it is currently assumed that MHN individuals will
not carry an unknown MH-pathogenic variant. To account for this possibility,
some degree of lenience should be integrated into the gtFilter programme used in
the bioinformatic pipeline. Currently, gtFilter only accounts for the possibility
of the presence of individuals incorrectly diagnosed as MHS. Importantly how-
ever, larger cohorts of individuals for both bioinformatic analyses to identify VOI
and segregation analyses would be necessary. It would be extremely difficult to
identify modifying variants, especially if a modifier was harboured by only one or
a handful of individuals within a family, however there is potential that greater
future understanding of molecular processes governing susceptibility to MH will
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aid in the discovery of modifying genetic elements.
There is one variant, JSRP1 G150A, which, at present, is the only common
polymorphism postulated to be disease-modifying for MH. A genotype-phenotype
association study was carried out on the variant, previously associated with re-
duced strength of excitation-contraction coupling upon a stimulation event221,
which sought to establish whether the variant could have an affect on IVCT
contracture responses. The polymorphism did not appear to be associated with
altered IVCT contracture values to either caffeine and halothane in the family
investigated.
Regarding the bioinformatic aspect of the project, this research has high-
lighted the importance of taking both the disorder under study and the sequenc-
ing data at hand into consideration when establishing a suitable bioinformatic
pipeline. In this case, a strict variant filtering system could not be used because
the diagnostic method for determining phenotype was imperfect62. Addition-
ally, the establishment of this bioinformatic pipeline required an understanding
of the quality of the whole exome sequencing (WES) data and the impact that
this would have on the ability to capture VOI. Somewhat uniquely, this study
involved the use of WES data from a range of technologies over a number of
years. It was quickly established that this had implications on the identification
and filtering of variants, as both low WES data quality and lack of agreement
between WES kit target regions meant that potential VOI were not identifiable
in some samples. It was important that the bioinformatic pipeline retain any
VOI, even if they were not identified, due to lack of coverage, in most of the
samples. One good example of the effectiveness of the established bioinformatic
pipeline was the identification of a WASHC2C variant in family B, in which only
two WES samples were genotyped due to a lack of coverage at the variant region
for other family B samples; a potential association between WASHC2C variation
and MH-susceptibility was recognised because of this, as variants within this gene
were also identified in families A and C.
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6.1 Future directions
6.1.1 Segregation analysis of identified variants
Confirmation of the presence of a variant by Sanger sequencing, followed by
segregation analysis using high resolution melting analysis, should be performed
for the other VOI identified in this project. For the identified copy number
variants (CNV), performing CNV analysis using CNVkit126 as described on other
WES data from the families would be necessary to ascertain whether a CNV is
segregating with MH-susceptibility. If segregation amongst the WES samples
was established, it would be useful to carry out a more comprehensive literature
search to see whether this CNV has been previously reported. Then, confirmation
of the presence of the CNV using gDNA from the WES-sampled individuals could
be carried out by quantitative-PCR.
6.1.2 Carrying out further sequencing
Increasing the number of sequenced samples will increase the probability of
identifying segregating variants of interest. If the pathogenic variant was missed
because of a lack of knowledge of protein function and/or MH pathomechanisms,
undertaking further sequencing on the families, and on other MH families, will
increase the likelihood of identification of common genes and variants. Addition-
ally, it could be beneficial to carry out whole genome sequencing, as this would
provide an opportunity to identify segregating CNVs and non-coding variants,
however this would be significantly more expensive and would require modifica-
tion of the current bioinformatic pipeline. Resequencing should be undertaken
on family D and family F due to the very low WES coverage.
6.1.3 Future reanalysis of WES data
The constant improvement in sequencing technologies, and in the collective
understanding of the human genome and human genetic disease, will translate
to improved sequencing data, bioinformatic tools, and bioinformatic resources.
This makes it imperative that reanalysis of WES data, as suggested by Nam-
bot et al. (2018)129, be undertaken in the future. Reanalysis would involve
analysing the WES data using the bioinformatic pipeline with the most recently
released versions and databases, including RefSeq102 (gene transcripts), the Gene
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Ontology116, 117 (known gene functions), dbSNP119 (known variants), the Hu-
man Protein Atlas121 (tissue gene expression), as well as other categorical and
functional annotations applied to variants by VarAFT123. Updated versions of
software, such as the Genome Analysis Toolkit94, used for processing human
genomic sequencing data should also be used to ensure WES data processing fol-
lows future best practices. Additionally, it would be beneficial to apply updated
allele frequencies to the variants, especially if large-scale genome sequencing is
undertaken on Māori or Pasifika populations. This has the potential to greatly
decrease the number of polymorphisms that appear rare within Māori or other
under-represented ethnicities due to the current European bias present within al-
lele frequency databases. To account for the possibility that a disease modifying
variant may be hindering identification of an MH-pathogenic variant by mask-
ing an MHS phenotype, the gtFilter programme should be updated to include a
leniency for MHN individuals.
6.1.4 Functional analysis of segregating variants
If a variant is identified and discovered to be segregating with MH-susceptibility
within a family, functional analysis of the effected protein should be undertaken.
Functional characterisation is a requirement for acceptance of a diagnostic MH
variant according to European Malignant Hyperthermia Group guidelines45. How
this functional analysis could be carried out would be dependent on the affected
protein. Currently, RYR1 variants are functionally characterised in vitro using
human HEK293T cell lines by transfection with RYR1 cDNA harbouring the
VOI55, 56. Ca2+ release is measured upon treatment with RyR1 agonists. How-
ever, these cells do not accurately mimic in vivo myocytes as they do not have a
sarcoplasmic reticulum and do not express skeletal muscle DHPR and other pro-
teins involved in the excitation-contraction coupling machinery. This is a current
major limitation in the functional characterisation of non-RYR1 variants. How-
ever, if a segregating variant was identified in a gene encoding a protein which is
believed to interact and functionally alter RyR1’s properties, Ca2+ release assays
could be carried out on a human cell line co-transfected with cDNA of RYR1 and
the gene of interest. Additionally, a mouse knock-out of the gene in question, fol-
lowed by knock-in of the variant gene, could help to dissect protein function and
and inform in vitro functional studies.
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6.2 Concluding remarks
Although this study has not uncovered a variant which strongly associates
with MH in any of the six families under study, the work described in this thesis
has provided a sound platform for future studies. A bioinformatic pipeline capable
of identifying VOI and filtering them in a phenotype-specific manner, whilst also
taking into account potential inaccurate diagnoses of the phenotype, has been
established. This pipeline has been demonstrated to be robust and can be used
to study other uncharacterised MH families. Additionally, segregation analysis
has not yet been carried out for a number of identified VOI, providing further
research avenues.
Although there have been a number of VOI that have been ruled out as
being pathogenic for MH-susceptibility, it is important to bear in mind that there
have been occurrences of MHN individuals harbouring familial variants that are
known to be pathogenic for MH227. Additional gDNA and phenotypic data will
be obtained from the families in future, providing the opportunity to perform
larger studies on segregation for VOI, and to carry out further WES or WGS for
bioinformatic analyses. In the meantime, the variants of interest identified in this
study should remain as such, simply variants of interest.
Bibliography
[1] D. Richfield. Medical gallery of david richfield. https://en.wikiversity.
org/wiki/WikiJournal_of_Medicine/Medical_gallery_of_David_
Richfield_2014, 2014. ISSN ISSN 2002-4436. Accessed on 2020-08-02.
[2] Blausen.com staff. Medical gallery of blausen medical. https:
//en.wikiversity.org/wiki/WikiJournal_of_Medicine/Medical_
gallery_of_Blausen_Medical_2014, 2014. ISSN 2002-4436. Accessed on
2019-05-23.
[3] E. Rios and G. Brum. Involvement of dihydropyridine receptors in exci-
tation contraction coupling in skeletal-muscle. Nature, 325(6106):717–720,
FEB 19 1987. ISSN 0028-0836. doi: {10.1038/325717a0}.
[4] C. Proenza, J. O’Brien, J. Nakai, S. Mukherjee, P. D. Allen, and K. G.
Beam. Identification of a region of RyR1 that participates in allosteric
coupling with the alpha(1s) (Ca(V)1.1) II-III loop. Journal Of Biological
Chemistry, 277(8):6530–6535, FEB 22 2002. ISSN 0021-9258. doi: {10.
1074/jbc.M106471200}.
[5] B. R. Nelson, F. Wu, Y. Liu, D. M. Anderson, J. McAnally, W. Lin, S. C.
Cannon, et al. Skeletal muscle-specific T-tubule protein STAC3 mediates
voltage-induced Ca2+ release and contractility. Proceedings of the National
Academy of Sciences of the United States of America, 110(29):11881–11886,
JUL 16 2013. ISSN 0027-8424. doi: {10.1073/pnas.1310571110}.
[6] A. A. Anderson, X. Altafaj, Z. Zheng, Z. Wang, O. Delbono, M. Ronjat,
S. Treves, et al. The junctional SR protein JP-45 affects the functional
expression of the voltage-dependent Ca2+ channel Ca(v)1.1. Journal of




[7] M. Fill and J. A. Copello. Ryanodine receptor calcium release channels.
Physiological Reviews, 82(4):893–922, OCT 2002. ISSN 0031-9333. doi:
{10.1152/physrev.00013.2002}.
[8] Z. Yan, X. Bai, C. Yan, J. Wu, Z. Li, T. Xie, W. Peng, et al. Structure of
the rabbit ryanodine receptor RyR1 at near-atomic resolution. Nature, 517
(7532):50+, JAN 1 2015. ISSN 0028-0836. doi: {10.1038/nature14063}.
[9] G. G. Rodney, B. Y. Williams, G. M. Strasburg, K. Beckingham, and
S. L. Hamilton. Regulation of RYR1 activity by Ca2+ and calmod-
ulin. Biochemistry, 39(26):7807–7812, JUL 4 2000. ISSN 0006-2960. doi:
{10.1021/bi0005660}.
[10] L. W. Xiong, J. Z. Zhang, R. He, and S. L. Hamilton. A Ca2+-binding
domain in RyR1 that interacts with the calmodulin binding site and modu-
lates channel activity. Biophysical Journal, 90(1):173–182, JAN 2006. ISSN
0006-3495. doi: {10.1529/biophysj.105.066092}.
[11] R. T. Rebbeck, F. R. Nitu, D. Rohde, P. Most, D. M. Bers, D. D. Thomas,
and R. L. Cornea. S100A1 protein does not compete with calmodulin for
ryanodine receptor binding but structurally alters the ryanodine receptor
center dot calmodulin complex. Journal Of Biological Chemistry, 291(30):
15896–15907, JUL 22 2016. doi: {10.1074/jbc.M115.713107}.
[12] W. Guo and K. P. Campbell. Association of triadin with the ryanodine re-
ceptor and calsequestrin in the lumen of the sarcoplasmic-reticulum. Jour-
nal Of Biological Chemistry, 270(16):9027–9030, APR 21 1995. ISSN 0021-
9258. doi: {10.1074/jbc.270.16.9027}.
[13] N. A. Beard, M. M. Sakowska, A. F. Dulhunty, and D. R. Laver. Calse-
questrin is an inhibitor of skeletal muscle ryanodine receptor calcium release
channels. Biophysical Journal, 82(1):310–320, JAN 2002. ISSN 0006-3495.
doi: {10.1016/S0006-3495(02)75396-4}.
[14] N. A. Beard and A. F. Dulhunty. C-terminal residues of skeletal muscle
calsequestrin are essential for calcium binding and for skeletal ryanodine
receptor inhibition. Skeletal Muscle, 5, FEB 22 2015. ISSN 2044-5040. doi:
{10.1186/s13395-015-0029-7}.
BIBLIOGRAPHY 145
[15] L. Wei, E. M. Gallant, A. F. Dulhunty, and N. A. Beard. Junctin and tri-
adin each activate skeletal ryanodine receptors but junctin alone mediates
functional interactions with calsequestrin. International Journal of Bio-
chemistry & Cell Biology, 41(11):2214–2224, NOV 2009. ISSN 1357-2725.
doi: {10.1016/j.biocel.2009.04.017}.
[16] S. Boncompagni, M. Thomas, J. R. Lopez, P. D. Allen, Q. Yuan, E. G.
Kranias, C. Franzini-Armstrong, et al. Triadin/junctin double null mouse
reveals a differential role for triadin and junctin in anchoring CASQ to the
JSR and regulating Ca2+ homeostasis. PLOS One, 7(7), JUL 2 2012. ISSN
1932-6203. doi: {10.1371/journal.pone.0039962}.
[17] B. Mosca, J. Eckhardt, L. Bergamelli, S. Treves, R. Bongianino, M. De Ne-
gri, S. G. Priori, et al. Role of the JP45-calsequestrin complex on calcium
entry in slow twitch skeletal muscles. Journal Of Biological Chemistry, 291
(28):14555–14565, JUL 8 2016. doi: {10.1074/jbc.M115.709071}.
[18] T. Wang, L. Zhang, C. Shi, R. Wei, and C. Yin. Interaction of the Homer1
EVH1 domain and skeletal muscle ryanodine receptor. Biochemical and
Biophysical Research Communications, 514(3):720–725, JUN 30 2019. ISSN
0006-291X. doi: {10.1016/j.bbrc.2019.04.199}.
[19] W. Feng, J. C. Tu, T. Z. Yang, P. S. Vernon, P. D. Allen, P. F. Worley, and
I. N. Pessah. Homer regulates gain of ryanodine receptor type 1 channel
complex. Journal Of Biological Chemistry, 277(47):44722–44730, NOV 22
2002. ISSN 0021-9258. doi: {10.1074/jbc.M207675200}.
[20] W. Feng, J. Tu, P. Pouliquin, E. Cabrales, X. Shen, A. Dulhunty, P. F.
Worley, et al. Dynamic regulation of ryanodine receptor type 1 (RyR1)
channel activity by Homer 1. Cell Calcium, 43(3):307–314, MAR 2008.
ISSN 0143-4160. doi: {10.1016/j.ceca.2007.06.001}.
[21] G. Avila, E. H. Lee, C. F. Perez, P. D. Allen, and R. T. Dirksen. FKBP12
binding to RyR1 modulates excitation-contraction coupling in mouse skele-
tal myotubes. Journal Of Biological Chemistry, 278(25):22600–22608, JUN
20 2003. ISSN 0021-9258. doi: {10.1074/jbc.M205866200}.
[22] M. Gaburjakova, J. Gaburjakova, S. Reiken, F. Huang, S. O. Marx,
N. Rosemblit, and A. R. Marks. FKBP12 binding modulates ryanodine
146 BIBLIOGRAPHY
receptor channel gating. Journal Of Biological Chemistry, 276(20):16931–
16935, MAY 18 2001. ISSN 0021-9258. doi: {10.1074/jbc.M100856200}.
[23] S. Reiken, A. Lacampagne, H. Zhou, A. Kherani, S. E. Lehnart, C. Ward,
F. Huang, et al. PKA phosphorylation activates the calcium release channel
(ryanodine receptor) in skeletal muscle: defective regulation in heart failure.
Journal of Cell Biology, 160(6):919–928, MAR 17 2003. ISSN 0021-9525.
doi: {10.1083/jcb.200211012}.
[24] A. M. Bellinger, S. Reiken, M. Dura, P. W. Murphy, S. Deng, D. W.
Landry, D. Nieman, et al. Remodeling of ryanodine receptor complex
causes “leaky” channels: A molecular mechanism for decreased exercise
capacity. Proceedings of the National Academy of Sciences of the United
States of America, 105(6):2198–2202, FEB 12 2008. ISSN 0027-8424. doi:
{10.1073/pnas.0711074105}.
[25] P. Aracena, W. T. Tang, S. L. Hamilton, and C. Hidalgo. Effects of S-
glutathionylation and S-nitrosylation on calmodulin binding to triads and
FKBP12 binding to type 1 calcium release channels. Antioxidants & Redox
Signaling, 7(7-8):870–881, JUL-AUG 2005. ISSN 1523-0864. doi: {10.1089/
ars.2005.7.870}.
[26] P. Aracena-Parks, S. A. Goonasekera, C. P. Gilman, R. T. Dirksen, C. Hi-
dalgo, and S. L. Hamilton. Identification of cysteines involved in S-
nitrosylation, S-glutathionylation, and oxidation to disulfides in ryanodine
receptor type 1. Journal Of Biological Chemistry, 281(52):40354–40368,
DEC 29 2006. doi: {10.1074/jbc.M600876200}.
[27] Q. Sun, B. Wang, M. Miyagi, D. T. Hess, and J. S. Stamler. Oxygen-
coupled redox regulation of the skeletal muscle ryanodine receptor/Ca2+
release channel (RyR1) sites and nature of oxidative modification. Journal
Of Biological Chemistry, 288(32):22961–22971, AUG 9 2013. doi: {10.1074/
jbc.M113.480228}.
[28] T. Yamada, O. Fedotovskaya, A. J. Cheng, A. S. Cornachione, F. C. Mi-
nozzo, C. Aulin, C. Friden, et al. Nitrosative modifications of the Ca2+ re-
lease complex and actin underlie arthritis-induced muscle weakness. Annals
of the Rheumatic Diseases, 74(10):1907–1914, OCT 2015. ISSN 0003-4967.
doi: {10.1136/annrheumdis-2013-205007}.
BIBLIOGRAPHY 147
[29] J. M. Dias and P. D. Vogel. Effects of small molecule modulators on ATP
binding to skeletal ryanodine receptor. Protein Journal, 28(5):240–246,
JUN 2009. ISSN 1572-3887. doi: {10.1007/s10930-009-9189-9}.
[30] D. R. Laver. Ca2+ stores regulate ryanodine receptor Ca2+ release channels
via luminal and cytosolic Ca2+ sites. Clinical and Experimental Pharma-
cology and Physiology, 34(9):889–896, SEP 2007. ISSN 1440-1681. doi:
{10.1111/j.1440-1681.2007.04708.x}.
[31] J. A. Copello, S. Barg, A. Sonnleitner, M. Porta, P. Diaz-Sylvester, M. Fill,
H. Schindler, and S. Fleischer. Differential activation by Ca2+, ATP and
caffeine of cardiac and skeletal muscle ryanodine receptors after block by
Mg2+. Journal of Membrane Biology, 187(1):51–64, MAY 1 2002. ISSN
0022-2631. doi: {10.1007/s00232-001-0150-x}.
[32] B. R. MacIntosh, R. J. Holash, and J. Renaud. Skeletal muscle fatigue - reg-
ulation of excitation-contraction coupling to avoid metabolic catastrophe.
Journal of Cell Science, 125(9):2105–2114, MAY 1 2012. ISSN 0021-9533.
doi: {10.1242/jcs.093674}.
[33] S. Burling. Contributions of calstabins acting on RYR1 in malignant hyper-
thermia susceptibility: a thesis presented in partial fulfilment of the require-
ments for the degree of Bachelor of Science with Honours in Biochemistry
at Massey University, Manawatu, New Zealand. 2019.
[34] D. H. MacLennan, W. J. Rice, and N. M. Green. The mechanism of Ca2+
transport by sarco(endo)plasmic reticulum Ca2+-ATPases. Journal Of Bi-
ological Chemistry, 272(46):28815–28818, NOV 14 1997. ISSN 0021-9258.
doi: {10.1074/jbc.272.46.28815}.
[35] I. C. Smith, E. Bombardier, C. Vigna, and A. R. Tupling. ATP consump-
tion by sarcoplasmic reticulum Ca2+ pumps accounts for 40-50% of resting
metabolic rate in mouse fast and slow twitch skeletal muscle. PLOS One,
8(7), JUL 1 2013. ISSN 1932-6203. doi: {10.1371/journal.pone.0068924}.
[36] Y. Kimura, K. Kurzydlowski, M. Tada, and D. H. MacLennan. Phospho-
lamban regulates the Ca2+-ATPase through intramembrane interactions.
Journal Of Biological Chemistry, 271(36):21726–21731, SEP 6 1996. ISSN
0021-9258. doi: {10.1074/jbc.271.36.21726}.
148 BIBLIOGRAPHY
[37] A. Odermatt, S. Becker, V. K. Khanna, K. Kurzydlowski, E. Leisner,
D. Pette, and D. H. MacLennan. Sarcolipin regulates the activity of
SERCA1, the fast-twitch skeletal muscle sarcoplasmic reticulum Ca2+-
ATPase. Journal Of Biological Chemistry, 273(20):12360–12369, MAY 15
1998. ISSN 0021-9258. doi: {10.1074/jbc.273.20.12360}.
[38] J. Soboloff, B. S. Rothberg, M. Madesh, and D. L. Gill. STIM proteins: dy-
namic calcium signal transducers. Nature Reviews Molecular Cell Biology,
13(9):549–565, SEP 2012. ISSN 1471-0072. doi: {10.1038/nrm3414}.
[39] D. E. Clapham. Calcium signaling. Cell, 131(6):1047–1058, DEC 14 2007.
ISSN 0092-8674. doi: {10.1016/j.cell.2007.11.028}.
[40] B. Nilius and A. Szallasi. Transient receptor potential channels as drug
targets: from the science of basic research to the art of medicine. Phar-
macological Reviews, 66(3):676–814, JUL 2014. ISSN 0031-6997. doi:
{10.1124/pr.113.008268}.
[41] C. Vandebrouck, D. Martin, M. C. V. Schoor, H. Debaix, and P. Gailly.
Involvement of TRPC in the abnormal calcium influx observed in dystrophic
(mdx) mouse skeletal muscle fibers. Journal of Cell Biology, 158(6):1089–
1096, SEP 16 2002. ISSN 0021-9525. doi: {10.1083/jcb.200203091}.
[42] H. Rosenberg, N. Pollock, A. Schiemann, T. Bulger, and K. Stowell. Ma-
lignant hyperthermia: a review. Orphanet Journal Of Rare Diseases, 10,
AUG 4 2015.
[43] K. M. Stowell. Malignant hyperthermia: a pharmacogenetic disorder.
Pharmacogenomics, 9(11):1657–1672, NOV 2008. ISSN 1462-2416. doi:
{10.2217/14622416.9.11.1657}.
[44] T. V. Mccarthy, J. M. S. Healy, J. Heffron, M. Lehane, T. Deufel,
F. Lehmannhorn, M. Farrall, et al. Localization of the malignant hyper-
thermia susceptibility locus to human-chromosome 19q12-13.2. Nature, 343
(6258):562–564, FEB 8 1990. ISSN 0028-0836. doi: {10.1038/343562a0}.
[45] P. M. Hopkins, H. Rueffert, M. M. Snoeck, T. Girard, K. P. E. Glahn,
F. R. Ellis, C. R. Mueller, et al. European Malignant Hyperthermia Group
guidelines for investigation of malignant hyperthermia susceptibility. British
BIBLIOGRAPHY 149
Journal of Anaesthesia, 115(4):531–539, OCT 2015. ISSN 0007-0912. doi:
{10.1093/bja/aev225}.
[46] R. C. Levitt, N. Nouri, A. E. Jedlicka, V. A. Mckusick, A. R. Marks, J. G.
Shutack, J. E. Fletcher, et al. Evidence for genetic-heterogeneity in ma-
lignant hyperthermia susceptibility. Genomics, 11(3):543–547, NOV 1991.
ISSN 0888-7543. doi: {10.1016/0888-7543(91)90061-I}.
[47] D. E. Iles, F. Lehmannhorn, S. W. Scherer, L. C. Tsui, D. O. Weghuis,
R. F. Suijkerbuijk, L. Heytens, et al. Localization of the gene encoding the
alpha(2)/delta-subunits of the L-type voltage-dependent calcium-channel
to chromosome 7q and analysis of the segregation of flanking markers in
malignant hyperthermia susceptible families. Human Molecular Genetics,
3(6):969–975, JUN 1994. ISSN 0964-6906. doi: {10.1093/hmg/3.6.969}.
[48] R. Sudbrak, V. Procaccio, M. Klausnitzer, J. L. Curran, K. Monsieurs,
C. Van Broeckhoven, R. Ellis, et al. Mapping of a further malignant hy-
perthermia susceptibility locus to chromosome 3q13.1. American Journal
of Human Genetics, 56(3):684–691, MAR 1995. ISSN 0002-9297.
[49] R. L. Robinson, N. Monnier, W. Wolz, M. Jung, A. Reis, G. Nuernberg,
J. L. Curran, et al. A genome wide search for susceptibility loci in three
European malignant hyperthermia pedigrees. Human Molecular Genetics,
6(6):953–961, JUN 1997. ISSN 0964-6906. doi: {10.1093/hmg/6.6.953}.
[50] J. Nakai, T. Tanabe, T. Konno, B. Adams, and K. G. Beam. Localization
in the II-III loop of the dihydropyridine receptor of a sequence critical for
excitation-contraction coupling. Journal Of Biological Chemistry, 273(39):
24983–24986, SEP 25 1998. ISSN 0021-9258. doi: {10.1074/jbc.273.39.
24983}.
[51] J. H. Kim, G. P. Jarvik, B. L. Browning, R. Rajagopalan, A. S. Gordon,
M. J. Rieder, P. D. Robertson, et al. Exome sequencing reveals novel rare
variants in the ryanodine receptor and calcium channel genes in malignant
hyperthermia families. Anesthesiology, 119(5):1054–1065, NOV 2013. ISSN
0003-3022. doi: {10.1097/ALN.0b013e3182a8a998}.
[52] D. Fiszer, M. Shaw, N. A. Fisher, I. M. Carr, P. K. Gupta, E. J. Watkins,
D. R. de Sa, et al. Next-generation sequencing of RYR1 and CACNA1S
150 BIBLIOGRAPHY
in malignant hyperthermia and exertional heat illness. Anesthesiology,
122(5):1033–1046, MAY 2015. ISSN 0003-3022. doi: {10.1097/ALN.
0000000000000610}.
[53] C. F. Perez, J. M. Eltit, J. R. Lopez, D. Bodnar, A. F. Dulhunty, S. Aditya,
and M. G. Casarotto. Functional and structural characterization of a novel
malignant hyperthermia-susceptible susceptible variant of DHPR-beta(1a)
subunit (CACNB1). American Journal of Physiology- Cell Physiology, 314
(3):C323–C333, MAR 2018. ISSN 0363-6143. doi: {10.1152/ajpcell.00187.
2017}.
[54] E. J. Horstick, J. W. Linsley, J. J. Dowling, M. A. Hauser, K. K. McDon-
ald, A. Ashley-Koch, L. Saint-Amant, et al. Stac3 is a component of the
excitation-contraction coupling machinery and mutated in Native Ameri-
can myopathy. Nature Communications, 4, JUN 2013. ISSN 2041-1723.
doi: {10.1038/ncomms2952}.
[55] A. H. Schiemann, N. Paul, R. Parker, N. Pollock, T. F. Bulger, and
K. M. Stowell. Functional characterization of 2 known ryanodine recep-
tor mutations causing malignant hyperthermia. Anesthesia and Analge-
sia, 118(2):375–380, FEB 2014. ISSN 0003-2999. doi: {10.1213/ANE.
0b013e3182a273ea}.
[56] C. Roesl, K. Sato, A. Schiemann, N. Pollock, and K. M. Stowell. Functional
characterisation of the R2452W ryanodine receptor variant associated with
malignant hyperthermia susceptibility. Cell Calcium, 56(3):195–201, SEP
2014. ISSN 0143-4160. doi: {10.1016/j.ceca.2014.07.004}.
[57] O. Mungunsukh, P. Deuster, S. Muldoon, F. O’Connor, and N. Sambu-
ughin. Estimating prevalence of malignant hyperthermia susceptibility
through population genomics data. British Journal of Anaesthesia, 123(3):
E461–E463, SEP 2019. ISSN 0007-0912. doi: {10.1016/j.bja.2019.06.007}.
[58] B. A. Britt and W. Kalow. Malignant hyperthermia - a statistical review.
Canadian Anaesthetists Society Journal, 17(4):293+, 1970. ISSN 0008-2856.
doi: {10.1007/BF03004694}.
[59] H. Ording. IIncidence of malignant hyperthermia in Denmark. Anesthesia
and Analgesia, 64(7):700–704, 1985. ISSN 0003-2999.
BIBLIOGRAPHY 151
[60] F. R. Ellis. A protocol for the investigation of malignant hyperpyrexia
(MH) susceptibility. British Journal of Anaesthesia, 56(11):1267–1269,
1984. ISSN 0007-0912.
[61] N. Pollock, E. E. Langton, K. M. Stowell, and T. F. Bulger. Safety of
exposure of malignant hyperthermia non-susceptible patients and their
relatives to anaesthetic triggering agents. Anaesthesia and Intensive
Care, 39(5):887–894, SEP 2011. ISSN 0310-057X. doi: {10.1177/
0310057X1103900514}.
[62] H. Ording, V. Brancadoro, S. Cozzolino, F. R. Ellis, V. Glauber, E. F.
Gonano, P. J. Halsall, et al. In vitro contracture test for diagnosis of
malignant hyperthermia following the protocol of the European MH Group:
Results of testing patients surviving fulminant MH and unrelated low-risk
subjects. Acta Anaesthesiologica Scandinavica, 41(8):955–966, SEP 1997.
ISSN 0001-5172. doi: {10.1111/j.1399-6576.1997.tb04820.x}.
[63] R. M. Quinlivan, C. R. Muller, M. Davis, N. G. Laing, G. A. Evans,
J. Dwyer, J. Dove, et al. Central core disease: clinical, pathological, and
genetic features. Archives of Disease in Childhood, 88(12):1051–1055, DEC
2003. ISSN 0003-9888. doi: {10.1136/adc.88.12.1051}.
[64] S. Wu, M. C. A. Ibarra, M. C. V. Malicdan, K. Murayama, Y. Ichihara,
H. Kikuchi, I. Nonaka, et al. Central core disease is due to RYR1 mutations
in more than 90
patients. Brain, 129(6):1470–1480, 04 2006. ISSN 0006-8950. doi: 10.1093/
brain/awl077. URL https://doi.org/10.1093/brain/awl077.
[65] P. J. Lynch, J. F. Tong, M. Lehane, A. Mallet, L. Giblin, J. A. Heffron,
P. Vaughan, et al. A mutation in the transmembrane/luminal domain of the
ryanodine receptor is associated with abnormal Ca2+ release channel func-
tion and severe central core disease. Proceedings of the National Academy of
Sciences of the United States of America, 96(7):4164–4169, MAR 30 1999.
ISSN 0027-8424. doi: {10.1073/pnas.96.7.4164}.
[66] N. Tilgen, F. Zorzato, B. Halliger-Keller, F. Muntoni, C. Sewry, L. M.
Palmucci, C. Schneider, et al. Identification of four novel mutations in
the C-terminal membrane spanning domain of the ryanodine receptor 1:
152 BIBLIOGRAPHY
association with central core disease and alteration of calcium homeostasis.
Human Molecular Genetics, 10(25):2879–2887, DEC 1 2001. ISSN 0964-
6906. doi: {10.1093/hmg/10.25.2879}.
[67] J. J. Dowling, S. Lillis, K. Amburgey, H. Zhou, S. Al-Sarraj, S. J. A. Buk,
E. Wraige, et al. King-Denborough syndrome with and without mutations
in the skeletal muscle ryanodine receptor (RYR1) gene. Neuromuscular
Disorders, 21(6):420–427, JUN 2011. ISSN 0960-8966. doi: {10.1016/j.
nmd.2011.03.006}.
[68] S. Guis, D. Figarella-Branger, N. Monnier, D. Bendahan, G. Kozak-
Ribbens, J. P. Mattei, J. Lunardi, et al. Multiminicore disease in a fam-
ily susceptible to malignant hyperthermia - Histology, in vitro contracture
tests, and genetic characterization. Archives of Neurology, 61(1):106–113,
JAN 2004. ISSN 0003-9942. doi: {10.1001/archneur.61.1.106}.
[69] J. M. Wilmshurst, S. Lillis, H. Zhou, K. Pillay, H. Henderson, W. Kress,
C. R. Mueller, et al. RYR1 mutations are a common cause of congenital
myopathies with central nuclei. Annals of Neurology, 68(5):717–726, NOV
2010. ISSN 0364-5134. doi: {10.1002/ana.22119}.
[70] A. Gottschalk, T. Heiman-Patterson, R. deQuevedo, and P. D. Quinn.
General anesthesia for a patient with centronuclear (myotubular) myopa-
thy. Anesthesiology, 89(4):1018–1020, OCT 1998. ISSN 0003-3022. doi:
{10.1097/00000542-199810000-00026}.
[71] J. A. Morgan-Hughes. Tubular aggregates in skeletal muscle: their func-
tional significance and mechanisms of pathogenesis. Current Opinion in
Neurology, 11(5):439–442, OCT 1998. ISSN 1350-7540. doi: {10.1097/
00019052-199810000-00005}.
[72] J. Lee and S. Noguchi. Calcium dyshomeostasis in tubular aggregate my-
opathy. International Journal of Molecular Sciences, 17(11), NOV 2016.
ISSN 1422-0067. doi: {10.3390/ijms17111952}.
[73] A. Mallick and A. R. Bodenham. MDMA induced hyperthermia: a survivor
with an initial body temperature of 42.9 degrees C. Journal of Accident &
Emergency Medicine, 14(5):336–338, SEP 1997. ISSN 1351-0622.
BIBLIOGRAPHY 153
[74] C. K. Dao, S. M. Nowinski, and E. M. Mills. The heat is on: Molecu-
lar mechanisms of drug-induced hyperthermia. Temperature, 1(3):183–191,
2014. doi: 10.4161/23328940.2014.985953. URL https://doi.org/10.
4161/23328940.2014.985953.
[75] E. M. Mills, M. L. Banks, J. E. Sprague, and T. Finkel. Pharmacology:
Uncoupling the agony from ecstasy - A mitochondrial protein may mediate
a dangerous side-effect of some recreational drugs. Nature, 426(6965):403–
404, NOV 27 2003. ISSN 0028-0836. doi: {10.1038/426403a}.
[76] O. M. Kelly, Y. M. McNamara, L. H. Manzke, M. J. Meegan, and R. K.
Porter. The preservation of in vivo phosphorylated and activated uncou-
pling protein 3 (UCP3) in isolated skeletal muscle mitochondria following
administration of 3,4-methylenedioxymethamphetamine (MDMA aka ec-
stasy) to rats/mice. Mitochondrion, 12(1, SI):110–119, JAN 2012. ISSN
1567-7249. doi: {10.1016/j.mito.2011.03.011}.
[77] M. J. Bamshad, S. B. Ng, A. W. Bigham, H. K. Tabor, M. J. Emond, D. A.
Nickerson, and J. Shendure. Exome sequencing as a tool for Mendelian
disease gene discovery. Nature Reviews Genetics, 12(11):745–755, NOV
2011. ISSN 1471-0056. doi: {10.1038/nrg3031}.
[78] C. Willyard. Expanded human gene tally reignites debate. Nature,
558(7710):354–355, JUN 21 2018. ISSN 0028-0836. doi: {10.1038/
d41586-018-05462-w}.
[79] G. Bernardi. The genomic code: a pervasive encoding/molding of chromatin
structures and a solution of the “non-coding DNA” mystery. Bioessays, 41
(12), DEC 2019. ISSN 0265-9247. doi: {10.1002/bies.201900106}.
[80] A. M. Meynert, M. Ansari, D. R. FitzPatrick, and M. S. Taylor. Variant
detection sensitivity and biases in whole genome and exome sequencing.
BMC Bioinformatics, 15, JUL 19 2014. ISSN 1471-2105. doi: {10.1186/
1471-2105-15-247}.
[81] A. Belkadi, A. Bolze, Y. Itan, A Cobat, Q. B. Vincent, A. Antipenko,
L. Shang, et al. Whole-genome sequencing is more powerful than whole-
exome sequencing for detecting exome variants. Proceedings of the National
154 BIBLIOGRAPHY
Academy of Sciences of the United States of America, 112(17):5473–5478,
APR 28 2015. ISSN 0027-8424. doi: {10.1073/pnas.1418631112}.
[82] J. Meienberg, R. Bruggmann, K. Oexle, and G. Matyas. Clinical sequencing:
is WGS the better WES? Human Genetics, 135(3):359–362, MAR 2016.
ISSN 0340-6717. doi: {10.1007/s00439-015-1631-9}.
[83] Y. Barbitoff, D. Polev, I. Shcherbakova, A. Kiselev, A. Glotov, E. Sere-
bryakova, A. Kostareva, et al. Systematic dissection of biases in whole
exome and whole genome strategies for human genome resequencing re-
veals major determinants of human coding sequence coverage. European
Journal of Human Genetics, 27(1):509, JUL 2019. ISSN 1018-4813. 51st
Conference of the European-Society-of-Human-Genetics (ESHG) in con-
junction with the European Meeting on Psychosocial Aspects of Genetics
(EMPAG), Milan, ITALY, JUN 16-19, 2018.
[84] C. F. Wright, D. R. FitzPatrick, and H. V. Firth. Paediatric genomics:
diagnosing rare disease in children. Nature Reviews Genetics, 19(5):253–
268, MAY 2018. ISSN 1471-0056. doi: {10.1038/nrg.2017.116}.
[85] V. Heinrich, J. Stange, T. Dickhaus, P. Imkeller, U. Krueger, S. Bauer,
S. Mundlos, et al. The allele distribution in next-generation sequencing
data sets is accurately described as the result of a stochastic branching
process. Nucleic Acids Research, 40(6):2426–2431, MAR 2012. ISSN 0305-
1048. doi: {10.1093/nar/gkr1073}.
[86] M. J. Clark, R. Chen, H. Y. K. Lam, K. J. Karczewski, R. Chen, G. Eu-
skirchen, A. J. Butte, et al. Exome sequencing reveals novel rare variants in
the ryanodine receptor and calcium channel genes in malignant hyperther-
mia familiesPerformance comparison of exome DNA sequencing technolo-
gies. Nature Biotechnology, 29(10):908–U206, OCT 2011. ISSN 1087-0156.
doi: {10.1038/nbt.1975}.
[87] D. S. Marchuk, K. Crooks, N. Strande, K. Kaiser-Rogers, L. Milko,
A. Brandt, A. Arreola, et al. Increasing the diagnostic yield of exome
sequencing by copy number variant analysis. PLOS One, 13(12), DEC 17
2018. ISSN 1932-6203. doi: {10.1371/journal.pone.0209185}.
BIBLIOGRAPHY 155
[88] R. Pfundt, M. del Rosario, L. E. L. M. Vissers, M. P. Kwint, I. M. Janssen,
N. de Leeuw, H. G. Yntema, et al. Detection of clinically relevant copy-
number variants by exome sequencing in a large cohort of genetic disorders.
Genetics in Medicine, 19(6):667–675, JUN 2017. ISSN 1098-3600. doi:
{10.1038/gim.2016.163}.
[89] A. Warr, C. Robert, D. Hume, A. Archibald, N. Deeb, and M. Watson.
Exome sequencing: current and future perspectives. G3- Genes Genomes
Genetics, 5(8):1543–1550, AUG 1 2015. ISSN 2160-1836. doi: {10.1534/g3.
115.018564}.
[90] C. Sekhar R. Chilamakuri, S. Lorenz, M. Madoui, D. Vodak, J. Sun,
E. Hovig, and others. Performance comparison of four exome capture sys-
tems for deep sequencing. BMC Genomics, 15, JUN 9 2014. ISSN 1471-
2164. doi: {10.1186/1471-2164-15-449}.
[91] D. Sims, I. Sudbery, N. E. Ilott, A. Heger, and C. P. Ponting. Sequenc-
ing depth and coverage: key considerations in genomic analyses. Na-
ture Reviews Genetics, 15(2):121–132, FEB 2014. ISSN 1471-0056. doi:
{10.1038/nrg3642}.
[92] H. Li and R. Durbin. Fast and accurate short read alignment with Burrows-
Wheeler transform. Bioinformatics, 25(14):1754–1760, JUL 15 2009. ISSN
1367-4803. doi: {10.1093/bioinformatics/btp324}.
[93] B. Langmead and S. L. Salzberg. Fast gapped-read alignment with Bowtie
2. Nature Methods, 9(4):357–U54, APR 2012. ISSN 1548-7091. doi: {10.
1038/NMETH.1923}.
[94] J. Chen, X. Li, H. Zhong, Y. Meng, and H. Du. Systematic compar-
ison of germline variant calling pipelines cross multiple next-generation
sequencers. Scientific Reports, 9, JUN 27 2019. ISSN 2045-2322. doi:
{10.1038/s41598-019-45835-3}.
[95] S. Kim, K. Scheffler, A. L. Halpern, M. A. Bekritsky, E. Noh, M. Kallberg,
X. Chen, et al. Strelka2: fast and accurate calling of germline and somatic
variants. Nature Methods, 15(8):591+, AUG 2018. ISSN 1548-7091. doi:
{10.1038/s41592-018-0051-x}.
156 BIBLIOGRAPHY
[96] H. Li, B. Handsaker, A. Wysoker, T. Fennell, J. Ruan, N. Homer,
G. Marth, et al. The sequence alignment/map format and SAMtools.
Bioinformatics, 25(16):2078–2079, AUG 15 2009. ISSN 1367-4803. doi:
{10.1093/bioinformatics/btp352}.
[97] Erik Garrison and Gabor Marth. Haplotype-based variant detection from
short-read sequencing, 2012.
[98] J. O’Rawe, T. Jiang, G. Sun, Y. Wu, W. Wang, J. Hu, P. Bodily, et al. Low
concordance of multiple variant-calling pipelines: practical implications for
exome and genome sequencing. Genome Medicine, 5, MAR 27 2013. ISSN
1756-994X. doi: {10.1186/gm432}.
[99] S. Hwang, E. Kim, I. Lee, and E. M. Marcotte. Systematic comparison of
variant calling pipelines using gold standard personal exome variants. Sci-
entific Reports, 5, DEC 7 2015. ISSN 2045-2322. doi: {10.1038/srep17875}.
[100] M. Kumaran, U. Subramanian, and B. Devarajan. Performance assessment
of variant calling pipelines using human whole exome sequencing and sim-
ulated data. BMC Bioinformatics, 20, JUN 17 2019. ISSN 1471-2105. doi:
{10.1186/s12859-019-2928-9}.
[101] F. Cunningham, P. Achuthan, W. Akanni, J. Allen, M. R. Amode, I. M.
Armean, R. Bennett, et al. Ensembl 2019. Nucleic Acids Research, 47(D1):
D745–D751, JAN 8 2019. ISSN 0305-1048. doi: {10.1093/nar/gky1113}.
[102] N. A. O’Leary, M. W. Wright, J. R. Brister, S. Ciufo, D. H. R. McVeigh,
B. Rajput, B. Robbertse, et al. Reference sequence (RefSeq) database
at NCBI: current status, taxonomic expansion, and functional annotation.
Nucleic Acids Research, 44(D1):D733–D745, JAN 4 2016. ISSN 0305-1048.
doi: {10.1093/nar/gkv1189}.
[103] D. J. McCarthy, P. Humburg, A. Kanapin, M. A. Rivas, K. Gaulton,
J. Cazier, P. Donnelly, et al. Choice of transcripts and software has a
large effect on variant annotation. Genome Medicine, 6, MAR 31 2014.
ISSN 1756-994X. doi: {10.1186/gm543}.
[104] K. Wang, M. Li, and H. Hakonarson. ANNOVAR: functional annotation
of genetic variants from high-throughput sequencing data. Nucleic Acids
BIBLIOGRAPHY 157
Research, 38(16):e164–e164, 07 2010. ISSN 0305-1048. doi: 10.1093/nar/
gkq603. URL https://doi.org/10.1093/nar/gkq603.
[105] W. McLaren, L. Gil, S. E. Hunt, H. S. Riat, G. R. S. Ritchie, A. Thormann,
P. Flicek, et al. The Ensembl variant effect predictor. Genome Biology, 17,
JUN 6 2016. ISSN 1474-760X. doi: {10.1186/s13059-016-0974-4}.
[106] P. Cingolani, A. Platts, M. Coon, T. Nguyen, L. Wang, S. J. Land,
X. Lu, et al. A program for annotating and predicting the effects of sin-
gle nucleotide polymorphisms, snpeff: Snps in the genome of drosophila
melanogaster strain w1118; iso-2; iso-3. Fly, 6(2):80–92, 2012.
[107] L. Clarke, S. Fairley, X. Zheng-Bradley, I. Streeter, E. Perry, E. Lowy,
A. Tasse, et al. The international genome sample resource (IGSR): A
worldwide collection of genome variation incorporating the 1000 Genomes
Project data. Nucleic Acids Research, 45(D1):D854–D859, JAN 4 2017.
ISSN 0305-1048. doi: {10.1093/nar/gkw829}.
[108] K. J. Karczewski, L. C. Francioli, G. Tiao, B. B. Cummings, J. Alföldi,
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Appendix
Primer name Sequence Tm
JSRP1 G150A experiment
Forward sequencing 5´ GAA TGA CCA ATT GAA AGA GCG 52.2 ℃
Reverse sequencing 5´ CGA ACT TAG GCT GCA AGA CA 55.1 ℃
HRM 1 forward 5´ AGG GAG GGA TGG ACA GTG T 57.9 ℃
HRM 3 forward 5´ GGA TGG ACA GTG TGG ACC GT 59.4 ℃
HRM 4 forward 5´ ACA GTG TGG ACC GTG CCT C 60.0 ℃
HRM 5 forward 5´ TGT CGC TGC AGA CGC CGT 62.9 ℃
HRM 1 reverse 5´ CAC ACG TGC TTG GAG TGC T 58.3 ℃
HRM 2 reverse 5´ CAC ACG TGC TTG GAG TGC TG 59.2 ℃
HRM 3 reverse 5´ GTG CTT GGA GTG CTG CCT CC 61.3 ℃
HybProbe 1 forward 5´ GGA TGG ACA GTG TGG ACC 55.3 ℃
HybProbe 1 reverse 5´ TCA GTG GAA GGA AGC TCT 52.7 ℃
HybProbe 2 reverse 5´ GGT CAG TGG AAG GAA GCT CT 56.6 ℃
PPIP5K1 experiment
Forward sequencing 5´ AAT GGC AGA TGA GAC TGC TTC C 57.3 ℃
Reverse sequencing 5´ GGC TCC TGG ATT CTT CCT CAT AT 56.1 ℃
HRM 1 forward 5´ TTG CAG GGG AGG TGA ATG AAG 57.4 ℃
HRM 1 reverse 5´ AGC AGC CAG GCC TCA GAT AAC 59.4 ℃
UCP3 sequencing
Forward sequencing 5´ GAC TTC TGC CTA AAT CCC CTT 54.4 ℃
Reverse sequencing 5´ CAT GGC AGT GAA GAC CAG AAT 55.1 ℃
PPARGC1A sequencing
Forward sequencing 5´ CAC GAA GAC GTG TAT TAT CAA C 51.4 ℃
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Reverse sequencing 5´ TGA TGC ATA GTG TTA CCT GCC 54.9 ℃
RYR1 sequencing
Forward sequencing 5´ CTG TTA CAG AGC AGG TAA GAG 52.3 ℃
Reverse sequencing 5´ TTC CCA GAT CTC AGG TTT CTG 54.1 ℃
TLR3 sequencing
Forward sequencing 5´ GTC TCT GAG TAA CAG CCA GC 55.2 ℃
Reverse sequencing 5´ CGC AAA CTT GTA AAG GAG TTG G 54.6 ℃
TRPV2 experiment
Forward sequencing 5´ GAG TCA ATG CCT GCA TTC TG 54.1 ℃
Reverse sequencing 5´ TTG TTA GAA CCC AGG AGT TTG 52.5 ℃
HRM 1 forward 5´ AAT GGG GCC AAT GTG CAT G 56.7 ℃
HRM 1 reverse 5´ CCA AGA AAG GCT CAC TCA C 53.3 ℃
PRKAA1 experiment
Forward sequencing 5´ CCA TCA ATA CTA CGG AAA TCC 50.6 ℃
Reverse sequencing 5´ GAC AAG CCC ACC TGA TTC TT 55.1 ℃
HRM 1 forward 5´ CTA TGG GTT TGC CAA ATA TGC 52.2 ℃
HRM 1 reverse 5´ ATG GCA GAA GTA TGT AGA GCA 53.4 ℃
Melting temperatures were calculated using the IDTTM OligoAnalyzer tool
Table A.1: List of primers used in this work
Probe Sequence Tm
Sensor 5´ CGC CGT CCC TCG GGA G -Fluoroscein 65.4 ℃
Anchor Cy5- 5´ AGC ACT CCA AGC ACG TGT GC -Phosphate 67.6 ℃
Melting temperatures were calculated using the Lightcycler Probe Design Software 2.0 (Roche)
Table A.2: JSRP1 G150A HybProbe assay probe sequences
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Primer set Forward primer Reverse primer Expected product size (bases)
HRM set 1 HRM 3 forward HRM 2 reverse 100
HRM set 2 HRM 1 forward HRM 1 reverse 106
HRM set 3 HRM 4 forward HRM 1 reverse 93
HRM set 4 HRM 5 forward HRM 1 reverse 49
HRM set 5 HRM 4 forward HRM 3 reverse 88
HRM set 6 HRM 5 forward HRM 3 reverse 44
HybProbe set 1 HybProbe 1 forward HybProbe 1 reverse 175
HybProbe set 2 HRM 1 forward HybProbe 2 reverse 183
Table A.3: Primer sets for JSRP1 G150A genotyping
Figure A.1: Quality control of extracted gDNA samples for new WES sequencing
of family B and E
250 ng of gDNA from individuals 44, 251, 1379, 1731, 2253 and 2259 were loaded onto a 0.8%
agarose gel and the gel was UV imaged to visualise the DNA. The first gel image indicates
suitable gDNA quality and quantity for all samples with the exception of sample 2259, with
a significant degree of degradation, which was prepared previously from muscle. The second
image shows a more recent 2259 gDNA preparation from muscle tissue and indicates improved
gDNA quality with less degradation. The third image indicates suitable gDNA quality and
quantity for sample 2253.
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Figure A.2: Sequence alignment of WES data from family A individuals 1480 and
1908 at the genomic position of the PRKAA1 K429R SNV
The red arrows indicate the variant position. The reads suggest that individual 1480 is het-
erozygous for the variant, whereas 1908 appears to be wild-type at that position.
Figure A.3: Alignment of Sanger sequencing results for 1479 and 1576 against the
PRKAA1 nucleotide sequence
The red arrow indicates the variant position. The results indicate that 1479 is heterozygous for
the PRKAA1 K429R variant whereas individual 1576 does not carry variant.
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Figure A.4: HRM melting curve for PRKAA1 K429R variant
Sanger-sequenced wild-type 1576 and heterozygous 1479 have characteristic single and double
peaks, respectively.
Figure A.5: HRM melting curve for PRKAA1 K429R variant
The results indicate that individual 1908, thought to be wild-type from the WES data, is
heterozygous for the variant.
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Figure A.6: Alignment of Sanger sequencing results for 1731 and 1412 against the
PPIP5K1 nucleotide sequence
The red arrow indicates the variant position. The results indicate that individual 1731 does not
carry the PPIP5K1 R1081H variant whereas individual 1412 is heterozygous for the variant.
Figure A.7: HRM melting curve for PPIP5K1 R1081H variant
1731 is confirmed wild-type for the variant and has a characteristic homoduplex single peak.
1412 is confirmed heterozygous for the variant and has a characteristic heteroduplex double
peak.
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Figure A.8: Alignment of Sanger sequencing results for 1367 and 26 against the
TRPV2 nucleotide sequence
The red arrow indicates the variant position. The results confirm that individual 26 does not
carry the TRPV2 R196C variant whereas individual 1367 is heterozygous for the variant.
Figure A.9: HRM melting curve for TRPV2 R196C variant
MHN is wild-type for the variant and has a characteristic homoduplex single peak. 1367 is
confirmed heterozygous for the variant and has a characteristic heteroduplex double peak.
Figure A.10: Alignment of Sanger sequencing results for 1247 against the RYR1
nucleotide sequence
The red arrow indicates the variant position. The results indicate that 1247 does not carry an
RYR1 E2820Q variant.
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Figure A.11: Alignment of Sanger sequencing results for 533, 919 and 1772 against
the JSRP1 nucleotide sequence
The red arrow indicates the variant position. The results indicate that 533 is wild-type for the
variant, 919 is homozygous and 1772 is heterozygous.
Figure A.12: HRM melting curve for JSRP1 G150A variant
Wild-type 533 and heterozygous 1772 have single and double peaks characteristic of the presence
of homoduplexes and heteroduplexes, respectively.
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Figure A.13: HRM melting curves for JSRP1 G150A variant
Wild-type 533 and homozygous 919 have a single peak characteristic of the presence of homod-
uplexes. Other peaks (not labelled) belong to samples 26, 27, 82, 456, 1367 and 1412.
Figure A.14: HRM melting curve for JSRP1 G150A variant
This assay was carried out with replacement of 0.5 µL H2O with GC-RICH solution (Roche).
Wild-type 533 and homozygous 919 have a single peak characteristic the presence of homodu-
plexes, and heterozygous 1772 has a double peak characteristic of the presence of a heterodu-
plex. The shift of homozygous 919 melting peak relative to that of wild-type 533 is no more
pronounced than previous assays (see Appendix A.13). Other peaks (not labelled) belong to
samples 432, 435, 491, 541, 544, 623, 649 and 685.
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Figure A.15: Agarose gel electrophoresis of PCR products using LightCycler®
Probe Design Software 2.0 designed primers for the JSRP1 G150A HybProbe
assay
A, B, C and D are PCRs carried out at annealing temperatures of 52℃, 54℃, 56℃ and 58℃,
respectively. E is a negative control carried out with the same conditions as B.
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Figure A.16: Representative fluorescence history and melting curve for JSRP1
G150A HybProbe assays
Samples 533, 919 and 1772, and a negative control, were included in this assay.
Figure A.17: HybProbe sensor and anchor probe fluorescence measurements taken
on the DeNovix fluorometer
RFU is relative fluorescence units. Emission was corrected for concentration by dividing the
RFU values by the probe concenctration in nM to achieve RFU per nM.
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Figure A.18: JSRP1 G150A RFLP genotyping PCR products set 1
’-’ is the negative control (H2O) lane.
Figure A.19: JSRP1 G150A RFLP genotyping RFLP products set 1
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Figure A.20: JSRP1 G150A RFLP genotyping PCR products set 2
’-’ is the negative control (H2O) lane.
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Figure A.21: JSRP1 G150A RFLP genotyping RFLP products set 2
Figure A.22: JSRP1 G150A RFLP genotyping PCR products set 3
’-’ is the negative control (H2O) lane.
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Figure A.23: JSRP1 G150A RFLP genotyping RFLP products set 3
Figure A.24: JSRP1 G150A RFLP genotyping PCR products set 4
’-’ is the negative control (H2O) lane.
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Figure A.25: JSRP1 G150A RFLP genotyping RFLP products set 4
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Figure A.26: JSRP1 G150A RFLP genotyping PCR products set 5
’-’ is the negative control (H2O) lane.
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Figure A.27: JSRP1 G150A RFLP genotyping RFLP products set 5
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Figure A.28: JSRP1 G150A RFLP genotyping PCR products set 6
’-’ is the negative control (H2O) lane.
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Figure A.29: JSRP1 G150A RFLP genotyping RFLP products set 6
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Figure A.30: JSRP1 G150A association study raw data Table 1
‘H’ is IVCT halothane contracture value. ‘C’ is IVCT caffeine contracture value. ‘MH’ is MH-susceptibility
status as determined by IVCT. ‘T4826I’ is carrier status of the RYR1 T4826I variant (‘P’ is heterozygous, ‘N’
is wild-type and ‘NA’ not tested). ‘RFLP set’ the RFLP set number. ‘Gel number’ is the well number of the
RFLP gel. ‘G150A’ is the JSRP1 G150A variant carrier status inferred by the RFLP results. Individual 1251
given in this table appears homozygous for the variant by RFLP analysis but was not confirmed by Sanger
sequencing and so was not included in the final analysed data.
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Figure A.31: JSRP1 G150A association study raw data Table 2
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Figure A.32: Variant annotation tools and database versions used by VarAFT
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Figure A.33: Table of information for all WES samples
SureSelect v6 is the SureSelectXT Human All Exon V6 (Cat. No. 5190-8863, Agilent) kit.
Nimblegen v3 is the Nimblegen SeqCap v3 (Cat. No. 06465684001, Roche Nimblegen) kit.
Sureselect is the SureSelect Human All Exon (Agilent). * is samples which do not have a lab
DNA number.
